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CHAPTER I
Introduction
1.1 Research overview
One of the most important fields in modern molecular biology is the study of
RNA, or transcriptomics. Historically, the central dogma of molecular biology has
been summarized as “DNA makes RNA and RNA makes protein”. Therefore, by
quantifying RNA production, one is can also infer protein abundance in the cell.
While that’s a very important aspect of transcriptomics, the RNA world is much
greater than that. Research in the past decades has demonstrated that there are
several different RNA populations, which have very specific roles inside cells.
Most researches, however, are interested mostly in protein coding genes. Because
of that, they focus on polyadenylated RNA. Conventional transcriptome studies (e.g.
ESTs, gene expression microarrays, RNA-seq) have been successfully used from gene
identification and annotation to finding disease biomarkers. Since these studies focus
on the mature form of transcripts, they tend to overlook much of the complexity
involved in gene regulation. Regular transcriptome studies quantify the abundance
of transcripts at a given time point. They do not, however, determine how those
values are reached. There are two non-exclusive ways that transcript abundance can
be reached:
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2Synthesis One possible way to regulate the abundance of a transcript is to deter-
mine how much of that RNA is transcribed in the system. Assuming that all
stays the same, a greater synthesis of a given transcript will eventually cause
its abundance to be increased.
Stability The degradation of molecules in a biological system is a natural occur-
rence. Not all transcripts, however, are degraded at the same rate. If two
transcripts are synthesized at the same rate but degraded at different rates,
their abundance will differ.
In order to better understand gene regulation, it is necessary to be able to discern
between transcript synthesis and transcript stability. This, however, is impossible
to do with conventional transcriptomics studies. The first step to accomplish this
goal is to be able to measure the synthesis of transcripts. This can be achieved by
measuring the rate at which RNA is transcribed during a short period of time. The
newly made RNA is referred to as nascent RNA. Two methods could potentially
be used to determine the stability of transcripts. The most straightforward method
would be to measure a transcript’s abundance in the nascent RNA and in the total
pool of RNA. RNA stability could be calculated as a function of abundance of a
transcript in the nascent and in the total pools of RNA. For example, an unstable
transcript could display high abundance in the nascent RNA and low abundance in
the total RNA pool. If homeostasis was disrupted, however, this technique would
falter. Since the stability measurements are based on the total pool of RNA, changes
in transcript stability would only be measurable once enough time had passed for the
total pool of RNA to be affected. Therefore, short-term stimulus-induced changes in
stability would be difficult to measure.
This problem can be circumvented if, instead of studying the complete RNA pool,
3one is able to focus on a limited pool of RNA that was transcribed synchronously.
This leads us to the second method to determine transcript stability. The abundance
of a transcript in the nascent RNA can be compared to its abundance in the same
RNA population after a given amount of time has passed. This allows for stability
measurements to be carried out in homeostasis or after a treatment.
The effect of treatments on gene expression can also be more quickly observed
when analyzing changes to the nascent RNA. When using standard techniques, such
as RNA-seq with polyadenylated transcripts, treatment-induced changes in the syn-
thesis of transcripts can only be observed once they have accumulated enough to
change the total pool of RNA. This is particularly relevant for large genes which
might take a long time to be transcribed. The treatment might induce immediate
change in the synthesis of the transcript, but that will go completely unnoticed un-
til the whole transcript is transcribed and polyadenylation takes place. Therefore,
nascent RNA sequencing allows for changes in transcript expression to be measured
much sooner.
This is particularly important when the focus of interest is not the final changes
in transcript abundance, but the effect of the treatment on the transcription pro-
cess. There are several drugs (e.g. camptothecin, etoposide) and environmental
factors (e.g. UV radiation, reactive oxygen species) that directly or indirectly affect
transcription. By analyzing the nascent RNA, it is possible to observe and better
determine how the treatment is changing transcription.
These treatments can also be used to better understand details about transcrip-
tion. Transcription is a complex, multistage process that involves a very large number
of proteins. Nascent RNA sequencing can allow us to observe how transcription is
affected in the absence of any one of these proteins. Also, more complex experimental
4designs can be used to answer questions about the individual steps of transcription.
For example, from how many different promoters does transcription initiate? What
is the elongation speed of RNA polymerase? Does transcription terminate always at
the same place?
In this thesis I used data generated from a set of techniques that have been
developed by Dr. Mats Ljungman’s research group as a tool to study nascent RNA
expression and the transcription process as a whole. I collaborated with Dr. Thomas
E. Wilson in establishing a pipeline for mapping and carrying out initial analysis
of this data. Several of the research questions addressed in this thesis could not
be solved with existent software. Therefore, most of my efforts involved developing
computational and statistical analysis approaches that could answer those questions.
1.2 Dissertation outline
This dissertation is divided into seven chapters. Chapter I provides an intro-
duction to the major themes discussed throughout the thesis, while chapter VII
summarizes the major findings, discusses their relevance and how this research could
be expanded upon. Chapters II to VI are the scientific reports that were generated
based upon the research carried out by myself and other laboratory members.
Our research group developed a technique based on metabolic labeling of RNA
using bromouridine (Bru) in order to study nascent RNA synthesis. This technique
was named Bru-seq. One of the main advantages of this approach is that it allowed for
a chase to be carried out after the labeling, which made studying RNA stability and
RNA post-transcription processing possible. The name given to this technique was
BruChase-seq. The experimental procedures necessary to carry out these techniques
and a thorough description of the analysis pipeline used with this data are described
5in chapter II. The same chapter also gives examples of how transcript synthesis,
stability and processing can be measured under homeostasis using these techniques.
Biological systems tend to change and adapt once homeostasis is disturbed. It is
well known that treatment-induced changes in gene expression can occur, but it is
not clear what proportion of these changes occur as a result of changes in the rates
of synthesis or stability. In chapter III, different aspects of transcription regulation
are tested by analyzing the effect of the proinflammatory cytokine Tumor Necrosis
Factor (TNF) in transcript synthesis and stability in human fibroblasts. The results,
show coordinated regulation at both the level of synthesis and stability.
The development of a technique which allows the study of nascent RNA makes it
possible to explore details of the RNA synthesis process. Several different approaches
could be taken, but we decided to focus on treatments that inhibit transcription at
one of its stages. In chapters IV to VI we explore three of these treatments and use
them to increase out knowledge of transcription.
UV radiation causes DNA lesions, which work as a barrier for elongating DNA
and RNA polymerases. In chapter IV we use the Bru-seq technique in cells that
were irradiated to understand exactly how transcription is affected. We observed
that the transcription signals were redistributed from bodies of genes to TSS and
putative enhancers, which is reasonable since elongation is inhibited but initiation is
unaffected. Due to the usefulness of accumulating signal around TSS and enhancers,
this chapter describes how this treatment could be used as a technique, referred to
as BruUV-seq.
Another treatment that inhibits transcription elongation is the antitumoral drug
camptothecin (CPT). While its mechanism of action is completely different from UV
radiation, we found that the effect it has on nascent RNA is fairly similar. In chapter
6V we explore the effect of CPT on transcript synthesis during and 15 and 30 minutes
after treatment. Due to CPT’s inhibition of elongation and the inability of blocked
RNAPII to resume transcription after CPT removal, transcript synthesis recovery
is delayed in larger genes. This might partially explain the antitumoral activity of
CPT since it leads to the inhibition of large proto-oncogenes and large anti-apoptotic
genes.
Transcript synthesis recovery after CPT demonstrated how important gene length
can be to the expression of a gene. Similarly, the speed of elongation of RNA poly-
merase is also very important to determine the time taken for transcription to be
completed. In chapter VI we describe a technique for measuring genome-wide tran-
script elongation rate called BruDRB-seq. While the gene’s elongation rate can be
quite different, we observed a correlation in the elongation rate of transcription across
genes in five cell lines.
Since chapters II to VI were prepared for publication in scientific journals, they
do not contain detailed background information. The next sections of this chapter
contain information that will aid the understanding of those chapters.
1.3 RNA transcription
RNA transcription is a very complex process, which is usually divided into three
steps, transcription initiation, transcription elongation and transcription termina-
tion. Initially, RNA polymerase II (RNAPII) and a wide range of general transcrip-
tion factors form a functional pre-initiation complex (PIC) and bind to the gene’s
promoter (see 1.3.1). Once bound, RNAPII transcribes a small number of nucleotides
(5-25). This stage, transcription initiation, may lead to productive elongation but
could lead to abortive transcription (see 1.3.2). If transcription is not aborted and
7RNAPII is released from the promoter it can move along while transcribing the
DNA strand, which is referred to as transcription elongation (see 1.3.4). Most of
the transcript processing, such as capping and splicing, happen while elongation is
taking place. The dissociation of RNAPII from the DNA molecule characterizes
transcription termination (see 1.3.5).
1.3.1 Formation of pre-initiation complex
The eukaryotic DNA molecule is highly organized and protected by histones and
other scaffolding proteins. Specialized proteins are necessary to aid in the identifica-
tion of the functional elements that lie in the genome. This identification happens
on the basis of conserved sequences that usually lie close to the promoter region of
the gene (Juven-Gershon et al., 2008). These core promoter elements (CPE) may
contain many different motifs (e.g. BRE, Inr, MTE, DCE). The TATA box is one
of the most studied examples of CPE. It is also one of the most ancient conserved
DNA sequences, present from Archaea through eukaryotes (Reeve, 2003).
The TATA box is recognized and bound to by TATA-box-binding-protein. Binding
to the TATA box leads to a change in conformation of the DNA molecule, which
makes it possible for other transcription factors (TF), such as TFIID, to bind to the
promoter region (Shandilya and Roberts, 2012). In the absence of the TATA box,
TFIID and other transcription factors will bind to other CPE, such as Initiator and
Downstream Promoter Element (Baumann et al., 2010). Several CPE are flanked by
TFIIB recognition elements, which are binding sites for transcription factor TFIIB.
The binding of TATA-box-binding-protein to the DNA molecule is stabilized by the
binding of TFIIB to the complex. The PIC is further stabilized by binding to RNAPII
and TFIIF (Deng and Roberts, 2007).
81.3.2 Transcription initiation
Formation of a stable PIC does not guarantee that transcription initiation will
take place. In some cases, transcription is aborted after RNAPII produces a tran-
script that is approximately 5 nucleotides long (Saunders et al., 2006). Abortive
initiation is related to structural changes that occur in the RNAPII-DNA complex
when the first nucleotides are polymerized. It has been suggested that abortive
initiation could act as a cellular checkpoint to avoid nonspecific transcription (Liu
et al., 2011). As more nucleotides are added to the polymerizing RNA molecule,
the tendency for a successful promoter escape increases. At approximately 10 nu-
cleotides, the likelihood of abortive initiation happening greatly decreases (Holstege
et al., 1997). At this time, the ATP and TFIIH requirements for the reaction end
and the transcription bubble collapses (Saunders et al., 2006). A reduction in up-
stream transcript slippage, the pairing of the RNA molecule with an upstream DNA
sequence, also occurs approximately after the polymerization of 10 nucleotides (Pal
and Luse, 2003). Once the RNA molecule reaches 25 nucleotides it is considered
that the transition from transcription initiation into transcription elongation was
successful. Roughly at that length, the cap structure is added to the 5’ end of the
transcript (Rasmussen and Lis, 1993).
In order for the capping to take place it is necessary for the fifth Serine of the
RNAPII C-Terminal domain (CTD) repeats to be phosphorylated (Komarnitsky
et al., 2000). Post-transcriptional modifications to the CTD are extremely impor-
tant for a successful transcription initiation. In humans, the CTD is composed of
52 repeats of the peptides Tyrosine (Y) - Serine (S) - Proline (P) - Threonine (T)
- S - P - S. The most common modifications that the CTD can be subjected to
are: peptidylprolyl isomerization of the Proline amino acids; glycosylation of Serine
9and Threonine; phosphorylation of Serine (Egloff and Murphy, 2008). The Serine
residues in the CTD of a RNAPII are usually hypo-phosphorylated when the en-
zyme is recruited to form a PIC. A very important stage of transcription initiation is
the phosphorylation of Serine 5 (Chapman et al., 2007). Post-transcriptional mod-
ifications of other proteins that make up the PIC also seem to be essential for a
successful transcription initiation. For example, in certain genes it is essential for
Ser65 of protein TFIIB to be phosphorylated (Wang et al., 2010).
1.3.3 Promoter-proximal pausing
A successful transcription initiation does not necessarily guarantee an immedi-
ate transition into transcription elongation. In approximately 30% of human genes,
RNAPII pauses after transcribing between 20 and 60 nucleotides. This pausing is
transient, which allows the RNAPII to resume transcription elongation (Adelman
and Lis, 2012). Evidence for promoter-proximal pausing was initially observed us-
ing UV protein-DNA crosslinking (Gilmour and Lis, 1986). The importance of this
event was only appreciated when it was observed to take place in a large number of
genes using genome-wide techniques such as RNAPII Chromatin Immunoprecipita-
tion (ChIP-chip) (Kim et al., 2005) and Global nuclear run-on sequencing (GRO-seq)
(Core et al., 2008) assays. The processes of pausing and release are regulated by two
factors. They are DRB sensitivity inducing factor (DSIF) (Wada et al., 1998a) and
negative elongation factor (NELF) (Yamaguchi et al., 1999). Release from pausing
is accomplished by phosphorylation of the DSIF/NELF complex by P-TEFb (Wada
et al., 1998b).
While it is clear that promoter-proximal pausing occurs in a wide range of eu-
karyotes, its function is still not well understood. The authors Adelman and Lis
(2012) propose four non-exclusive models for its function: (1) The presence of a
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stalled RNAPII leads to a nucleosome depleted promoter, which improves the bind-
ing of transcription factors; (2) Certain gene expression programs depend on rapid
response to stimuli. Changes in gene expression can be expedited by skipping the
PIC recruitment and transcription initiation stages. Therefore, genes with paused
RNAPII would be able to be activated more swiftly; (3) Promoter pausing is another
regulatory step in gene expression; (4) Due to co-transcriptional processing, RNAPII
is associated to several other proteins during transcription. Promoter pausing could
function as a checkpoint to determine if all necessary protein complexes were coupled
to RNAPII.
1.3.4 Transcription elongation
Transcription elongation starts when RNAPII is able to move away from the pro-
moter and into the body of the genomic feature being transcribed. As indicated
in 1.3.2, post-transcriptional modifications of RNAPII’s CTD is very important for
RNA transcription. The conventional view is that Serine 5 phosphorylation is high
around the TSS and, as RNAPII progresses through the gene, Serine 5 phosphory-
lation is lost while Serine 2 phosphorylation is gained (Egloff and Murphy, 2008).
Phosphorylation of Serine 7 seems to follow the same pattern as the observed in
Serine 5 (Glover-Cutter et al., 2009). Similarly, to Serine 2, Threonine 4 also is
phosphorylation towards the 3’ end of genes (Hintermair et al., 2012).
A large portion of the transcription elongation literature seems to heavily focus
on the release from promoter-proximal pausing (Peterlin and Price, 2006). While
this transition is very important, such studies tend to overlook the complexity of the
events that take place while RNAPII is engaged in elongation. For example, RNAPII
does not move at a constant pace during transcription elongation. Not only does the
elongation rate vary, but the enzyme can pause during elongation for several minutes
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(Darzacq et al., 2007a). These changes in elongation rate can be very important for
the fate of the RNA molecule. Co-transcriptional alternative splicing can be caused
by changing the elongation rate of RNAPII (Shukla and Oberdoerffer, 2012). This
can be achieved by causing mutations to the CTD in RNAPII that lead to slower
elongation rates (de la Mata et al., 2003) or by adding a pausing sequence a gene
(Roberts et al., 1998).
During elongation, RNAPII can pause at many sites within a gene. The pausing
seems to happen most frequently at an adenine nucleotide, which is usually followed
by a thymine and then a guanine (Churchman and Weissman, 2011). Pausing is
usually associated with backtracking of RNAPII and cleavage of the RNA molecule.
In order to backtracking take place, it is necessary to destabilize the 3-proximal
RNADNA hybrid (Nudler et al., 1997). The RNA-DNA hybrid is between 8 and
9 base pairs long and is the most important molecule to maintain the stability of
the RNAPII elongating complex (Kireeva et al., 2000). The length of the RNA-
DNA hybrid is of extreme importance. One it is shortened, RNAPII changes from
transcription elongation into transcription termination (Komissarova et al., 2002).
1.3.5 Transcription termination
Accumulation of Serine 2 phosphorylation on RNAPII’s CTD is extremely im-
portant for a successful transcription termination. In the absence of such phospho-
rylation, enzymatic complexes necessary for proper processing of the 3’ end of the
RNA molecule are not recruited (Ahn et al., 2004). A very large number of pro-
teins, more than 80, are either directly involved or associated with pre-mRNA 3’
processing (Shi et al., 2009). Depending on the biological organism and/or the type
of molecule being transcribed, there are several different pathways that are used to
achieve transcription termination. In eukaryotes, termination can happen through a
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Sen1-dependent or a Poly(A)-dependent pathway. Processing of small nucler RNA
and small nucleolar RNA is carried out by the Sen1-dependent pathway and does
not lead to polyadenylation. The Poly(A)-dependent pathway, on the other hand,
is used in the processing of mRNA and leads to polyadenylated molecules (Kuehner
et al., 2011).
1.4 Nascent RNA technologies
As discussed in 1.1, in order to carry out the work presented in this thesis, it
was necessary to study the nascent RNA expression. This was accomplished by
exposing cell cultures to bromouridine for a set amount of time. Bru is incorporated
into RNA molecules that are being synthesized during the labeling period. These
molecules can be isolated using anti-Bromodeoxyuridine (BrdU) antibodies. Analysis
of these molecules will provide information regarding RNA transcription and any
RNA processing that might have taken place during the labeling period. In addition,
including a chase period in which the Bru is washed out and cells are incubated in a
high concentration of regular uridine, allows us to study the fate of the nascent RNA
over time. Depending on how long the pulse-chase lasts, analysis of the reminiscent
labeled molecules can be used to learn more about different steps of RNA processing.
For example, a short chase might be helpful to understand RNA splicing, while a
longer can be used to measure RNA stability. The technique used in this thesis is
thoroughly described in chapters II and III. In the next sections we will discuss other
available techniques that could be used on similar studies.
1.4.1 GRO-seq
The most widely used nascent RNA sequencing technique is global run-on se-
quencing (GRO-seq) (Core et al., 2008). Nuclear run-on assays were used to mea-
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sure overall or gene-specific transcription rates for a very long time prior to the
development of GRO-seq (Hirayoshi and Lis, 1999). Nuclear run-on techniques are
based on isolating the cell’s nuclei and then allowing polymerases to move through
the DNA molecule. This happens in the presence of the detergent sarkosyl, which
inhibits the coupling to the DNA of new polymerases, but does not interfere with
the bound molecules (Gariglio and Mousset, 1975). Transcription elongation is al-
lowed to happen in vitro in the presence of a labeling agent, usually radioactive
uridine or bromouridine. Since the reaction happens in vitro, there is very little
RNA degradation during the labeling phase. Therefore, unstable RNA molecules,
such as enhancer RNA (eRNA), can be detected in greater extent than in total RNA
(Core et al., 2012). GRO-seq can also be used to gain insight into the transcription
process by interfering with gene expression prior to labeling. RNAPII transcription
elongation rates have been measured using GRO-seq by activating a cellular signaling
pathway (Danko et al., 2013) or by exposing the cells to flavopiridol (Jonkers et al.,
2014). Since the labeling happens in vitro, however, it is impossible to use GRO-seq
to analyze post-transcription RNA processing such as splicing and stability.
1.4.2 NET-seq
A lot can be learned about RNA transcription based on the distribution of RNAP
throughout the genome. RNAP ChIP-seq, for example, can be used to determine the
distribution of the complex through chromosomes, but the data does not indicate
which strand is bound by the complex and if there is active transcription happening
(Lefranc¸ois et al., 2009). In order to determine the position of actively elongating
RNAP, native elongating transcript sequencing (NET-seq) was developed. Since the
DNA-RNA-RNAP ternary complex is extremely stable (Cai and Luse, 1987), it is
possible to immunoprecipitate the whole ternary complex using antibodies specific
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for RNAP. Sequencing of the 3’ ends of the isolated RNA molecules indicates the po-
sition of RNAP at a nucleotide resolution. This technique was used to demonstrate
that there are a very high number of RNAP pause sites in yeast. Interestingly, a high
level of conservation was observed in the sequence of the identified pause sites, indi-
cating that these are not random events (Churchman and Weissman, 2011). Since
NET-seq focuses on RNA that is still bound to the ternary complex, it enriches for
unstable RNA molecules. Transcription can occur on the non-canonical direction of
a promoter, leading to the production of PROMPT or cryptic unstable transcript.
A non-essential gene deletion screening was used in combination with NET-seq to
determine that cryptic unstable transcript production is facilitated by H3K56 hyper-
acetylation (Marquardt et al., 2014).
1.4.3 Nascent-seq
Similarly to NET-seq, Nascent-seq is also based on the high stability of the DNA-
RNA-RNAP ternary complex. For Nascent-seq, however, this stability is explored
differently. The nuclei of cells are extracted and fractionated into a pellet and a su-
pernatant. The pellet contains the DNA, histones and ternary complexes, while the
supernatant contains the nonhistone proteins and RNA molecules that are not at-
tached to a ternary complex (Wuarin and Schibler, 1994). Since the RNA present in
the pellet was transcribed in vivo and is still associated to RNAPII, any modifications
to it must have occurred cotranscriptionally. Using Nascent-seq, it was estimated
that up to 13% of introns in Drosophila have poor cotranscriptional splicing. Inter-
estingly, cotranscriptional splicing was more efficient in cells expressing a RNAPII
mutant which has lower elongation rate (Khodor et al., 2011). Another type of RNA
processing is the chemical modification of adenosine into inosine by the RNA editing
enzyme ADAR (Kim et al., 1994). Nascent-seq data indicated a correlation in the
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amount of modification observed in nascent and mature RNA, demonstrating the
cotranscriptional nature of this processing event. Even though these modifications
are usually enriched in exonic regions in comparison to intronic regions, the same
study found that introns that were poorly spliced had a disproportionate amount of
adenosine into inosine modifications (Rodriguez et al., 2012).
1.4.4 Metabolic labeling
The research described in chapters II to VI is based on metabolic labeling of
nascent RNA with Bru (Paulsen et al., 2013b,a). Since this approach does not
depend on complex protocols that involved enucleation of cells (such as GRO-seq
and Nascent-seq) or immunoprecipitation of the ternary complex (such as NET-
seq), it has been implemented by several different research groups. The basic idea
is to use bromouridine or 4-thiouridine (4sU) to label the RNA produced during a
given time frame. Such approach was used to compare RNA populations between
asynchronous and G2-arrested cells. Differential expression was observed both at
the nascent and the mature RNA level, but there was only a small overlap in genes
differently regulated across these two RNA pools (Ohtsu et al., 2008).
Transcript decay can be computated by comparing the abundance of a transcript
in the nascent and in the mature RNA pools. The response to lipopolysaccharide
by bone marrowderived dendritic cells was assessed both at the nascent and mature
levels. While transcript synthesis was the main factor determining transcript abun-
dance in the mature RNA pool, transcript degradation was very important to enable
sharp changes in the mature RNA levels (Rabani et al., 2011). As it would be ex-
pected, impairment of RNA transcription and mRNA degradation lead respectively
to decreased mRNA synthesis and mRNA decay. Interestingly, impairment of RNA
transcription also affected transcript stability, while RNA transcription was affected
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by impairment of the mRNA degradation machinery (Sun et al., 2012).
The previous approaches involved comparing a transcript’s nascent expression to
its abundance in the mature RNA to calculate degradation rates. This can also be
achieved by pulse-labeling the nascent RNA for a given time and chasing the labeling
agent. By comparing the abundance of a transcript immediately after labeling to its
abundance after a period of time has passed, one can calculate how much degradation
took place within that period. This approach demonstrated that regulatory non-
coding RNA and mRNA had a shorter half-life than housekeeping RNAs (Tani et al.,
2012).
1.5 Treatments used to explore transcription
Chapter II explores the steady-state RNA synthesis and stability in several dif-
ferent cell lines. While that’s very informative, certain questions about transcription
cannot be answered unless the cell is perturbed. This allows one, for example,
to study treatment-induced changes in synthesis and stability. Furthermore, well
planned transcription disruptions can be used to learn details about specific events
in the transcription process, such as the elongation rate of RNAPII. This section
provides information on the treatments that were used to interfere with transcript
synthesis and stability in chapters III to VI.
1.5.1 Tumor Necrosis Factor (TNF)
TNF was originally discovered when it was noticed that a factor released by
activated macrophages had cytotoxic effects in neoplastic cell lines (Carswell et al.,
1975). Through decades of studying, it has been determined that TNF (and other
cytokines in the TNF superfamily) are some of the most important molecules involved
in the pro-inflammatory response (Aggarwal et al., 2012). TNF’s cellular response
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is dependent on binding to one out of two possible type I transmembrane proteins,
TNFRI or TNFRII (Hehlgans and Pfeffer, 2005). While a lot was previously known
about the effect of TNF on steady-state RNA (Tian et al., 2005), the regulatory
mechanism responsible for the changes in RNA expression were not well understood.
On the other hand, it was known that transcript stability played an important role
in the regulation of the inflammatory response (Hao and Baltimore, 2009; Anderson,
2010).
In Chapter III we explore the TNF induced effect on RNA synthesis and stability.
Cells were exposed to TNF either prior to or after Bru labeling. The exposure of
cells to TNF prior to labeling was carried out in order to determine the TNF induced
effects on gene expression. On the other hand, cells were exposed to TNF after
labeling in order to determine the effects of TNF in gene stability. The observed
results are reported in sections 3.3.7, 3.3.8 and 3.3.9. Our study was the first to
elucidate the TNF-mediated acute inflammatory response effect of RNA synthesis
and stability.
1.5.2 Ultraviolet Light
Exposure to UV light can lead to various molecular effects in a cell, many of which
are harmful. One of the immediate effects of UV exposure are DNA lesions. The most
common type of DNA damage caused by UV light are cyclobutane pyrimidine dimers
and 6-4 photoproducts. These lesions occur on neighboring pyrimidines and are most
likely to occur when these bases happen to be thymines. The number of lesions in
the genome is dependent on the UV dosage and its distribution is more or less
random (Friedberg et al., 2006). These UV-induced lesions function as a barrier for
the movement of RNAPII. When a traveling RNAPII enzyme encounters a damage
site it stalls and recruits the transcription-coupled repair complex to remove the
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damage. Independently from transcription, the global genomic machinery identifies
UV damage sites in the whole genome. (Tornaletti and Hanawalt, 1999)
We exposed cells to UVC radiation prior to bromouridine-labeling and sequencing
and reported the results in Chapter IV. Since UV-induced lesions block transcription
elongation but not transcription initiation, the sequencing signal is enriched around
TSS. In section 4.3.1, we show that this leads to greater signal around gene promoters,
which can be used to determine TSS usage in nascent RNA. Unexpectedly, UV
treatment also leads to an increase in the signal around potential enhancers identified
by the ENCODE consortium, as demonstrated in sections 4.3.7. The promoter and
enhancer aspects of this project are brought together when we demonstrate that
treatment induced changes in gene expression are correlated to changes in enhancer
RNA expression in section 4.3.8.
1.5.3 Camptothecin
DNA metabolic processes, such as transcription or replication, require the separa-
tion of the two strands of the duplex, which leads to the creation of DNA supercoiling
upstream and downstream from the polymerizing complex. DNA topoisomerases are
responsible for releasing the tension in the overwound DNA molecule. They cleave
one (or both) of the DNA’s strand, assist on the its controlled rotation and religate
the nicked DNA molecule (Wang, 2002). DNA topoisomerase I (Top1) is inhibited
by the drug camptothecin. This drug stabilizes the binding of Top1 to DNA prior
to the controlled rotation stage (Hsiang and Liu, 1988). This becomes a barrier for
the polymerizing complex which caused the tension build up in the first place. If the
enzyme involved was RNAPII, the inhibition of Top1 by camptothecin leads to an
inhibition in elongation (Ljungman and Hanawalt, 1996). Similarly, CPT treatment
can cause a replication fork to be blocked. Since CPT inhibits Top1 after the DNA
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has been nicked, the replication machinery creates a double-strand DNA break due
to the run-off from the CPT-induced single-strand DNA break. This initiates a stress
response mediated by the kinase ATM, which activates the p53 response pathway
(Pommier, 2006).
In Chapter V, we explored how camptothecin exposure affected RNA synthe-
sis. This treatment is extremely interesting, since it not only induces transcription
changes, but it also interferes with the transcription machinery. In sections 5.4.1
and 5.4.2, we discuss the effects of a one hour long exposure to camptothecin on
transcription. Another interesting aspect of this drug is that its inhibition of Top1
is reversible. In order to understand the cell’s recovery from camptothecin, the drug
was washed out and transcription was measured in the next 15 and 30 minutes. An
analysis of the recovery of gene expression after camptothecin exposure is given in
sections 5.4.3 to 5.4.5.
1.5.4 5,6-dichlorobenzimidazole 1-β-D-ribofuranoside (DRB)
As discussed in section 1.3.3, promoter-proximal pausing is regulated by DSIF and
NELF (Wada et al., 1998a; Yamaguchi et al., 1999). Phosphorylation of these factors
is necessary for the transition from early transcription initiation into productive
transcription initiation. This process is carried out by the CDK9 kinase subunit of
P-TEFb (Shandilya and Roberts, 2012). The drug 5,6-dichlorobenzimidazole 1-β-D-
ribofuranoside (DRB) inhibits the phosphorylation of DISF and NELF by binding
to CDK9 in a reversible manner (Zhu et al., 1997).
Since gene expression is not synchronized in cell cultures, certain genomic pro-
cesses are very hard to study. An example is measuring the speed at which RNAPII
translocates along a gene while transcribing it. In Chapter VI we exposed cells to
DRB for one hour in order to inhibit the transition of RNAPII from initiation to
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elongation transcription elongation. This was followed by DRB washout and im-
mediate bromouridine labeling (Singh and Padgett, 2009) during 10 minutes. This
allowed us to synchronize transcription initiation across the cells and capture the
RNA produced within those 10 minutes. In sections 6.3.1 and 6.3.2, we demonstrate
how this data was used to measure genome-wide elongation rates in five cell lines.
Furthermore, transcript elongation rates were positively correlated across these cell
lines. In sections 6.3.3 to 6.3.6 we attempt to identify genomic features that are
associated with elongation rates in order to better understand factors that influence
transcription elongation.
1.6 Bioinformatics challenges
In chapters II to VI, we use nascent RNA sequencing to explore transcription and
RNA stability. The nature of the data created by nascent RNA sequencing techniques
is very similar to that of the more commonly used RNA-seq (Nagalakshmi et al.,
2008). The RNA populations assayed by these techniques, however, can be very
different. This allows one to answer questions with nascent RNA sequencing which
would be unanswerable using RNA-seq. In order to carry out such novel research
it is necessary to develop computational tools specific for the questions being asked.
In this section, I will expose some of these challenges and explore how they were
approached.
1.6.1 Genomic read mapping
Answering the questions raised in this thesis relied heavily on the use of compu-
tational tools. Before tools could be developed to answer specific questions, it was
necessary to create an analysis pipeline to carry out the initial and general steps
to which every sample was subjected. The nascent RNA libraries were sequenced
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using Illumina HiSeq 2000 machines at the University of Michigan Sequencing Core
and downloaded into the University of Michigan Molecular and Behavioral Neuro-
science Institute computing cluster. A full description of the basic pipeline is given
in chapter II. The first step is to confirm the sequencing quality of the individual
samples using the software fastQC (Andrews, 2010). If quality control standards
are matched, the sample reads were initially mapped against the human ribosomal
DNA complete repeating unit (RefSeq ID U13369.1) using Bowtie (Langmead et al.,
2009). The reads that did not map to the ribosomal DNA were mapped against
the human genome (hg19 assembly) using TopHat (Trapnell et al., 2009). In both
cases, only reads that map uniquely, with up to two read segment mismatches, are
accepted. Several different analysis are carried out based upon the mapping results.
Most of these analysis rely greatly on standard bioinformatics and statistics tools
such as Samtools (Li et al., 2009), BEDTools (Quinlan and Hall, 2010) and R (R
Development Core Team, 2011).
1.6.2 RNA synthesis and stability measurements
RNA sequencing technologies are used to determine the abundance of RNA molecules
in a given RNA population in the cell. In very basic terms, the RNA population
of interest is isolated and its complementary DNA is sequenced and mapped to the
genome. The number of reads mapped to a region of the genome is correlated to the
amount of RNA transcripts that contain such sequence. Therefore, these techniques
allow one to quantify RNA abundance in the cell. In order to normalize expression
values to genomic feature length and library size, the reads per kilobase per million
mapped reads (RPKM) expression metric used is usually used (Mortazavi et al.,
2008). In RNA sequencing techniques that focus on mature RNA, most of the signal
accumulates in exons. Therefore, the gene annotation used is limited to the exons
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and only reads overlapping the exons are used to calculate transcription values. Due
to the presence of intronic signal in nascent RNA, we used the signal distributed
through the whole gene to determine synthesis values.
In order to calculate transcript stability, it was first necessary to measure tran-
script abundance after RNA processing and degradation took place. In our studies we
allowed six hours to pass after the initial bromouridine labeling. During this period,
most intronic signal was removed and degraded. Therefore, we measured RPKM
values for the six hours old RNA based solely on the gene’s exons annotation. In
order to calculate transcript stability, a ratio between transcript abundance in six
hour old RNA and RNA synthesis was calculated. This approach has the advantage
of estimating RNA stability based solely on two samples. In previous work, half-life
assessment was used to estimate RNA stability, which demanded a higher number
of samples (Rabani et al., 2011; Tani et al., 2012).
1.6.3 De novo discovery of transcription units
One of the greatest characteristics of high-throughput sequencing techniques is
that it allows observing genomic events in a non targeted way. Such approaches
can be used to discover splice variants, binding sites for transcription factors, 3
dimensional chromatin interactions, and many other genome-wide processes (Wang
et al., 2009; Park, 2009; Fullwood et al., 2009). In our nascent transcription studies,
we observed that RNA synthesis was not limited to sites where genes had been
previously annotated. In fact, we noticed that large transcription units existed in
regions that would previously have been considered gene deserts. In order to identify
such transcription units we used a Hidden Markov Model (HMM) (described in detail
in chapter II). The nascent RNA expression values were used to organize the genome
into segments with qualitatively different expression. This enabled us to identify
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RNA producing genomic regions lacking gene annotation.
1.6.4 Using UV-induced signal redistribution to identify active TSS and putative
enhancers
The genomic segmentation based on nascent RNA expression approach described
in section 1.6.3 is extremely useful in classifying regions according to gene expression
values. This signal becomes confounded, however, in genomic regions where overlap-
ping transcription units are active. For example, several genes present multiple tran-
script isoforms which might share different portions of the same open reading frame.
Understanding what percentage of the transcription signal is derived from which iso-
form is extremely challenging. In RNA-seq this problem is usually approached by
analyzing the number of reads overlapping transcript-specific splice junctions with
software such as Cuﬄinks (Trapnell et al., 2010). Since nascent RNA is mostly un-
spliced, such approaches would not be successful. By exposing cell cultures to UV
light prior to bromouridine labeling, we are able to redistribute the sequencing sig-
nal around active TSS (see section 1.5.2). In chapter IV we describe how this signal
accumulation can be used to identify which TSS are active. We used the widely
encompassing ENSEMBL’s gene annotation in order to assay as many known TSS
as possible (Flicek et al., 2013). Basically, a two state HMM was used to identify
a low expression pre-TSS state and a post-active TSS high expression state. When
this transition happened within 500 base pairs of an annotated TSS, we considered
it to be actively transcribing.
As discussed in section 1.6.3, due to the non targeted nature of sequencing tech-
niques, focusing solely on annotated TSS can be very limiting. By comparing regular
nascent signal with UV-irradiated nascent RNA signal, it is possible to recognize ge-
nomic regions where reads accumulated post irradiation (see chapter IV). Basically,
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a two state HMM is used to classify the genome into UV repressed and UV en-
hanced regions. The emission probabilities of UV repressed regions are based upon
the expression signal observed 20kb downstream from the TSS of expressed genes.
Most UV enhanced regions overlapped gene’s promoter regions. The signal around
a significant proportion of UV enhanced regions, however, did not resemble gene ex-
pression. Further investigation demonstrated that these sites were potentially eRNA
producing enhancers. These results indicated that UV irradiation prior to bromouri-
dine labeling lead to an increase in the eRNA signal, similarly to how it enhanced
TSS signal.
1.6.5 Measuring RNAPII elongation rate
Transcription elongation is a very important albeit poorly studied step in the tran-
scription process (see section 1.3.4). An important aspect of transcription elongation
is the rate at which RNAPII moves along the DNA molecule during transcription,
which is called the elongation rate. Several studies have attempted to measure the
elongating speed of RNAPII (Darzacq et al., 2007a; Wada et al., 2009; Singh and
Padgett, 2009; Danko et al., 2013), but these studies were carried out in a small
number of genes. In chapter VI, we arrested RNAPII at promoters for one hour.
After this, we allowed transcription elongation and bromouridine labeling to happen
during ten minutes. The goal of this analysis was to determine how far along the
gene RNAPII had moved in the 10 minutes of labeling post DRB inhibition. Identi-
fying the position of RNAPII on the genome is very challenging, therefore we used
the binned expression signal as an indicator of the presence of transcribing RNAPII.
The signal was strongest close to the promoter and steadily decreased until reaching
background levels. We measured the elongation rate by identifying where the signal
reverted to background levels. This was carried out using a three-state HMM. The
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model is described on section 6.5.5 of the thesis. Basically, it was used to identify a
region upstream from the promoter (state A), the transcription wave (state B) and
the region downstream from the elongation wave (state C). The emission probabil-
ities were calculated based on regions that displayed the signal of each state and
the transition probability was set to 10−5. The Viterbi algorithm was used to esti-
mate the most likely states in each genomic position. These algorithms were used as
implemented in the R package msm(Jackson, 2011).
1.6.6 Clustering of transcripts according to elongation rate
We used the technique described above to measure the elongation rate in five
different cell lines. We observed a positive correlation between the transcript’s elon-
gation rate across every pair-wise comparison made between these cell lines. This
prompted us to look for groups of transcripts that displayed similar elongation rate
across cells (details on section 6.5.6). The Euclidean distance of elongation rates was
used as the metric for the clustering. Due to the large size of the data set, we used
the partitioning around medoids (PAM) algorithm (implemented in(Maechler et al.,
2013)) to organize the genes into a predefined number of k = 3 clusters. Transcript’s
elongation rate across cell lines within clusters was very similar. This analysis iden-
tified groups of transcripts with high, intermediate and low elongation rates across
cell lines.
1.6.7 Correlation between elongation rate and gene features
Due to the similarities in elongation rate observed across cell lines we postu-
lated that the features present in the gene sequence could affect the elongation rate.
The idea was that RNAPII would move faster or slower while transcribing certain
sequences. If a relationship actually existed, the density of these features in the
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genomic region covered by RNAPII in a transcript during labeling would be corre-
lated to the elongation rate calculated for said transcript. This analysis was made
more challenging due to the non-random distribution of certain features through the
genome. Some features are very frequent in the proximity of promoters, so their
density is high for any transcript with small elongation rate. Therefore, a regular
regression analysis would not effectively test the correlation between these variables.
In order to test the correlation between elongation rate and gene features we used
a permutation analysis (details on section 6.5.8). Basically, a slope was calculated
for the regression between gene feature density and elongation rate (oi). Next, the
transcript’s elongation rates were randomized and the regression slope was calculated
and stored (pin). The previous step was repeated n = 2, 000 times. A p-value was
calculated by counting the percentage of the times that a value more extreme than
oi was observed within pin. Lastly, since the correlation with several different gene
features was tested, the p-values were corrected for multiple testing using the FDR
method.
CHAPTER II
Use of Bru-Seq and BruChase-Seq for genome-wide
assessment of the synthesis and stability of RNA
2.1 Abstract
Gene expression studies commonly examine total cellular RNA, which only pro-
vides information about its steady-state pool of RNA. It remains unclear whether
differences in this steady-state difference reflects variable rates of transcription or
RNA degradation. To specifically monitor RNA synthesis and degradation genome-
wide, we developed Bru-Seq and BruChase-Seq. These assays are based on metabolic
pulse-chase labeling of RNA using bromouridine (Bru). In Bru-Seq, recently labeled
RNAs are sequenced to reveal spans of nascent transcription in the genome. In
BruChase-Seq, cells are chased in uridine for different periods of time following Bru-
labeling, allowing for the isolation of RNA populations of specific ages. Here we
describe these methodologies in detail and highlight their usefulness in assessing
RNA synthesis and stability as well as splicing kinetics with examples of specific
genes from different human cell lines.
Official citation:
Paulsen, M.T., Veloso, A., Prasad, J., Bedi, K., Ljungman, E.A., Magnuson, B., Wilson, T.E., Ljungman, M. Use
of Bru-Seq and BruChase-Seq for genome-wide assessment of the synthesis and stability of RNA. Methods, In Press.
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2.2 Introduction
The steady-state level of a particular RNA in a cell is a balance between its
rates of production and degradation. Production of RNA is regulated by epige-
netic marks, transcription factors binding to enhancer and promoter elements and
by release of RNA polymerases from transcription pause sites. Regulation of tran-
scriptional elongation may also influence the output of RNA (Danko et al., 2013).
Post-transcriptional regulation of RNA is mediated by the binding of miRNA or
specific RNA-binding proteins to 3’-UTR sequences of selected transcripts to direct
the recruitment of factors involved in RNA degradation (Houseley and Tollervey,
2009). Knowing the relative contribution of RNA synthesis and degradation to the
steady-state level of particular transcripts is critical in order to better understand the
mechanisms of regulation of these transcripts. Furthermore, when cell homeostasis
is changed by environmental stimuli or stress and the steady-state levels of certain
RNAs are altered, it would be of great interest to explore whether the ensuing gene
expression changes were the result of altered RNA synthesis, stability or both.
A number of techniques have recently been developed to assess nascent RNA syn-
thesis genome-wide. In global run-on and sequencing (GRO-Seq), nuclei from a cell
sample are isolated and initiated RNA polymerases are allowed to “run-on” in vitro
in the presence of bromouridine (Core et al., 2008). RNA polymerases that were
arrested in vivo are released in vitro revealing which promoters harbored arrested
RNA polymerases. GRO-Seq also allows for the detection of unstable RNAs such as
promoter divergent transcripts since very little RNA degradation takes place in the
in vitro run-on assay (Core et al., 2012). In native elongating transcript sequencing
(NET-Seq), nascent RNA is isolated by immunoprecipitation of the RNA polymerase
29
II elongation complex followed by deep sequencing of the 3’ ends of nascent tran-
scripts associated with the RNA polymerases (Churchman and Weissman, 2011).
This technique allows for nucleotide-level resolution of nascent transcription and has
revealed that RNA polymerase II frequently pauses and backtracks when encounter-
ing nucleosomes in the bodies of genes (Churchman and Weissman, 2011). Nascent-
Seq is based on the isolation of chromatin-bound nascent RNA obtained from the
lysis of cells and washing of cell nuclei with NUN buffer consisting of high concen-
trations of NaCl, urea and NP-40 (Khodor et al., 2011). This technique has been
used to monitor the efficiency of intron splicing and has provided evidence that not
all splicing events occur co-transcriptionally. A different approach to assess nascent
transcription is through metabolic labeling of RNA with tagged ribonucleotides fol-
lowed by isolation and analysis using microarrays or deep sequencing (Ohtsu et al.,
2008; Rabani et al., 2011; Schwanhusser et al., 2011; Schwalb et al., 2012; Sun et al.,
2012). This approach has been extended to also estimate the half-lives of transcripts
by computationally comparing nascent and steady-state levels of RNA.
Bromouridine sequencing (Bru-Seq) and bromouridine-chase sequencing (BruChase-
Seq) are based on the metabolic pulse-chase labeling of nascent RNA with bromouri-
dine. Bromouridine has been used to label steady state RNA (Tani et al., 2012)
and nascent RNA (Haider et al., 1997; Ohtsu et al., 2008) both in vitro and in cells
(Core et al., 2008). While other ribonucleotide analogs, such as 4-thiouridine (4sU)
and ethynyluridine (EU), can be used to specifically label and isolate nascent RNA,
bromouridine is less toxic to cells than these other analogs (Tani et al., 2012). Fur-
thermore, the low cost of bromouridine and the availability of excellent anti-BrdU
antibodies make bromouridine labeling of nascent RNA an attractive approach to
study transcriptional and post-transcriptional regulation.
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Following labeling, Bru-containing RNA is specifically captured using anti-BrdU
antibodies conjugated to magnetic beads. cDNA libraries are then produced from
the isolated Bru-RNA and subjected to deep sequencing (Paulsen et al., 2013b). By
chasing Bru-labeled cells with uridine for different periods of time, RNA populations
of defined ages can be isolated and analyzed. This allows for the estimation of the
relative stability of all transcripts and splicing kinetics of all introns. We recently
used these techniques to obtain signatures of the TNF-induced acute inflammatory
response in human fibroblasts and found a complex pattern of altered synthesis
and/or stability of specific RNAs (Paulsen et al., 2013b). We also found interesting
patterns of synthesis, stability and splicing in untreated cells suggesting that steady-
state RNA levels are controlled by intricate transcriptional and post-transcriptional
regulation.
Here we describe Bru-Seq and BruChase-Seq in detail and show examples of how
the stability of transcripts vary in a cell type-specific manner. Furthermore, we show
that BruChase-Seq can be used to predict nonsense and frameshift mutations in genes
by revealing increased mRNA turnover rates. Finally, using segmentation analysis
of nascent transcription spans we show how Bru-Seq can detect unannotated, long
non-coding RNAs (lncRNA) with a highly cell type-specific expression pattern.
2.3 Description of Methods
The Bru-Seq and BruChase-Seq techniques were recently described (Paulsen et al.,
2013b). We will here provide a more detailed description of the materials and pro-
cedures involved in the different steps of these techniques.
2.3.1 Materials
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Buffer Composition
RPMI growth medium PMI 1640, 10% FBS, 100 U/ml penicillin,
100 U/ml streptomycin
DMEM growth medium DMEM, 10% FBS, 100 U/ml penicillin, 100
U/ml streptomycin
MEM growth medium Minimal Essential Medium, 10% FBS,
1X MEM Amino Acids, 1X Non-Essential
Amino Acids, 2 mM L-glutamine, 1X
antibiotic-antimycotic, 1X MEM vitamin
mixture, 0.15% (w/v) sodium bicarbonate
6x gel loading buffer 10mM Tris, pH 7.6, 60% glycerol, 60 mM
EDTA, 0.03% bromophenol blue
Material Supplier, catalog number
(-)-5-Bromouridine Sigma-Aldrich, 850187
Uridine Sigma, U3750
Trizol Reagent Invitrogen, 15596-018
Chloroform Fisher, BP1145
Isopropanol Sigma-Aldrich, 190764
Diethyl pyrocarbonate (DEPC) Sigma, D5758
Bovine Serum Albumin (BSA) Roche, 03116999001
Dynabeads Goat anti-Mouse IgG Invitrogen, 110.33
Mouse anti-BrdU BD Pharmingen, 555627
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Material Supplier, catalog number
RNaseOUT, Ribonuclease In-
hibitor
Invitrogen, 10777-019
Superscript II Invitrogen, 18064-014
Random Primers (3µg/µl) Invitrogen, 48190-011
100mM dNTP set Invitrogen, 10297-018
ActinomycinD Sigma, A9415
AmPure RNAclean beads Fisher, APN000494
10X NEBuffer 2 New England Biolabs, B7002S
dUTP Roche, 11934554001
RNase H Invitrogen, 18021-014
DNA Polymerase I Invitrogen, 18010-017
AmPure XP beads Fisher, NC9933872
TruSeq RNA Preparation Kit Illumina, RS-122-2001
NuSieve 3:1 agarose Lonza, 50090
10X TAE Buffer Lonza, 50844
50bp ladder Invitrogen, 10416-014
Gel Excision Tips The Gel Company, PKB6.5-R
QIAEX II Gel Extraction Kit Qiagen, 20021
USER enzyme New England Biolabs, M5505L
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2.3.2 Procedures
2.3.2.1 Cell culturing
1. Grow cells in appropriate growth medium. For this study, RPMI (BxPC3),
DMEM (Panc1, MiaPaCa2, HeLa) and MEM (NF) were used.
2. Follow normal cell culture protocols to expand cells. For most cell lines, we
recommend using 2 to 3 10-cm plates, or a minimum of 4× 106 cells per sample.
3. Cells are grown to approximately 80% confluency before the addition of bro-
mouridine.
2.3.2.2 Bromouridine labeling
• Make a stock solution of 50 mM Bromouridine in PBS
• Make a stock solution of 1 M uridine in PBS for chase (stability analysis)
• Use conditioned media for all treatments
1. Remove 3-4 ml of media from each plate of cells to a clean tube and add BrU
to a final concentration of 2 mM. Discard remaining media from plate, or save
to use for a uridine chase.
2. Add back BrU-containing media to plate and incubate at 37◦C for 30 min.
3. If doing a chase, after the 30 min incubation, rinse plate twice with PBS, then
add back saved media containing 20 mM uridine and incubate for desired time
period (6 hours may be an appropriate time to start with).
4. To collect cells (pooling plates as necessary), either add Trizol directly to the
plate to lyse cells, or trypsinize cells, spin to pellet and resuspend in 3-5 ml
Trizol. Vortex until no cell pellet is visible. Store samples at −80◦C if not
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isolating RNA immediately. We recommend collecting the cells in 14ml round-
bottom centrifuge tubes (e.g. BD 352059).
2.3.2.3 Isolation of RNA
1. To each Trizol-lysed sample, add 0.2 ml chloroform per 1ml of Trizol used ini-
tially. Cap tube and shake vigorously for 5-10 seconds. Remove cap, cover tube
with parafilm and centrifuge at 4◦C for 15 min at 12,000g in a Sorvall RC5C
floor centrifuge with SS-34 rotor (or equivalent).
2. Transfer the upper aqueous layer to a new round-bottom 14 ml tube and add
0.5 ml isopropanol per 1 ml of Trizol used initially. Cover tube with parafilm
and mix gently. Incubate at room temperature for 10 min before centrifuging
at 4◦C for 10 min at 12,000g to pellet RNA.
3. Remove supernatant and wash pellet by adding 1 ml of 75% ethanol per 1ml of
Trizol used initially. Cover tube with parafilm and centrifuge at 4◦C for 5 min
at 7,500g.
4. Remove supernatant and invert tube to allow pellet to dry slightly. Resuspend
the pellet in 200µl DEPC-water and incubate at 55◦C for 10 min to ensure
RNA is fully dissolved. Store RNA at −80◦C unless immediately proceeding to
isolation of Bru-RNA.
2.3.2.4 Preparation of magnetic beads conjugated with anti-BrdU antibodies
1. Transfer 50µl of anti-mouse IgG magnetic Dynabeads (Invitogen) per sample
to a 1.5 ml microfuge tube. Capture beads with a magnetic stand (Novagen)
and aspirate storage buffer.
2. Add 200µl 0.1% BSA in DEPC-PBS, flick the tube to resuspend beads, capture
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beads on the magnetic stand and aspirate supernatant. Repeat 2 more times
for a total of 3 washes. After the final wash, resuspend each bead pellet in 200µl
0.1% BSA in DEPC-PBS and add 0.5µl RNaseOUT.
3. To each tube, add 4µl (2µg) anti-BrdU antibody and 0.5µl (20U) RNaseOUT.
Incubate with gentle rotation for 1 hour at room temperature.
4. Wash beads 3 times with 200µl 0.1% BSA in DEPC-PBS as detailed above.
After the final wash, resuspend conjugated beads in 200µl 0.1% BSA in DEPC-
PBS and add 0.5µl RNaseOUT.
2.3.2.5 Isolation of Bru-labeled RNA
1. Heat isolated RNA in an 80◦C heat block for 10 min, then immediately put
samples on ice.
2. Remove 90% of the sample (180µl) and add to prepared beads. Flick tube to
ensure sample is mixed well and place on rotator for 1 hour at room temperature.
3. Wash beads with 0.1% BSA in DEPC-PBS for 5 minutes on the rotator. Do
2 additional brief washes with 0.1% BSA in DEPC-PBS, making sure to com-
pletely remove the final wash.
4. Resuspend the bead pellet in 40µl DEPC-water and incubate for 10 min in a
95◦C heat block to elute Bru-RNA from the beads.
5. Centrifuge tubes briefly, then capture beads in the magnetic stand.
6. Remove the supernatant to a clean 1.5 ml microfuge tube, quantitate Bru-RNA
concentrations (Nanodrop, Thermo Scientific), and store at −80◦C if not using
immediately for library preparation.
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2.3.2.6 cDNA library preparation
• Start with at least 250 ng Bru-RNA
• Unless otherwise stated, use a Thermomixer R (Eppendorf) for all incubations.
Fragment mRNA
1. Pre-mix (per sample):
(a) 8µl 5x First-strand buffer (comes with Superscript II)
(b) 1µl Random primer (3µg/µl)
2. Add 9µl of pre-mix to each PCR tube
3. Add 16µl RNA to each tube
4. Incubate in PCR machine at 85◦C for 10min. Cool down to 4◦C
Synthesize First Strand cDNA (for strand specificity)
1. Mix the following reagents (per sample):
(a) 4.0µl 100 mM DTT (comes with Superscript II)
(b) 0.8µl 25 mM dNTP
(c) 0.5µl RNaseOUT
(d) 0.8µl ActinomycinD (2.5µg/µl stock)
(e) 6.9µl ddH2O
(f) 2.0µl Superscript II
2. Add 15µl mixture to each 25µl RNA sample.
3. Incubate samples on thermal cycler using the following program:
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(a) 25◦C for 10 minutes
(b) 42◦C for 50 minutes
(c) 70◦C for 15 minutes
(d) Hold at 4◦C
Purify First Strand DNA with AMPure RNAclean beads
1. Mix 40µl cDNA mixture with 72µl RNAclean beads.
2. Bind at room temp for at least 10 min (with 500 rpm shaking).
3. Wash beads twice with 80% ethanol. Spin briefly and remove any additional
ethanol.
4. Dry beads at 37◦C for 3min.
5. Add 42µl of 5 mM Tris, pH 8.0, mix well.
6. Incubate at 28◦C for 10-15 min (with shaking).
7. Capture beads and transfer 40µl supernatant to a new tube.
Synthesize Second Strand cDNA
1. Mix the following reagents:
(a) 20µl 10X NEBuffer 2
(b) 1.2µl 25 mM dG+dA+dU+dC mix
(c) 35.3µl ddH2O
(d) 1µl RNase H
(e) 5µl DNA polymerase I
2. Add 60µl mixture to each 40µl First strand sample.
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3. Incubate samples on thermal cycler at 16◦C for 2.5 hours
Clean Up with AMPure beads
1. Vortex AMPure beads and add 150µl to each 100µl sample.
2. Pipette up and down to mix thoroughly.
3. Incubate at room temp with shaking for 10-15 min.
4. Capture beads for 5 min.
5. Remove and discard supernatant from each sample.
6. With the tubes still in the stand, add 200µl freshly prepared 80% ethanol to
each sample without disturbing the beads
7. Incubate at room temp for 30 sec, then remove and discard supernatant from
each sample.
8. Repeat steps 6 & 7 for a total of two ethanol washes.
9. Spin samples briefly and remove any remaining ethanol
10. Incubate samples at 37◦C until dry.
11. Add 62µl Resuspension Buffer (from TruSeq kit) to each sample
12. Pipette up and down to mix thoroughly.
13. Incubate samples at room temp (with shaking) for 10-15 min.
14. Place samples on magnetic stand for 5 min.
15. Transfer 60µl of the supernatant (ds cDNA) to a new tube.
*** Can stop here and store samples at −20◦C for up to seven days
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From this step (End Repair) forward, the reagents will be from Illumina’s TruSeq
Kit Perform End Repair
• Thaw End Repair Mix, Resuspension Buffer at room temperature.
• Make sure AMPure beads are at room temperature.
• Pre-heat Thermomixer to 30◦C
1. Add 40µl End Repair Mix to each 60µl sample.
2. Adjust pipette to 100µl and pipette up and down to mix thoroughly.
3. Incubate samples in Thermomixer (no shaking) at 30◦C for 30 min.
Clean Up with AMPure beads
1. Vortex AMPure beads and add 160µl to each sample.
2. Pipette up and down to mix thoroughly.
3. Incubate at room temp (with shaking) for 10-15 min.
4. Capture beads for 5 min or until liquid appears clear.
5. Remove and discard supernatant from each sample.
6. With the tubes still in the stand, add 200µl freshly prepared 80% ethanol to
each sample without disturbing the beads.
7. Incubate at room temp for 30 sec, then remove and discard supernatant from
sample.
8. Repeat steps 7 & 8 for a total of two ethanol washes.
9. Spin samples briefly and remove any remaining ethanol.
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10. Incubate samples at 37◦C until dry.
11. Resuspend the dried pellet with 20µl Resuspension Buffer.
12. Pipette up and down to mix thoroughly.
13. Incubate samples at room temp (with shaking) for 10-15 min.
14. Place samples on magnetic stand for 5 min, or until liquid appears clear
15. Transfer 17.5µl of the supernatant to a new tube.
*** Can stop here and store samples at −20◦C for up to seven days
Adenylate 3’ Ends
• Thaw Resuspension Buffer and A-Tailing Mix at room temp
• Pre-heat Thermomixer to 37◦C
1. Add 12.5µl A-Tailing Mix to each sample
2. Pipette up and down to mix thoroughly.
3. Incubate samples at 37◦C for 30 min (no shaking).
Ligate Adaptors
• Thaw RNA Adaptor Index tubes, Stop Ligation Buffer, and Resuspension Buffer
at room temp.
• Make sure AMPure beads are at room temp
• Pre-heat Thermomixer to 30◦C
1. Add 2.5µl Resuspension Buffer to each sample.
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2. Add 2.5µl Ligation Mix to each sample. (Remove Ligation Mix from −20◦C
just before using and return to −20◦C immediately after using).
3. Add 2.5µl desired RNA Adaptor Index to appropriate sample.
4. Adjust pipette to 37.5µl and pipette up and down to mix thoroughly.
5. Incubate samples in Thermomixer at 30◦C for 10 min (no shaking).
6. Add 5µl Stop Ligation Buffer to each sample.
7. Adjust pipette to 42.5µl and pipette up and down to mix thoroughly.
Clean Up with AMPure beads
1. Vortex AMPure beads and add 65µl to each sample.
2. Pipette up and down to mix thoroughly.
3. Incubate at room temp for 15 min.
4. Capture beads for 5 min or until liquid appears clear.
5. Remove and discard supernatant from each sample.
6. With the tubes still in the stand, add 200µl freshly prepared 80% ethanol to
each sample without disturbing the beads.
7. Incubate at room temp for 30 sec, then remove and discard supernatant from
sample.
8. Repeat steps 6 & 7 for a total of two ethanol washes.
9. Spin samples briefly and remove any remaining ethanol
10. Incubate samples at 37◦C until dry.
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11. Resuspend the dried pellet with 32µl 5 mM Tris.
12. Pipette up and down to mix thoroughly.
13. Incubate samples at room temp (with shaking) for 10-15 min.
14. Place samples on magnetic stand for 5 min, or until liquid appears clear
15. Transfer 30µl of the supernatant to a new tube.
*** Can stop here and store samples at −20◦C for up to seven days
Size Selection by Agarose gel electrophoresis
• Cast 3% gel using NuSieve 3:1 agarose
• Remove buffer from wells before loading
• Load order: ladder, sample, ladder, sample, ladder, sample, etc.
• Run gel in 1XTAE and do not cover gel with buffer
1. Add 5µl 6x gel loading buffer to each sample
2. Use 50 bp ladder
3. Load the gel and run at 65 V for 1hour 40min
4. Rinse gel with distilled water
5. Excise gel slices in the 300 bp region using a gel excision tip with a 1000µl
pipettor. Cut out backup gel slice as well of a 350 bp size.
6. Purify the gel slices with QIAEXII kit as follows:
(a) Add 900µl QX buffer and 10µl QIAEX II suspension beads and mix well.
(b) Incubate at 40◦C with shaking for 15 min
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(c) Spin 13,000 rpm for 30 sec. Remove supernatant
(d) Add 500µl QX, vortex, spin at 13,000 rpm for 30 sec
(e) Remove supernatant, add 500µl PE buffer, spin at 13,000 rpm for 30 sec
(f) Repeat PE wash
(g) Remove supernatant, spin again at 13,000 rpm
(h) Remove supernatant, dry beads at 37◦C until they turn white.
7. Add 22µl Resuspension Buffer to elute DNA. Mix well and incubate at room
temperature (with shaking) for 10-15 min.
8. Transfer 20µl of the supernatant to a PCR tube.
*** Can stop here and store samples at −20◦C for up to seven days
Uridine Digestion/Enrich DNA Fragments
• Thaw PCR Master Mix and PCR Primer Cocktail at room temp and spin briefly.
• Make sure AMPure beads are at room temperature.
1. Mix the following reagents (per sample):
(a) 25.0µl PCR Master Mix
(b) 5.0µl PCR Primer Cocktail
(c) 1.0µl USER enzyme
2. Add 31µl to each sample.
3. Pipette up and down to mix thoroughly
4. Incubate samples on thermal cycler using the following program:
(a) 37◦C for 15 min (uridine digestion)
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(b) 98◦C for 30 sec
(c) 15 cycles of:
i 98◦C for 10 sec
ii 60◦C for 30 sec
iii 72◦C for 30 sec
(d) 72◦C for 5 min
(e) Hold at 10◦C
Clean Up with AMPure beads
1. Vortex AMPure beads and add 50µl to each sample.
2. Pipette up and down to mix thoroughly.
3. Incubate at room temp with shaking for 10-15 min.
4. Capture beads for 5 min or until liquid appears clear.
5. Remove and discard supernatant from each sample.
6. With the tubes still in the stand, add 200µl freshly prepared 80% ethanol to
each sample without disturbing the beads.
7. Incubate at room temp for 30 sec, then remove and discard supernatant from
sample.
8. Repeat steps 6 & 7 for a total of two ethanol washes.
9. Spin samples briefly and remove any remaining ethanol
10. Incubate samples at 37◦C until dry.
11. Resuspend the dried pellet with 27µl 5mM Tris Buffer.
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12. Pipette up and down to mix thoroughly.
13. Incubate at room temp with shaking for 10-15 min.
14. Place samples on magnetic stand for 5 min, or until liquid appears clear
15. Transfer 25µl of the supernatant to a new PCR tube.
Validation
1. Use 3µl of each library to run on a thin 1.5% agarose gel to ensure there is a
single band running around 300 bp
2. Quantitate libraries using Nanodrop. Set 20µl of sample aside and save. The
rest of the samples are now ready for sequencing.
2.3.3 Deep sequencing
Sequencing can be performed using any preferred platform. We use Illumina
HiSeq 2000 via the University of Michigan Sequencing Core. We also take advantage
of cost-saving associated with sample indexing. Acceptable results can often be
obtained for most expressed genes when the reads ( 40 million at a time, in our case)
are distributed across multiple samples.
2.3.4 Data analysis pipeline
The conceptual bioinformatics approaches used in Bru-Seq and BruChase-Seq
were recently described (Paulsen et al., 2013b). Our data analysis pipeline, which
uses common bioinformatics tools for sequence read analysis (section 2.4.1) as well as
custom scripts, is implemented using the q pipeline manager (http://sourceforge.
net/projects/q-ppln-mngr/).
2.3.4.1 Major programs used
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Program Version
TopHat (Trapnell et al., 2009) v1.4.1
Bowtie (Langmead et al., 2009) v0.12.8
BEDTools (Quinlan and Hall, 2010) v2.16.2
Samtools (Li et al., 2009) v0.1.18
R (R Development Core Team, 2011) v2.15.1
DESeq (Anders and Huber, 2010) v1.4.1
2.3.4.2 Read mapping (q master map )
1. Map reads to the human ribosomal DNA complete repeating unit (U13369.1)
using Bowtie; keep rRNA read counts and non-rRNA read sequences.
2. Map non-rRNA reads to the human reference genome assembly hg19/GRCh37,
or other appropriate genome, using TopHat.
(a) Keep only reads that map uniquely, with up to two read segment mis-
matches.
(b) Reads are allowed to split between exons in RefSeq or another preferred
transcript annotation, but de novo splice junction calling is not performed
since nascent RNA reads are mainly intronic.
(c) Duplicate reads are maintained and expected in mature RNA samples where
reads cluster in exons.
2.3.4.3 Genome annotation
1. In preparation for counting, condense the RefSeq transcript isoforms of genes
into one BED file of non-redundant intron and exon spans, using create
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transcriptome map.pl (http://tewlab.path.med.umich.edu/software/utilities/
utilities.html) or another utility, so that genome bases will have only one
assigned identity.
(a) When isoforms conflict, give priority to annotation as an exon to prevent a
stable exon from being annotated as an intron.
(b) Overlapping regions of different genes are termed ambiguous and ignored
when determining the expression level of the involved genes.
2.3.4.4 Expression scoring (q master map )
1. Determine the strand-specific coverage over each genome base so that a read
might be fractionally attributed to different exons, bins or other features.
(a) Count the number of reads in a given orientation overlapping each base,
using BEDTools.
(b) Divide by the length of the sequenced reads.
2. Sum the base coverages across a given feature to determine its read coverage.
(a) For gene expression in Bru-Seq samples, calculate the RPKM using all
introns and exons.
(b) For gene expression in BruChase-Seq samples, calculate the RPKM using
all, and only, exons.
3. Similarly sum the base coverages and calculate RPKM for each 1 Kb genome
bin, or other desired bin size, in preparation for segmentation.
2.3.4.5 Combining replicates (q master merge )
1. Sum the fractional base coverages and bin coverages over all replicate samples
and recalculate feature and bin RPKM as in 2.4.4.
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2.3.4.6 Genome segmentation (q master segment )
1. Normalize the 1 kb genome bins by discarding unmappable bins and dividing
remaining bin RPKM values by the fractional mappability, determined using
extractKmers.pl or another utility, to prevent unmappable regions from breaking
contiguous transcription units.
2. Apply wavelet smoothing to the normalized bin RPKM using smooth.pl (http:
//sourceforge.net/projects/smooth-stream/) or another utility.
3. Establish the emission probabilities of a hidden Markov model:
(a) Score the bins by rounding each into one of 17 logarithmically distributed
RPKM input states.
(b) Score annotated genes by rounding each into one of 10 logarithmically dis-
tributed RPKM output states.
(c) Assign emission probabilities as the frequency of input bin states observed
over all gene output states. See Supplementary Figure S2.1.
4. Set the transition probability to 0.005 for all bins.
5. Solve the model using the Viterbi algorithm using segment.pl (http://sourceforge.
net/projects/segment-stream/) or another utility to establish the most likely
bin expression states.
6. Fuse adjacent bins of the same state into genome segments of sustained con-
tiguous expression.
2.3.4.7 Rank synthesis and stability (q master assemble )
1. Score relative synthesis by ranking the RPKM of genes, segments, or other
features obtained from nascent RNA collected immediately after Bru labeling.
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2. Score relative stability by ranking the ratio of the RPKM of features obtained
from aged RNA samples over paired nascent RNA samples.
3. Score splicing extent as intron retention, i.e. the RPKM of a specific intron
divided by the RPKM of all exons of the same gene.
2.3.4.8 Inter-sample comparisons (q master compare )
1. Apply the DESeq R package to compare the replicates that gave rise to one
merged sample to the replicates of a different merged sample of the same type
(nascent or aged).
(a) Use genes and other annotated feature as is.
(b) Split hidden Markov segments at all inter-segment boundaries encountered
in either sample to provide the complete set of potentially divergent tran-
scription segments.
2. Compare Bru-Seq samples to explore differences in nascent RNA synthesis for
genes, individual exons, or other features.
3. Compare BruChase-Seq samples to explore differences in RNA stability, but
only when both samples were split from the same Bru-labeled cell stock prior to
a manipulation that might affect transcript stability, so that the input nascent
RNA is identical.
2.4 Results
2.4.1 BruChase-Seq reveals cell type-specific regulation of RNA stability
RNA degradation is regulated by specific miRNA and RNA-binding proteins that
bind to the 3’-UTR or internal sequences of mature transcripts. By comparing
the amount of exonic RNA reads present 6 hours after Bru-labeling with the total
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amount of reads for the entire gene directly after Bru-labeling, an estimation of the
relative stability of each transcript can be made. To test whether RNA stability is
transcript-specific or whether the stabilities of specific RNAs differ in a cell type-
specific manner, we performed BruChase-Seq on a set of human cell lines. As can
be seen in Figure 2.1a, the NFKB1 transcript showed robust stability in normal
fibroblasts as determined by the relatively high exonic signal at 6 hours (red) com-
pared to the nascent transcript level (blue). However, the exonic signal was found
to be much less prominent at 6 hours in either HeLa or H146 cells (Fig. 2.1b&c).
In contrast, the transcript of DPC2 exhibited a low relative level of exonic signal
in human fibroblasts (Fig. 2.1d) while the relative exonic signal was much higher in
K562 and H146 cell lines suggesting that this transcript is more stable in these cancer
cell lines (Fig. 2.1e&f). These results demonstrate the usefulness of BruChase-Seq
in monitoring the relative stability of transcripts and indicate that the stability of
some transcripts varies in a cell type-specific manner.
2.4.2 Stability of the MYC transcript is elevated in some cancer cell lines
The expression of the oncoprotein MYC is frequently upregulated in human can-
cers. This upregulation is sometimes caused by amplification of the MYC gene and
in the case of HeLa cells is due to integration and amplification of viral regulatory
regions proximal to the MYC gene (Lazo et al., 1989; Macville et al., 1999). To
test whether MYC transcripts may be regulated at the level of stability in cancer
cells we used BruChase-Seq. The MYC transcript was found to be quite unstable
in both human fibroblasts and HeLa cells as previously shown for many cell lines
Dani et al. (1984) (Fig. 2.2a&b). However, in the pancreatic cancer cell lines BxPC3
and MiaPaCa2, the exonic reads at 6 hours were quite robust suggesting that the
MYC transcript is more stable in these cell lines as compared to human fibroblasts
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and HeLa cells. The BruChase-Seq technique thus revealed that the MYC tran-
script shows differential stability in different cell lines, suggesting that regulation of
transcript stability may contribute to MYC overexpression in human tumors.
2.4.3 Nonsense and frame-shift mutated transcripts show low stabilities
Transcripts containing premature translation termination codons are targeted by
the nonsense-mediated decay (NMD) pathway, removing these defective transcripts
through RNA degradation during attempted translation (Brogna and Wen, 2009).
To test whether BruChase-Seq can reveal a higher rate of degradation of transcripts
from genes bearing nonsense mutations, we compared the relative stabilities of RB1
mRNA in human fibroblasts, where the RB1 gene is wild-type, and in H146 cells
where it carries a nonsense mutation (CCLE, Broad Institute). The wild-type RB1
transcript had high exonic reads at 6 hours in human fibroblasts (Fig. 2.3a). How-
ever, the mutated RB1 transcript in H146 cells had a low level of exonic reads at 6
hours (Fig. 2.3b). Frameshift mutations can also lead to the formation of premature
translation termination codons activating NMD (Pereira et al., 2006; Micale et al.,
2009). The TP53 gene in H146 cells contains such a frameshift mutation Forbes
et al. (2006). To explore whether it causes the TP53 transcripts to become unstable,
we used BruChase-Seq comparing the exonic reads of TP53 in human fibroblasts
and in H146 cells. The wild-type TP53 transcripts had a high level of exonic reads
after a six-hour chase in the fibroblasts while the mutant TP53 transcript in H146
cells had much lower levels of exonic reads, demonstrating that it is much less stable
(Fig. 2.3c&d). Using the BruChase-Seq approach, we have confirmed that the sta-
bilities of mutant RB1 and TP53 transcripts in H146 cells are reduced, presumably
through the activation of NMD.
52
2.4.4 Using BruChase seq to explore splicing kinetics
A variation of BruChase-Seq is to use different durations of uridine chase to allow
RNAs of defined ages to be isolated and analyzed. This approach is very useful
when exploring post-transcriptional processing of primary transcripts. Four different
ages of RNA expressed from the CD44 gene are shown in Figure 2.4. At 0 hours
(nascent RNA), the complete and predominantly unspliced primary transcript can
be observed. After a 2-hour chase, most of the intronic signal has disappeared as a
function of splicing and degradation, while the reads covering exons and the 3’-UTR
are enhanced. One region of the CD44 transcript, however, is not processed with
the same kinetics as other regions. This represents the so called “variable region” of
the CD44 transcript, which is commonly omitted in the mature transcript of most
cell types (To¨lg et al., 1993). The variable region, notably, was still present after 4
hours, but by 6 hours it had nearly disappeared. This “retention” of the variable
region over time may be due to slow splicing of the introns in this region, which
would suggest that this process occurs post-transcriptionally. Alternatively, most of
the transcripts may have their variable regions spliced out co-transcriptionally, but
the transcripts retaining the variable region are subjected to accelerated degradation
and are lost more quickly than the fully-spliced population. A third possibility is
that the variable region is co-transcriptionally spliced but that this spliced intron
possesses a non-coding function allowing it to escape degradation. Regardless of the
mechanism, BruChase-seq allows determination of intron retention genome-wide and
should provide new insights into the regulation of splicing in human cells.
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2.4.5 Bru-Seq reveals cell type-specific expression of long, non-coding RNAs
The use of RNA-Seq technology has revealed a myriad of lncRNAs generated
throughout the genome (Wang and Chang, 2011). The functions of these RNA
species are mostly unknown. By emplying a hidden Markov model-based segmen-
tation analysis, we were able to identify transcription units independently of prior
gene annotation. We applied this method across five different cell types (human
whole blood, normal human fibroblasts and the cancer cell lines K562, BxPC3 and
Panc1) and identified numerous unannotated lncRNAs, . some of which were very
large, spanning over 100 Kb in length (Fig. 2.5a). When compared across the five
cell types, these lncRNAs exhibited distinctive cell type-specific expression patterns.
The lncRNA shown in Figure 2.5a was only found to be expressed in BxPC3 cells
while the lncRNA shown in Figure 2.5b was expressed only in whole blood cells.
Human fibroblasts contained the least (15) and K562 cells contained the most (153)
previously unannotated lncRNAs of the five cell types analyzed (Fig. 2.5c). Strik-
ingly, most of the lncRNAs were uniquely expressed in each cell line and it appeared
that the lncRNA transcripts were either highly expressed or not expressed at all
(Fig. 2.5 a&b). We conclude that Bru-Seq can be used to identify non-annotated
lncRNA genome-wide and our results suggest that these RNAs have a very strong
cell type-specific expression pattern.
2.5 Conclusions
To better understand the underlying mechanisms regulating the steady state lev-
els of RNA in cells, the contributions of both RNA synthesis and RNA degradation
must be taken into account. To study both RNA synthesis and degradation in living
cells, we developed the Bru-Seq and BruChase-Seq approaches based on metabolic
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pulse-chase labeling of nascent RNA with bromouridine Paulsen et al. (2013b). We
have here outlined these techniques in detail and have provided examples of their
usefulness in assessing RNA synthesis and RNA stability for selected genes across
multiple cell lines. The results obtained with these techniques suggest that transcript
stability is differentially regulated in different cell types. For example, NFKB1 tran-
script were turned over faster in the cancer cell lines HeLa and H146 than in normal
human fibroblasts while the DCP2 transcript is more stable in the cancer lines K562
and H146 than in the human fibroblasts. The MYC transcript was very unstable
in human fibroblasts and HeLa cells but much more stable in the cancer cell lines
BxPC3 and MiaPaCa2. BruChase-Seq also confirmed that mutations causing prema-
ture translation termination codons generate highly unstable transcripts, probably
due to the activation of NMD to degrade these defective transcripts.
Comparing RNA populations of different ages, obtained from cells chased for
different periods of time following bromouridine labeling, allows for the detailed
exploration of post-transcriptional processing events such as splicing. As an example,
BruChase-Seq revealed a much slower removal of the variable region of the CD44
compared to adjacent introns. The reason for this is not clear but it could be due
to (i) slow splicing, (ii) a faster decay of transcripts containing a retained variable
region or (iii) enhanced stability of the spliced intron, perhaps due to the presence of
a putative functional sequence. We are currently exploring the regulation of splicing
and intron retention genome-wide using BruChase-Seq.
Finally we showed examples of the power of Bru-Seq to identify nascent RNA
transcripts outside of any prior annotation via segmentation analysis. We found that
most unannotated lncRNA species were expressed in a very cell type-specific manner
when comparing across five different cell lines. The functions of these lncRNAs and
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how they are regulated are poorly understood but of great interest, and the Bru-
Seq technique is ideally suited to identify and characterize expression of these RNA
species in diverse cell types and during cellular processes such as differentiation and
transformation.
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Figure 2.1: BruChase-Seq reveals differential RNA stabilities across cell lines. (a) High exonic reads
at 6 h for the NFKB1 transcript in human broblasts indicating high relative stability. Low exonic
reads at 6 h of NFKB1 transcripts in (b) HeLa and (c) H146 cells indicating low relative stability.
(d) Low exonic reads at 6 h for the DCP2 transcript in human broblasts indicating low relative
stability. High level of exonic reads at 6 h of the DCP2 transcript in (e) K562 and (f) H146 cells
indicating relative high stability. Nascent RNA corresponds to the blue trace and the 6-h old RNA
corresponds to the red trace. The gene maps are from RefSeq Genes hg19 (UCSC genome browser
http://genome.ucsc.edu/)
57
Scale
chr8:
MYC
2 kb
Scale
chr8:
MYC
2 kb
Scale
chr8:
MYC
2 kb
Scale
chr8:
MYC
2 kb
Scale
chr8:
MYC
2 kb
Scale
chr8:
MYC
2 kb
Scale
chr8:
MYC
2 kb
Scale
chr8:
MYC
2 kb
0
5
10
15
20
25
RP
KM
0
50
100
150
200
250
300
RP
KM
0
20
40
60
80
RP
KM
0
20
40
60
80
100
RP
KM
a b
c d
NF HeLa
BxPC3 MiaPaCa2
Figure 2.2: The MYC transcript show enhanced stability in the pancreatic cancer lines BxPC3
and MiaPaCa2 as assessed by BruChase-Seq. Low relative stability of MYC transcripts found
in (a) human broblasts and (b) HeLa cells assessed by the low level of exonic reads at 6 h in
these two cell lines. High relative stability of MYC transcripts in (c) BxPC3 and (d) MiaPaCa2
assessed by BruChase-Seq. Nascent RNA corresponds to the blue trace and the 6-h old RNA
corresponds to the red trace. The gene maps are from RefSeq Genes hg19 (UCSC genome browser
http://genome.ucsc.edu/).
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Figure 2.3: Results obtained with BruChase-Seq show reduced stability of mutant transcripts. (a)
The wild-type RB1 transcript is stable in human broblasts as assessed by the high exonic reads
from the 6-h RNA sample. (b) The RB1 transcript containing a nonsense mutation in H146 cells
shows low stability as assessed by the low exonic reads from the 6-h RNA. (c) The wild-type TP53
transcript in human broblasts shows high relative stability while (d) the TP53 transcript with a
frameshift mutation in H146 cells shows low stability. Nascent RNA corresponds to the blue trace
and the 6-h old RNA corresponds to the red trace. he gene maps are from RefSeq Genes hg19
(UCSC genome browser http://genome.ucsc.edu/).
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Figure 2.4: Use of BruChase-Seq to assess splicing kinetics of the CD44 transcript. HeLa cells were
incubated with 2 mM bromouridine for 30 min to label nascent RNAfollowed by chases in uridine for
0, 2, 4 and 6 h to generate RNA populations of different ages. It can be noted that intronic sequences
that are in the region termed “variable region” are removed/degraded much slower than adjacent
intronic sequences. The gene maps are from RefSeq Genes hg19 and only one of the many isoforms
of the CD44 gene are shown for simplicity (UCSC genome browser http://genome.ucsc.edu/).
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Figure 2.5: Cell type-specic expression of non-annotated lncRNAs identied using Bru-Seq. (a)
Example of lncRNA exclusively expressed in BxPC3 cells. (b) Example of lncRNA exclusively
expressed in whole blood. (c) Table listing cell types examined, the number of non-annotated
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cell types. For simplicity, the reads in (a) and (b) are shown as positive values with transcription
going from right to left.
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Supplementary Fig. 1.  Example of the hidden Markov model emission probabilities calculated 
for sample nf0h3ab, as generated by q master ‘segment’. Each trace shows the frequency of 
different bin input states (indicated on the X axis) for each of ten different output states 
(indicated in the legend). Probabilities were trained based on observed bin RPKM in annotated 
genes and subsequently applied genome wide.  
 
Figure S2.1: Example of the hidden Markov model emission probabilities calculated for sample
nf0h3ab, as generated by q master segment. Each trace shows the frequency of different bin input
states (indicated on the X axis) for each of ten different output states (indicated in the legend).
Probabilities were trained based on observed bin RPKM in annotated genes and subsequently
applied genome wide.
CHAPTER III
Coordinated regulation of synthesis and stability of RNA
during the acute TNF-induced pro-inflammatory response
3.1 Abstract
Steady-state gene expression is a coordination of synthesis and decay of RNA
through epigenetic regulation, transcription factors, miRNAs and RNA-binding pro-
teins. Here we present Bru-Seq and BruChase-Seq to assess genome-wide changes to
RNA synthesis and stability in human fibroblasts at homeostasis and after exposure
to the pro-inflammatory tumor necrosis factor (TNF). The inflammatory response in
human cells involves rapid and dramatic changes in gene expression and the Bru-Seq
and BruChase-Seq techniques revealed a coordinated and complex regulation of gene
expression both at the transcriptional and post-transcriptional levels. The combina-
tory analysis of both RNA synthesis and stability using Bru-Seq and BruChase-Seq
allows for a much deeper understanding of mechanisms of gene regulation than af-
forded by the analysis of steady-state total RNA and should be useful in many
biological settings.
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3.2 Introduction
The acute inflammatory response is critical for the defense against infections and
in the healing of damaged tissues (Medzhitov, 2008). The orchestration of the re-
programming of gene expression associated with the acute inflammatory response is
complex and involves both transcriptional and post-transcriptional regulation (Tian
et al., 2005; Hao and Baltimore, 2009; Anderson, 2010; Khabar, 2010). Conventional
exploration of gene expression using total RNA does not fully capture this complex-
ity since it does not provide insight into the contribution of nascent RNA synthesis
or RNA decay to steady-state RNA changes. A number of different approaches have
recently been developed to assess nascent RNA synthesis in cells such as GRO-Seq
(Core et al., 2008), NET-Seq (Churchman and Weissman, 2011), NUN-RNA-Seq
(Khodor et al., 2011), and metabolic labeling of nascent RNA using microarrays
(Ohtsu et al., 2008) or RNA-Seq (Rabani et al., 2011; Schwanhusser et al., 2011).
By comparing the data obtained with metabolically labeled nascent RNA with the
steady-state RNA levels, the rates of degradation of all transcripts can be compu-
tationally estimated. The stability of steady-state RNA can also be estimated from
the decay rate of steady-state RNA following transcription inhibition (Lam et al.,
2001; Raghavan et al., 2002; Gerstein et al., 2012) or by immunoprecipitation of
metabolically labeled steady-state RNA following different chase periods (Munchel
et al., 2011; Tani et al., 2012). These approaches work well when the system is at
homeostasis but not when conditions are altered by environmental stimuli or stress,
such as the induction of the acute inflammatory response, when the rates of decay of
transcripts are expected to change (Rabani et al., 2011; Schwanhusser et al., 2011).
In this study, we present Bru-Seq and BruChase-Seq based on bromouridine
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pulse labeling of nascent RNA followed by chases in uridine to obtain RNA pop-
ulations of specific ages. The Bru-labeled RNA is then immunocaptured followed
by deep sequencing. These new techniques allowed us to assess changes in the rates
of both synthesis and degradation of RNA globally following the activation of the
pro-inflammatory response by TNF. Our results provide a comprehensive and com-
plex picture of the contribution of transcriptional and post-transcriptional regulation
during homeostasis and in the reprogramming of gene expression during the acute
TNF-induced pro-inflammatory response.
3.3 Results
3.3.1 Metabolic labeling of nascent RNA with bromouridine
To explore the contributions of both transcriptional and post-transcriptional regu-
lation to the acute pro-inflammatory response, we developed Bru-Seq and BruChase-
Seq. These approaches are based on a short labeling (30 min) of nascent RNA with
bromouridine (Bru), followed by direct isolation (Bru-Seq) or a chase in uridine for
different periods of time (BruChase-Seq). Following labeling and chase, the Bru-
containing RNA is specifically isolated from total RNA using anti-BrdU antibodies.
This material is then converted into a strand-specific cDNA library (Illumina TruSeq
RNA Sample Prep Kit) and subjected to deep sequencing (Illumina Hi-Seq) followed
by analysis of mapped read density across the reference genome (Fig. 3.1A). Bro-
mouridine has been used previously to label nascent RNA (Haider et al., 1997; Ohtsu
et al., 2008) or steady state RNA (Tani et al., 2012) in cells or in vitro (Core et al.,
2008) followed by capturing of Bru-labeled RNA using specific anti-BrdU antibodies
and it is less toxic to cells than the analogs 4-thiouridine (4sU) and ethynyluridine
(EU) (Tani et al., 2012). The BruChase-Seq approach is unique in that the nascent
RNA pool is labeled followed by uridine chases for different periods of time, making
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it possible to analyze RNA populations of distinct ages.
Incubation of human fibroblasts with 2 mM bromouridine for 30 min gave a robust
RNA incorporation as measured by immunocytochemistry using anti-BrdU antibod-
ies. As expected, this Bru incorporation was reduced by simultaneous incubation
with the transcription inhibitors actinomycin D or DRB. Moreover, removal of the
bromouridine from the culture plates followed by a chase in 20 mM uridine resulted
in the gradual disappearance of the nuclear signal as nascent RNAs are expected to
be processed and exported out of the nucleus. The retention of some Bru signal even
after a 2-hour chase is most likely due to a continuation of BrUTP incorporation
during the beginning of the chase until the supplied uridine in the chase media is
converted to UTP and to the extended time required to complete transcription of
long genes.
The capturing of Bru-labeled RNA is performed using anti-BrdU antibodies con-
jugated to magnetic beads. The amount of unlabeled RNA captured as background
with these antibody-conjugated beads was estimated to be below 0.4%. Notably, the
isolated Bru-labeled RNA had a size distribution that differed markedly from the
steady state RNA from which it was captured. This size distribution is similar to
what was reported for isolation of nuclear RNA (NUN) in Drosophila cells (Khodor
et al., 2011).
3.3.2 Bru-Seq
Sequencing and mapping of cDNA libraries prepared from nascent RNA captured
immediately after the 30 min Bru-labeling pulse (0-hour) informs on where in the
genome and at what rate transcription occurs across the cell population under study
during the labeling period (the transcriptome). As can be seen in Figure 3.1B, the
mapped reads from the nascent RNA covered entire genes, including both introns and
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exons. This is in sharp contrast to the traditional mapping of steady-state RNA,
which contains almost exclusively mature RNAs lacking intronic sequences. For
some of the genes shown, reads could be detected on the opposite strand upstream
of transcriptional start sites. This signal corresponds well to previously described
promoter upstream transcripts (PROMPTs) (Preker et al., 2008), which are typi-
cally extremely short lived and not readily detectable using steady-state RNA. This
illustrates the power of Bru-Seq for detecting unstable transcripts.
The relative rate of transcription of genes within and between samples can be
inferred by integrating the read signal throughout the gene and normalizing for the
length of the gene and the total number of reads in the library to obtain “reads per
thousand base pairs per one million reads” (RPKM). Due to ongoing splicing and
degradation of intronic sequences during the labeling period, the integrated signal
across the whole gene will be slightly underestimated. However, when the transcrip-
tion rate of a particular gene is compared between two samples, this underestimation
should not impact the estimation of the fold difference in expression between the two
samples. The results obtained with Bru-Seq were highly reproducible when compar-
ing different biological samples of the same cell line, and data from Bru-Seq correlated
well with data obtained with the established in vitro run-on technique GRO-Seq on
human lung fibroblasts. The transcriptome data for all genes (> 300bp) in human
fibroblasts using Bru-Seq can be found in table S3. The highest transcribed gene in
growing human fibroblasts was MALAT1, which encodes a nuclear ncRNA thought to
promote alternative splicing of various transcripts (Tripathi et al., 2010). Over 4,000
annotated genes ( 20%) were silent at our level of detection in human fibroblasts.
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3.3.3 BruChase-Seq
By chasing Bru-treated cells with uridine, RNA populations of defined ages can be
obtained and many features of transcription, splicing and RNA degradation can be
observed with a clarity not afforded by other techniques. We obtained similar ranking
order of the intrinsic stabilities of most transcripts using a 2-hour or a 6-hour chase.
However, since the length of a gene, i.e. the time it takes to complete transcription,
and the lag time for effective uridine quenching of the BrUTP pool may influence
the assessment of RNA stability using short chase periods, we decided to use a 6-
hour chase for all subsequent BruChase-Seq experiments. We find close correlation
between data obtained with BruChase-Seq and with BruChase-qRT-PCR. As can be
seen in Figure 3.1C, the 6h old Bru-labeled SMAD4 RNA was highly enriched for
exons, consistent with maturation by splicing. By comparing the RPKM values of
the exons in the 6h old sample with the RPKM values throughout the gene in the
nascent RNA sample, the intrinsic stability of a transcript can be estimated. An
example of a stable transcript is HIF1A (Fig. 3.1D) and an example of an unstable
transcript is BTG2 (Fig. 3.1E). A list of relative intrinsic stabilities of transcripts
in human fibroblasts can be found in table S3. Finally, highly unstable pre-miRNA
transcripts were readily detected when sequencing nascent RNA (Bru-Seq) but not
when sequencing 6h old RNA (BruChase-Seq). An example of this is shown in
Figure 3.1F for the transcript of the miR23-A, miR24-2 and miR27 cluster that has
not been completely annotated previously.
3.3.4 Genome-wide analyses
When analyzing the distribution of sequence reads throughout the genome of
human fibroblasts, 10% of the Bru-Seq reads came from exonic regions, 75% from
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intronic regions, 3% was antisense RNA and 12% came from unannotated, inter-
genic regions (Fig. 3.2A). The distribution of reads of the 6-hour old RNA with
BruChase-Seq showed that the relative abundance of exonic reads increased to 49%
while intronic reads decreased to 24% reflecting the higher stability of exons relative
to introns. Using a Hidden Markov Model (HMM) segmentation analysis to map
all transcription units independently of prior gene annotations (see Online Materials
and Methods), we were able to estimate that about 34% of the fibroblast genome
was giving rise to a detectable transcription signal while 66% of the genome did not
generate any signal detectable above background (Fig. 3.2B). Thus, at our sequenc-
ing depth and growth conditions, we estimate that the “transcriptome” in human
fibroblasts is confined to about 34% of the genome which is in concordance with re-
cent reports using a similar HMM segmentation approach for other human cell lines
(Djebali et al., 2012).
When plotting the transcriptome against the RNA stabilome of both mRNAs and
annotated ncRNAs we did not observe a clear relationship between relative transcrip-
tion rate and relative RNA stability (Fig. 3.2C). The distribution of transcription
rates and stabilities of mRNAs and annotated ncRNAs were fairly similar, suggest-
ing that synthesis and turnover of mRNA and ncRNAs may be regulated by similar
mechanisms as recently suggested (Clark et al., 2012; Tani et al., 2012). Performing
DAVID gene ontology analysis to test for gene enrichment we found that genes in-
volved in the KEGG pathway “ribosome” were significantly enriched in the highest
transcribed gene set (p-value < 6.84× 10−54) (Fig. 3.2D). Interestingly, the “ribo-
some” pathway was also highly enriched in the gene set of the least stable transcripts
(p-value < 1.37× 10−52). This finding that transcripts from ribosomal protein genes
are very unstable concur with a study in S. cerevisiae (Grigull et al., 2004) and sug-
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gests a unique mechanism whereby cells regulate ribosome biogenesis. In addition,
14 of the 100 most highly transcribed genes were found to generate transcripts that
were among the 100 least stable transcripts. These genes were CYR61, DUSP1,
DUSP6, EGR1, EID3, FAM43A, FOS, FOSB, ID1, JUN, JUNB, KLF6, MCL1, and
ZFP36.
3.3.5 Analysis of RNA synthesis and stability of mitochondrial and ribosomal RNA
The human mitochondrial genome is circular and consists of 16,569 bp encod-
ing 8 mRNAs, 2 rRNAs and 22 tRNAs (Asin-Cayuela and Gustafsson, 2007). The
observation that the steady-state levels of the individual transcripts differ greatly
despite being transcribed in a polycistronic fashion indicates that the levels of these
transcripts must be under post-transcriptional regulation (Mercer et al., 2011). Us-
ing BruChase-Seq we directly assessed the relative stability of the mitochondrial
RNAs. While the two mitochondrial-encoded ribosomal RNAs, RNR1 and RNR2,
showed high relative stability, the transcripts of the protein-coding genes were highly
unstable.
To assess the synthesis and stability of ribosomal rRNA in human fibroblasts, we
first collapsed the approximately 400 rDNA genomic repeat sequences into one rDNA
sequence and aligned all the reads to this single locus as recently described (Zentner
et al., 2011). Significant processing of intergenic spacer RNA in the primary rRNA
transcript is apparent. Due to a size selection step of cDNA prior to sequencing,
we did not obtain sufficient amounts of the short 5.8S RNA for our analysis. Using
BruChase-Seq to assess the stability of the ribosomal RNA transcripts 18S and 28S
relative to all other transcripts showed an expected high stability. When calculating
the contribution of mitochondrial and ribosomal RNA to the total pool of nascent
RNA reads, rRNA made up about 10% and mitochondrial RNA about 7%. These
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numbers increased to 38% and 9% respectively when analyzing the pool of 6-hour
old RNA reflecting their overall relative stability.
3.3.6 Intron retention
We observed a number of genes that produced transcripts where specific introns
were retained even following a 6-hour chase. A strong correlation was found between
the intron retention fraction, defined as the signal in an intron relative to the exons
of the same gene, and the fraction of reads crossing the boundaries of the intron
that were unspliced, indicating that these intronic reads originated from introns
retained in the transcripts rather than from reduced rates of degradation of spliced
introns. We found 360 introns that were retained to more than 10% in the 6-hour
old RNA. Of these introns, 116 were found on genes with at least one additional
retained intron suggesting that when one intron is poorly spliced there is a high
likelihood that an additional intron will be poorly spliced. According to DAVID
gene ontology analysis, the gene list of transcripts with retained introns was highly
enriched in “phosphoproteins” (p-value < 1.7× 10−20). We are currently analyzing
splicing kinetics genome-wide using multiple chase time points.
3.3.7 The TNF-induced transcriptome
We next applied Bru-Seq to explore alterations in the transcriptome following an
acute exposure to the inflammatory cytokine TNF in human fibroblasts. It is well
known that the pro-inflammatory response involves dramatic changes in RNA levels
in cells and these changes are thought to be due both to transcriptional and post-
transcriptional regulation (Tian et al., 2005; Hao and Baltimore, 2009; Anderson,
2010; Khabar, 2010). We first performed time course experiments with Bru-labeling
of nascent RNA and observed dramatic induction of nascent RNA synthesis already
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after 30 minutes of TNF-treatment. The induction of nascent RNA synthesis for
these genes peaked at 2 to 6 hours after addition of TNF (Fig. 3.3 A&B). Performing a
genome-wide Bru-Seq data analysis of TNF-induced and repressed genes using DESeq
analysis (Anders and Huber, 2010) we found that 472 genes were up regulated and
204 genes down regulated at least 2-fold following a one hour incubation with TNF.
Examples of up regulated genes were IL1A and IL1B while HES1 and KLF4 represent
genes down regulated at the level of RNA synthesis (Fig. 3.3C-F).
3.3.8 The TNF-induced RNA stabilome
The rapid changes in gene expression following the induction of the pro-inflammatory
response in human fibroblasts treated with TNF have been shown to depend on the
induction of synthesis of genes with low intrinsic transcript stability, (Hao and Bal-
timore, 2009). We first assessed the intrinsic stability of inflammation-associated
transcripts using the bromouridine pulse-chase strategy coupled to real-time RT-
PCR arrays and we confirmed that many of the pro-inflammatory genes generated
very unstable transcripts (Fig. 3.3G) (Hao and Baltimore, 2009). We next assessed
whether exposure to TNF may affect the stability of these transcripts in unperturbed
cells using the bromouridine pulse-chase approach. Cells were pulse-labeled for 30
min in the absence of TNF and were then chased for 6 hours in the presence or ab-
sence of TNF and as can be seen, TNF dramatically increased the stability of many
of these transcripts (Fig. 3.3H). We next used BruChase-Seq to examine the effect
of TNF on RNA stability genome-wide and detected significantly increased stabili-
ties of 152 transcripts, such as SOD2 and ICAM1 (Fig. 3.3I&J). We also observed
58 transcripts significantly destabilized by TNF treatment after Bru-labeling, such
as GAS1 and HOXA9 (Fig. 3.3K&L). Other members of the HOXA gene cluster,
such as HOXA6, HOXA11, HOXA13 and HOTAIR, also showed reduced transcript
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stability following TNF-treatment during the chase.
3.3.9 Coordinated and complex regulation of the transcriptome and RNA stabilome
after TNF
The results show that cells induce the acute pro-inflammatory response by regu-
lating both synthesis and stability of RNA. Some genes were found to be up regulated
transcriptionally, post-transcriptionally or both. Other genes were down regulated
transcriptionally, post-transcriptionally, or both, or through a mixture of up and
down regulation. We also observed dramatic induction of primary transcripts of
miR155, miR146A and miR3142 and repression of primary transcripts of miR143,
miR145 and miR614 following a 1-hour TNF treatment. MIR155 and MIR146 have
been shown to be induced by NFkB during inflammation (Taganov et al., 2006;
O’Connell et al., 2007) and MIR155 has been shown to suppress MIR143 (Jiang
et al., 2012).
Finally, in very large genes with affected transcription following TNF treatment
we could “visualize” the wave of induced or repressed transcription moving through
the gene. For the 300 kb long FNDC3B we observed that the front of the induced
transcription wave had reached about 260 kb into the gene during the 90 minute
experiment (Fig. S3.1). For the TOX gene we saw reduced RNA synthesis in the
first 180 kb into the gene suggesting reduced initiation and then the spread of reduced
transcription into the gene. The transcription signal from the SAMD4A gene showed
a “hump” suggesting that this gene was transiently induced following TNF exposure.
This illustrates the power of Bru-Seq in capturing dynamic events such as initiation
and elongation of transcription.
Performing DAVID gene ontology enrichment analysis on the genes that were
induced at the transcriptional and/or post-transcriptional level by TNF treatment
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we found a number of pathways affected by TNF (Fig 3.4). Bru-Seq showed over
470 genes induced by TNF and they were enriched in pathways that are known to
be induced as part of the acute pro-inflammatory response such as “inflammation”,
“cytokine production” and “anti-apoptosis”. In addition, Bru-Seq detected over 200
genes being repressed rapidly after TNF exposure and these genes were enriched
in pathways such as “negative regulation of transcription”, “nucleosome core” and
“ubiquitin conjugation”. Using BruChase-Seq we found that over 200 genes were
regulated post-transcriptionally following TNF treatment and some of these path-
ways were in common with those affected transcriptionally such as “inflammatory
response”, “response to wounding” and “antiapoptosis”.
3.4 Discussion
TNF is an important pro-inflammatory cytokine that mediates its biological ef-
fects by activating NFkB, AP-1 and p38 (Beg and Baltimore, 1996; Aggarwal, 2003).
NFkB and AP-1 are transcription factors regulating transcription initiation while
p38 is a kinase that has been shown to regulate mRNA stability by phosphorylating
RNA-binding proteins such as tristetraproline (TTP) (Anderson, 2010). Numerous
studies have profiled TNF-induced gene expression and mRNA stabilization in dif-
ferent cells using steady-state RNA and the transcription inhibitor actinomycin D.
However, actinomycin D induces cellular stress responses involving p53 (Ljungman
et al., 1999) and have been shown to introduce artifacts in mRNA stability deter-
minations Do¨lken et al. (2008); Munchel et al. (2011). In this study we developed
Bru-Seq and BruChase-Seq to profile the transcriptome and RNA stabilome of un-
perturbed human skin fibroblasts at homeostasis and following induction of the pro-
inflammatory response by TNF treatment. While the two new techniques confirmed
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changes to genes known to respond to TNF, which thus validated the techniques,
the novelty of this study lies in the comprehensive nature of the global analysis of
both synthesis and stability of RNA during the acute pro-inflammatory response.
Our results revealed that the TNF-induced pro-inflammatory response elicits a co-
ordinated and complex reprogramming of gene expression by induction or repression
of transcription and/or RNA stability. It was noticeable that many of the pro-
inflammatory cytokines and chemokines were induced both transcriptionally and
post-transcriptionally by TNF. It is possible that this dual induction occurs as a
result of the activation of two separate signaling arms, such as NFkB for induction
of gene-specific transcription and p38 kinase for promoting RNA stabilization via
phosphorylation of specific RNA-binding proteins. Alternatively, the reduced decay
of these transcripts may be due to “mass action” where the machinery that normally
targets these transcripts for degradation becomes overwhelmed by the dramatically
increased amounts of transcripts generated. Future studies will be aimed at distin-
guishing between these models.
The data obtained with the Bru-Seq and BruChase-Seq techniques provides a
record of both ongoing transcription (transcriptome) and the rate of decay of the
generated RNA (RNA stabilome). In addition, the approaches can determine splic-
ing efficiencies genome-wide and detect and map the generation of short-lived RNA
species such as PROMTs and pre-miRNAs. Since the Bru-Seq approach only measure
newly made RNA, rapid reduction in transcription rates can be estimated without
relying on the decay of pre-existing RNAs. Thus, our list of genes rapidly inhibited
following TNF treatment is novel and should contribute to the understanding of the
acute pro-inflammatory response. We believe that the Bru-Seq and BruChase-Seq
techniques should have a wide utility in many biological settings were transcriptional
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and post-transcriptional regulation is desired to be assessed on a genome-wide scale.
3.5 Material and Methods
3.5.1 Bromouridine pulse-chase labeling and isolation of Bru-RNA
Bromouridine (Aldrich) was added to the media of normal diploid fibroblasts to a
final concentration of 2 mM and cells were incubated at 37C for 30 min. Cells were
then washed 3 times in PBS and either collected directly (nascent RNA, Bru-Seq)
or chased in conditioned media containing 20 mM uridine for 6 hours at 37C (6-hour
old RNA, BruChase-Seq). For TNF treatments, recombinant human TNF-alpha
(R&D Systems, Minneapolis, MN) was added to a concentration of 10 ng/ml from
a 10 g/ml stock solution in PBS either one hour before (and included during) Bru-
labeling (Bru-Seq) or directly following Bru-labeling during the 6h uridine chase
(BruChase-Seq). Total RNA was isolated using TRIzol reagent (Invitrogen) and
Bru-labeled RNA was isolated from the total RNA by incubation with anti-BrdU
antibodies (BD Biosciences) conjugated to magnetic beads (Dynabeads, Goat anti-
Mouse IgG, Invitrogen) under gentle agitation at room temperature for 1 hour. For
more detail, please see Online Materials and Methods.
3.5.2 cDNA library preparation and Illumina sequencing
Isolated Bru-labeled RNA was used to prepare strand-specific DNA libraries us-
ing the Illumina TruSeq Kit (Illumina) according to the manufacturers instructions
with modifications noted in Online Materials and Methods. Sequencing of the cDNA
libraries prepared from nascent RNA or 6-hour old RNA was performed at the Uni-
versity of Michigan Sequencing Core using the Illumina HiSeq 2000 sequencer.
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3.5.3 Data analysis
Base calling was performed by the University of Michigan DNA Sequencing Core
using Illumina Casava v1.8.2. and read mapping was performed using TopHat ac-
cepting only reads that could be mapped uniquely to the genome. For determin-
ing exon, intron, and gene coverage, a single condensed transcriptome map of the
genome was constructed. Bedtools was then used to determine the coverage within
each exon and intron region, similar to base and bin coverage. Subsequently, cover-
age values for all exons of each gene were summed, as well as separately all introns
of each gene. Finally, values for all exons and all introns were summed to obtain the
coverage for the entire gene. For comparing and ranking genome feature coverage,
we calculated RPKM values as previously described (Mortazavi et al., 2008). For
identifying transcribed genome regions independently of any prior annotation, we
performed genome segmentation using a Hidden Markov model (HMM). For more
details, please see Online Materials and Methods.
3.5.4 Data availability
The primary data used in the analyses will be deposited at NCBI’s Gene Expres-
sion Omnibus.
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3.7 Online Methods
3.7.1 Cell lines, TNF treatment and bromouridine pulse-chase labeling
Diploid human foreskin fibroblasts (gift from Dr. Mary Davis, Department of
Radiation Oncology, University of Michigan) were hTERT immortalized and grown
as monolayers in MEM supplied with 10% fetal bovine serum and antibiotics (Invit-
rogen). Bromouridine (Aldrich) was added to the media to a final concentration of 2
mM and cells were incubated at 37◦C for 30 min. Cells were then washed 3 times in
PBS and either collected directly (nascent RNA, Bru-Seq) or chased in conditioned
media containing 20 mM uridine for 6 hours at 37◦C (6-hour old RNA, BruChase-
Seq). Incubation of human fibroblasts with 2 mM bromouridine for 30 min gave a
robust incorporation as measured by immunocytochemistry using anti-BrdU anti-
bodies. As expected, this Bru incorporation was blocked by simultaneous incubation
with the transcription inhibitors actinomycin D or DRB. Moreover, removal of the
bromouridine from the culture plates followed by a chase in 20 mM uridine resulted
in the gradual disappearance of nuclear signal as nascent RNAs were processed and
exported out of the nucleus. The retention of some Bru signal even after a 2-hour
chase is most likely due to the extended time needed for long genes to complete
transcription. For TNF treatments, recombinant human TNF-alpha (R&D Systems,
Minneapolis, MN) was used in a concentration of 10 ng/ml from a 10 µg/ml stock
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solution in PBS.
3.7.2 Isolation of total RNA using TRIzol reagent
Following the bromouridine labeling, the culture medium was aspirated and cells
were rinsed with PBS, trypsinized and collected in 10 ml ice-cold media and put on
ice. The cells were then counted and equal numbers of cells from each sample (at
least 2 million cells) were spun down. The medium was aspirated and the cell pellets
were resuspended in 1 ml PBS and spun again. The PBS was aspirated and the
cell pellet resuspended in 3 ml of TRIzol reagent (Invitrogen). The samples were
homogenized by vigorous pipetting and stored at −80◦C until further processing.
To isolate total RNA, the frozen samples were thawed and vortexed for 30 s. To
the 3 ml TRIzol lysates, 0.6 ml chloroform was added and the samples were shaken
vigorously for 10 s. The caps were removed and the tubes were sealed with parafilm
and centrifuged at 12,000 g for 15 min at 4◦C. The upper clear aqueous phase,
containing RNA, was transferred to new tubes and 1.5 ml of isopropanol was added
to each tube and the samples gently agitated. The tubes were sealed with parafilm
and centrifuged at 12,000 g for 10 min at 4◦C. The supernatants were aspirated and
3 ml of ice-cold 75% ethanol added to each tube and centrifuged at 7,500 g for 5 min
at 4◦C. The supernatants were carefully aspirated immediately and the tubes placed
upside down for RNA pellets to dry. The dry pellets were then dissolved in 200 µl
DEPC-treated water and the samples were heated at 55 for 10 min to fully dissolve
the RNA. From each sample, 20 µl aliquots were put aside for RNA quantification
(NanoDrop, Thermo Scientific) and for potential future analysis of steady-state RNA
levels. The total RNA samples were stored at −80◦C or directly used for Bru-labeled
RNA isolation.
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3.7.3 Conjugation of anti-BrdU antibodies to magnetic beads
Magnetic beads (Dynabeads, Goat anti-Mouse IgG, Invitrogen) in storage buffer
were transferred to Eppendorf tubes (50 µl bead slurry for each sample to be pro-
cessed). The magnetic beads were captured using a magnetic stand and the storage
buffer was aspirated. The captured beads were then washed 3 times with 0.1% BSA
in PBS and resuspended in 0.1% BSA in PBS. To each sample (50 µl of original bead
slurry), 2 µg (4µl) of anti-BrdU monoclonal antibodies (BD Biosciences) and 1 µl
RNase inhibitor (Invitrogen) were added. The magnetic beads and the antibodies
were gently mixed for 1 hr at room temperature followed by 3 washes with PBS
containing 0.1% BSA. The beads were then resuspended in PBS containing 0.1%
BSA and RNase inhibitor and the beads were distributed evenly to new tubes (200
µl/sample).
3.7.4 Isolation of Bru-containing RNA
The samples containing the isolated total RNA were heated for 10 min at 80◦C
to denature any double-stranded RNA structures. The heated RNA samples were
then added to the tubes with the prepared antibody-conjugated magnetic beads and
incubated with gentle rotation for 1 hr at room temperature. The beads were washed
3 times with 200µl PBS containing 0.1% BSA, rotating for 5 minutes for each wash.
The captured beads were resuspended in 50µl of DEPC-treated water and transferred
to new tubes to avoid any non-specific RNA adhering to the walls of the old tubes.
The samples were boiled for 10 min to release the Bru-labeled RNA and the samples
cooled and briefly centrifuged before the beads were magnetically captured. The
supernatants were transferred into new tubes and stored at −80◦C until further use.
The fraction of Bru-labeled RNA isolated in this procedure makes up 2-10% of total
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RNA depending on the cell type and chase time used.
The amount of unlabeled RNA captured as background with these antibody-
conjugated beads was estimated to be below 0.4% (table S1). Notably, the isolated
Bru- labeled RNA had a size distribution that differed markedly from the steady
state RNA from which it was captured. Very little of the immunoprecipitated RNA
was longer than the 28S rRNA (5 kb) while the average length was similar to that
of the 18S RNA (1.9 kb). This size distribution is similar to what was reported for
isolation of nuclear RNA (NUN) in Drosophila cells (Khodor et al., 2011).
3.7.5 cDNA library preparation
Bru-labeled RNA was mixed with first strand buffer and random primers and
fragmented by heating at 85◦C for 10 minutes. The first strand cDNA was then
synthesized, in the presence of Actinomycin D to result in strand specific reads when
indicated in table S2. After purifying the first strand cDNA using AMPure RNAclean
beads (Beckman Coulter), the second strand cDNA was synthesized. The resulting
cDNA was purified with AMPure XP beads, after which the Illumina TruSeq RNA
Sample Prep Kit was used to repair the cDNA ends, adenylate and ligate adaptors
to the cDNA. The samples were then run on a 3% agarose gel and size-selected by
excising gel slices in the 300bp region. These gel slices were purified using the QIAEX
II Gel Extraction Kit (Qiagen) and then the Illumina TruSeq Kit PCR reagents were
used to enrich the DNA fragments. After a final purification using AMPure XP
beads, the quality and concentration of the DNA libraries were determined using an
Agilent Bioanalyzer.
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3.7.6 Illumina Hi-Seq sequencing
Sequencing of the cDNA libraries prepared from nascent RNA or 6-hour old RNA
was performed at the University of Michigan Sequencing Core using the Illumina
HiSeq 2000 sequencer according to manufacturer guidelines.
3.7.7 Read mapping
Base calling was performed by the University of Michigan DNA Sequencing Core
using Illumina Casava v1.8.2. All steps after base calling were performed on the Linux
cluster maintained by the University of Michigan Molecular and Behavioral Neuro-
science Institute. In addition to standard Linux command line utilities, the following
software was used in the Bru-Seq and BruChase-Seq data analysis pipeline: Tophat
v1.3.2, Samtools v0.1.18. Bedtools v2.15.0, create transcriptome map.pl v1.0.0, ex-
tractKmers.pl v1.0.0, smooth.pl v1.0.0, and segment.pl v1.0.0, where the latter four
Perl scripts written for this work are available via:
http://tewlab.path.med.umich.edu/software/utilities/utilities.html.
Throughout, the reference genome was hg19/Build 37, with the NCBI RefGene
annotation of transcripts and isoforms serving as a guide to known genes.
Read mapping was performed using TopHat (Trapnell et al., 2009), accepting only
reads that could be mapped uniquely to the genome. Reads were allowed to split
between annotated exons, even for BruSeq 0-hour nascent RNA samples, but de novo
splice junction calling was not performed. A coverage determination was then made
for every base in the genome using Bedtools (Quinlan and Hall, 2010) such that a
base covered by one read was recorded as having a coverage of 1/read length. Values
for all reads covering a base were summed to obtain the total coverage, noting that
all coverage values here and below can be fractional. The genome was then grouped
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into bins by summing the base coverage over contiguous genome spans, with the bin
of a base set as round(position/bin size)*bin size. Strand reversal, to account for the
fact that the library construction caused the 1st strand cDNA to be sequenced, was
applied to all coverage files, but Tophat BAM files contain reads as initially mapped.
A description of all of the samples used and their mapping data can be found in
table S2.
3.7.8 Gene synthesis and stability
For determining exon, intron, and gene coverage, a single condensed transcrip-
tome map of the genome was constructed (create transcriptome map.pl) by merging
all annotated transcripts such that, whenever possible, each genome base on each
strand was assigned to one and only one gene region of type intergenic, exon sense,
intron sense, exon antisense, intron antisense, or ambiguous. When conflicts arose
between genes, annotation preference was given to a gene on the sense strand. Thus,
genes on opposite strands were not considered to be overlapping. When conflicts
arose between genes, or gene isoforms, on the same strand, preference was given
to annotating the base as an exon, so that no read that might be exonic would be
counted as intronic, which is important when examining BruChase-Seq data. When
conflicts could not be resolved (e.g. a region contained within an intron of two dif-
ferent genes on the same strand) the base was called ambiguous. Ambiguous regions
were omitted from all subsequent gene coverage determinations so that values in-
cluded only bases identifiable as belonging to a specific gene. Bedtools (Quinlan and
Hall, 2010) was then used to determine the coverage within each exon and intron
region, similar to base and bin coverage. Subsequently, coverage values for all exons
of each gene were summed, as well as separately all introns of each gene. Finally,
values for all exons and all introns were summed to obtain the coverage for the entire
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gene.
For comparing and ranking genome feature coverage, we calculated RPKM values
as described (Mortazavi et al., 2008). RPKM values from Bru-Seq data were taken to
reveal the relative level of nascent RNA labeling, and thus ongoing transcription, i.e.
synthesis, for different genome features or feature sets. Relative transcript stability
is expressed as the ratio of BruChase-Seq/6-hour (exons only) to Bru-Seq/0-hour
(exons plus introns) RPKM values to account for the fact that signal levels at 6-
hour post-labeling are dependent on stability as well as the very different levels
of gene synthesis during the labeling period. Gene coverage for unspliced/0-hour
samples was calculated using exons plus introns since both are present in nascent
RNAs and introns in fact typically account for the majority of a gene’s signal. In
contrast, gene coverage for spliced/6-hour samples was determined using only exons
since introns have largely been spliced away by 6-hour post-labeling and therefore
generate little or no relevant signal. Importantly, RPKM values (synthesis) or RPKM
ratios (stability) serve only to rank genes; they do not represent rates or half-lives. In
table S3, synthesis is shown for genes > 300 bp, and, for stability, where the 0-hour
RPKM value exceeded 0.5 to ensure reliable numerical assessments.
3.7.9 Genome segmentation into transcription units
For identifying transcribed genome regions independently of any prior annotation,
we performed genome segmentation using a Hidden Markov model (HMM). Bin cov-
erage values at a bin size of 1000 bp were first subjected to minimal smoothing
(smooth.pl, J=1) using the wavelet algorithm as described (Day et al., 2007). Prior
to smoothing, bins were identified for which the fraction of mappable bases was less
than 10%, where extractKmers.pl was used to parse the genome into all potential
reads for determining uniqueness at each genome position, given the requirement
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that reads map uniquely to the genome. Such bins were disregarded during seg-
mentation and the remaining bins were adjusted so that the corrected coverage =
coverage/mappable fraction. Corrected bin data were then indexed into a series of
bounded integer observation values from 0 through 17, logarithmically spaced across
bin RPKM values from < 0.0005 to > 100 (table S4). Bins with very low hit densi-
ties, including many bins with no coverage, accumulated in index 0 while rare bins
with exceptionally high hit densities accumulated in index 17. Emission probabilities
were trained from sample data and annotated genes, where the expression level of a
gene was used to infer its state index similarly to bin observations but using a smaller
set of 10 indices. A frequency distribution of the observation indices for all bins in
genes of a given state was used as the estimate of the emission probabilities. Bin
to bin transition probabilities were established by a single persistence parameter of
0.995, defined as the probability of remaining in state; all inter-state transitions were
equally weighted. The starting probability of state 0, i.e. no transcription, was esti-
mated at 0.5; all other states were equally weighted. The most likely sequence of bin
states for the resulting HMM and the set of bin observations was finally determined
using the Viterbi algorithm (segment.pl), which established genome segments of in-
ferred transcription states (table S4). Using this segmentation approach we defined
over 38,000 segments generating reads above background throughout the genome of
human fibroblasts (tables S4). These segments do not all represent unique transcrip-
tion units since some genes generate, in addition to a segment over the body of the
gene, a less intense segment covering a region of transcriptional read-through past
the 3’-end termination site.
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Figure 3.1: Comparisons of nascent and 6-h-old RNA from human fibroblasts using Bru-Seq and
BruChase-Seq. (A) Diagram illustrating the main steps in Bru-Seq and BruChase-Seq (see text
for details). (B) Sequencing reads from nascent RNA (Bru-Seq) mapping to the SMAD4 gene
with reference sequence annotation below with exons and UTRs denoted as black lines. It can
be noted that the nascent RNA maps to intronic and exonic sequences and to sequences beyond
the 3-end of the gene. Also, mapping of sequence reads on the opposite strand upstream of the
SMAD4 transcription start site represents divergent PROMPTs. (C) Sequence reads from 6-h-old
SMAD4 RNA (BruChase-Seq) (D) The ratio of the exonic signal in the 6-h old RNA to the signal
throughout the gene in the nascent RNA reflects the relative stability of the mature RNA. The
mature HIF1A transcript is an example of a stable transcript, whereas the BTG2 transcript (E) is
an example of an unstable transcript. (F) The primary transcripts of the miR24-2, miR27A, and
miR23A microRNAs are clearly captured by using Bru-Seq but not when analyzing the 6-h-old
RNA with BruChase-Seq implicating that the primary miRNA transcripts are rapidly processed
into mature miRNAs and size excluded from our analysis. The gene maps are from RefSeq Genes
(University of California, Santa Cruz (UCSC) genome browser, http://genome.ucsc.edu/)
.
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Figure 3.2: Genomic distribution of sequencing reads obtained with Bru-Seq and BruChase-Seq.
(A Left) The relative size of exonic, intronic, antisense, and intergenic compartments in the hu-
man genome. (A Center) Relative distribution of sequencing reads in these four compartments
for nascent RNA (Bru-Seq). (A Right) Relative distribution of sequencing reads from the four
different compartments for 6-h-old RNA (BruChase-Seq). (B) Assessment of the portion of the
genome generating transcripts using a HMM segmentation analysis. (C) The transcriptome vs.
the RNA stabilome with the RPKM values for synthesis (0-h) plotted against the relative stability
score (6-h/0-h) for mRNAs (gray circles) and ncRNAs (red circles). (D) KEGG pathway gene en-
richment analysis using the DAVID bioinformatics resource showing fold enrichment and P values
for pathways enriched in the top 2,000 highly transcribed genes (Top), the top 2,000 most stable
transcripts (Middle), and the 2,000 least stable transcripts (Bottom).
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Figure 3.3: Effects of TNF on the synthesis and stability of RNA. (A and B) Human fibroblasts
were treated with 10 ng/mL TNF for different periods of time at 37◦C with 2 mM bromouridine
present during the last 30 min. Total RNA was isolated and Bru-containing RNA isolated by using
anti-BrdU antibodies and analyzed by using real-time RT-PCR array technology (inflammation and
autoimmunity RT-PCR array; SABiosciences). The values represent the average of two indepen-
dent experiments. (C and D) TNF-induced transcription of IL1A and IL1B. Blue color represent
control, and yellow represent a 60+30 min treatment with TNF. (E and F) Rapid down-regulated
transcription of the HES1 and KLF4 genes by TNF. (G) Intrinsic RNA stability of inflammatory
cytokine RNAs. Human fibroblast were incubated with 2 mM bromouridine for 30 min followed by
a 6-h uridine chase, isolation of Bru-containing RNA from total RNA and real-time PCR analysis
using RT-PCR array technology (inflammation and autoimmunity RT-PCR array; SABiosciences).
The values are normalized to five housekeeping genes (5 HKG) on the array, which are set to 1.00,
and they represents the average of two independent experiments with error bars showing the SD.
(H) Same as in G but 10 ng/mL TNF was added at the beginning of the 6-h chase period. The rel-
ative abundance of a particular RNA after the 6-h chase in the presence of TNF was compared with
its relative abundance after a 6-h chase in the absence of TNF. (I and J) TNF increased stability of
the SOD2 and ICAM transcripts. Blue color represents control 6-h chase and yellow represent TNF
treatment during the 6-h chase (K and L) TNF treatment resulted in the de-stabilization of the
GAS1 and HOXA9 transcripts. The gene maps are from RefSeq Genes (UCSC genome browser,
http://genome.ucsc.edu/).
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Figure 3.4: Pathway enrichment analysis using DAVID gene ontology for genes affected transcrip-
tionally or posttranscriptionally at least twofold by TNF treatment. (A) Pathway enrichment of
genes induced transcriptionally (472 genes) or (B) posttranscriptionally (152 transcripts). (C) Path-
way enrichment for genes repressed transcriptionally (204 genes) or (D) posttranscriptionally (58
transcripts). The bars represent fold enrichment of the particular pathway and are shown in order
of significance (P values) listed on the right of the bars.
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Supplementary Figure 24. Bru-Seq analysis of TNF-treated human fibroblasts showing a wave of TNF-mediated induction and 
repression of tree large genes. (A) The FNDC3B gene is induced rapidly after exposure to TNF but since it is around 300 kb long, 
the “wave” of induced nascent RNA synthesis did not reach the end of the gene during the 90 minute treatment. (B) The synthesis 
of the TOX gene is rapidly inhibited by TNF exposure and the “wave” of reduced nascent RNA synthesis reached about 180 kb 
into the gene during the 90 minute incubation. (C) The SAMD4A gene is induced transiently by TNF treatment generating a wave 
of induced RNA synthesis with the rate of initiation returning to background levels by the end of the 90 min treatment. Blue color 
represent control and yellow represent a 60+30 min treatment with TNF. The gene maps are from RefSeq Genes (UCSC genome 
browser)
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Figure S3.1: Bru-Seq analysis of TNF-treated h an fi roblasts sho ing a wave of TNF-mediated
induction and repression of tree large genes. (A) The FNDC3B gene is induced rapidly after
exp sure to TNF but since it is around 300 kb long, the “wave” of induced nascent RNA synthesis
did not reach the end of the gene during the 90 minute treatment. (B) The synthesis of the
TOX gene is api ly inhibited by TNF exposure and th wave of reduced nasce t RNA sy thesis
reached about 180 kb into the gene during the 90 minute incubation. (C) The SAMD4A gene is
induced transiently by TNF treatment generating a wave of induced RNA synthesis with the rate of
initiation returning to background levels by the end of the 90 min treatment. Blue color represent
control and yellow represent a 60+30 min treatment with TNF. The gene maps are from RefSeq
Genes (UCSC genome browser)
CHAPTER IV
Characterization of active promoters and enhancers in
nascent RNA sequencing using BruUV-seq
4.1 Abstract
We present BruUV-seq, which utilizes UV light to introduce transcription-blocking
DNA lesions prior to bromouridine-labeling and deep sequencing of nascent RNA.
By inhibiting transcription elongation, but not initiation, pre-treatment with UV
light causes a redistribution of the mapped reads, markedly enhancing the signal
just downstream of transcription start sites (TSSs) and around active enhancers.
Using BruUV-seq we show that while the majority of expressed genes utilized a
single transcription start site (TSS), other genes had up to 5 active TSSs. Some
gene clusters were transcribed from a single TSS suggesting their organization into
operons in human cells. Furthermore, BruUV-seq identified treatment-inducible en-
hancers with increased eRNA production concomitant with up-regulation of nearby
treatment-induced genes. Taken together, BruUV-seq is a powerful new approach
for making detailed comparisons of promoter and enhancer utilization genome-wide
within and between cell types.
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4.2 Introduction
The main steps in the transcriptional cycle are initiation, elongation and termina-
tion. Initiation occurs after recruitment of RNA polymerase II to promoter elements
by transcription factors and by the aid of active enhancer elements (Lenhard et al.,
2012; Spitz and Furlong, 2012). Many genes have multiple promoter elements regu-
lated by different transcription factors and epigenetic chromatin marks that allow for
specific RNA isoform expression in different tissues or under different environmental
conditions (Sandelin et al., 2007; Lenhard et al., 2012; Sanyal et al., 2012; Core et al.,
2012). Which promoter(s) are utilized by a particular gene in a particular state is an
important predictor of its context-specific RNA and protein product(s), and methods
are required that fully reveal this variety of gene states.
Alteration in gene expression is an important strategy for cells to respond to
a particular stimulus or stress. While it takes some time for these changes to be
manifested in the total, steady-state RNA, these changes are almost immediately
reflected in the pool of nascent RNA. RNA sequencing approaches using nascent
RNA as a starting material, such as global run-on sequencing (GRO-seq) (Core et al.,
2008), precision run-on sequencing (PRO-seq) (Kwak et al., 2013) and bromouridine
labeling and sequencing (Bru-seq) (Paulsen et al., 2013b), have been developed to
specifically study this nascent RNA pool.
A number of strategies exist for identifying transcription start sites (TSS) and
enhancer elements on a genome-wide scale, but none has been optimized for nascent
RNA. One approach is ChIP-seq analysis of either transcription initiation com-
plexes (Venters and Pugh, 2013) or specific histone modifications such as H3K4me1,
H3K4me3 and H3K27ac1. ChIP-seq analysis on its own does not conclusively pro-
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vide information on promoter or enhancer usage but rather indicates the potential
of a chromatin region or transcription initiation complex to mark a TSS or enhancer
element. Another approach to identify TSS and enhancers genome-wide involves
tagging of the 5’-ends of transcripts, examples of which include “cap analysis gene
expression” (CAGE) (Shiraki et al., 2003; Valen et al., 2009), “5’-end serial anal-
ysis of gene expression” (SAGE) (Hashimoto et al., 2004) and “gene identification
signature” analysis (GIS) with “pair end tags” (PET) (Ng et al., 2005). These tech-
niques are very accurate in providing single-nucleotide resolution of TSSs, however,
since these approaches rely on steady-state RNA they cannot account for alterations
due to post-transcriptional processing. Furthermore, it has been reported that some
recapping of degradation products of mature forms of RNA may occur in the cy-
toplasm and thus, some false TSS and enhancer predictions may occur when using
CAGE-based assays (Lenhard et al., 2012).
RNA Pol II can generate RNA from enhancer elements, leading to the production
of enhancer RNA (eRNA) whose function, if any, has not yet been established.
eRNA is often transcribed from a bidirectional TSS and can be generated without
polyadenylation (Kim et al., 2010). The chromatin surrounding enhancer elements is
generally characterized by high levels of H3K4me1 and H3K27ac modifications and
binding of acetyltransferase P30 while having low levels of H3K4me3 modifications
(Zentner and Scacheri, 2012). Genome-wide annotations based on specific histone
modifications have allowed for the identification of thousands of putative enhancer
elements (Hoffman et al., 2013). However, not all putative enhancers generate eRNA.
The ones that do often score higher in in vitro assays for enhancer activity suggesting
that production of eRNA is linked to functional activity (Andersson et al., 2014).
Here we present BruUV-seq, an approach that complements the Bru-seq tech-
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nique by enhancing nascent RNA signal around promoters and enhancers genome-
wide. UVC light (254 nm) introduces predominantly cyclobutane pyrimidine dimers
and 6-4 photoproducts in DNA that are distributed more or less randomly in the
genome (Friedberg et al., 2006). These lesions are strong blocks to RNA polymerase
II elongation complexes, causing them to stall (Donahue et al., 1994; Tornaletti and
Hanawalt, 1999). In BruUV-seq, such lesions are introduced by UV irradiation prior
to the metabolic labeling of nascent RNA with bromouridine (Bru), isolation of
Bru-RNA and deep sequencing (Fig. 4.1a). Although elongating RNA polymerases
stall at UV-induced lesions within gene bodies, new initiation and transcription near
active TSS and enhancer elements is expected to continue (Donahue et al., 1994; Tor-
naletti and Hanawalt, 1999). The net result is an increase in read density at TSSs
and at enhancer elements generating eRNA. BruUV-seq can thus readily determine
how many promoters a particular gene is utilizing, identifying active enhancer ele-
ments genome-wide, and accurately determine changes in transcription levels both
at promoter and enhancer regions following exposure to a stimulus or stress.
4.3 Results
4.3.1 UV light blocks elongation and redistributes RNA reads to TSSs
It is predicted that inhibition of gene expression by UV light is proportional to
both the dose of UV light and the size of the gene. Inactivation of nascent RNA
synthesis by randomly introduced transcription-blocking lesions by UV light has
been previously used to determine genomic sizes of individual genes (Sauerbier and
Hercules, 1978). To test what effect gene size has on the inactivation of nascent RNA
synthesis on a genome-wide scale, we mock-irradiated or irradiated K562 cells with
20 J/m2 of UVC light (254 nm) and immediately labeled nascent RNA with 2 mM
bromouridine (Bru) for 30 min. Bru-labeled RNA was isolated and subjected to deep
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sequencing (see Methods and Fig. 4.1a). A strong negative correlation was observed
between the ratio of UV-irradiated to mock-irradiated RPKM values and gene size
(Fig. 4.1b). Thus, the larger the gene, the less overall signal it gives following
UV-irradiation. We also found that, similar to Bru-seq (Paulsen et al., 2013b),
BruUV-seq was highly reproducible when performed in parallel on two similarly
grown biological samples (Pearsons r=0.9971, Fig 4.1c).
We next examined the effect of UV-irradiation on the distribution of RNA reads
within genes. Genes of at least 50 kb in length were aligned by their annotated
TSSs and an aggregate view (median binned RPKM) was produced. Nascent Bru-
seq data exhibited a relatively even distribution of signal from the TSSs into the
gene (Fig. 4.1d). Following exposure to 25 J/m2 (Fig. 4.1e) or 100 J/m2 (Fig.
4.1f) of UVC radiation, the read distribution shifted markedly toward the TSSs in
a dose-dependent manner. Although some of the enhancement of reads at some
TSSs may be caused by UV-stimulated transcription initiation, the nearly uniform
redistribution of reads across all genes in the genome indicates that the effect is
strongly predominated by reduced generation of nascent RNA in gene bodies due to
the UV-induced elongation blockage. The result is a relative rather than an absolute
increase in read recovery near TSSs. Thus, we predicted that BruUV-seq could be
used to reveal TSS utilization based on the redistribution of nascent RNA reads in
the bodies of genes following UV-irradiation
4.3.2 Identification of active TSSs using BruUV-seq
To explore the behavior of individual genes, we performed Bru-seq to obtain
genome-wide transcription rates, BruUV-seq to assess TSS usage, and our previously
described BruChase-seq technique to obtain the splicing pattern of 6-hour old RNA
(Paulsen et al., 2013b,a). In genes such as TLE4, which has one putative TSS
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as predicted by its single H3K4me3 peak (Fig. 4.2a), BruUV-seq generated one
single peak at the proximal boundary of the Bru-seq signal span, demonstrating
how the phenomenon of UV-induced read redistribution enhances the signal around
the TSS of an individual gene. Together, Bru-seq, BruUV-seq and BruChase-seq
complement each other to provide a comprehensive picture of many unique aspects
of the regulation of the TLE4 gene and other genes.
The primary transcripts of miRNAs are poorly annotated because these tran-
scripts are rapidly processed into mature miRNA sequences of around 22 nucleotides
while the rest of the primary transcript is degraded. In Figure 4.2b it can be seen
that Bru-seq records a long nascent transcript emanating some 80 kb upstream of
the mature MIR138-1 DNA sequence. BruUV-seq generated a single peak coinciding
with a single H3K4me3 peak, suggesting that the TSS of the primary transcript is
indeed located 80 kb upstream of the MIR138-1 sequence. BruChase-seq confirmed
that the primary miRNA transcript was unstable since very little primary transcript
signal was detectable after a 6-hour chase.
Other genes demonstrate efficient detection of more complex and multiple TSSs.
For the divergent genes COL4A1 and COL4A2, the BruUV-seq technique readily
confirmed the presence two very closely spaced divergent TSSs in human fibroblasts
(Fig. 4.2c). For genes such as RERE for which multiple potential TSSs are suggested
by multiple H3K4me3 peaks, BruUV-seq generated peaks over all four of these sites
in human fibroblasts (Fig. 4.2d) but not in K562 cells where only three TSSs were
used (Fig. 4.2e). Moreover, the relative intensity of the individual BruUV-seq peaks
differed between the cell lines suggesting that their regulation of TSS usage differs
fundamentally. This observation was consistent with the much higher Bru-seq signal
in the proximal end of the RERE gene in K562, but only with the addition of BruUV-
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seq data could the pattern of differential promoter utilization be fully appreciated.
To determine the extent of TSS complexity genome-wide in a single sample, we
scored TSS usage at all individual genes using BruUV-seq. We found that the ma-
jority of expressed genes ( 95%) in human fibroblasts had only one active TSS, but
we identified many genes utilizing 2 to 5 TSSs (Fig. 4.2f) ( 5% with > 1 TSS).
Thus, differential promoter usage is a substantial contributor to the generation of
gene isoforms even for a given cell type in a given cell state.
Cap CAGE is a powerful technique to identify TSSs by capturing RNA molecules
via their 5’-CAP. However, existing CAGE data has been generated from steady-
state levels of RNA and is therefore not directly comparable to the nascent RNA
analysis of TSS utilization performed here using BruUV-seq. As can be seen, the
two techniques do not fully correspond to each other with some genes showing a
TSS peak for BruUV-seq but not for CAGE. It is possible that even though the
data is collected from the same cell line, different growth conditions may have lead
to differences in gene expression. Alternatively, due to fast turnover rates or lack of
5’-capping, some transcripts are not easily captured by CAGE in steady-state RNA
isolations. For these reasons we did not further compare these techniques.
4.3.3 Potential operons in human cells
Gene clusters coding for related proteins transcribed in the same orientation some-
times share a common promoter and are transcribed as a “neighborhood” or operon.
This polycistronic arrangement is common in bacteria and in some eukaryotes such
as C. elegans and Drosophila melangoster (Spieth et al., 1993; Blumenthal, 2004).
However, the evidence for the presence of operons in human cells is scarce. To iden-
tify potential operons in human cells, we compared mapped data from both Bru-seq
and BruUV-seq. We first analyzed a gene cluster coding for zinc finger proteins on
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chromosome 12 and although these genes were transcribed at similar levels and in
the same orientation, BruUV-seq revealed that each of the genes utilized their own
TSS (Fig. 4.3a). In contrast, a region on chromosome 14 encoding a large set of
snoRNAs and miRNAs appeared to be transcribed as a neighborhood from a single
common TSS (Fig. 4.3b). Furthermore, the TTTY15 and USP9Y genes on the Y
chromosome appeared to be expressed from a common TSS according to the BruUV-
seq data and the BruChase-seq data shows that the primary transcript appeared to
have been spliced within the 6-hour chase (Fig. 4.3c). Taken together, the BruUV-
seq approach clarifies where genes initiate transcription, whether multiple promoters
are used and, in combination with Bru-seq, whether genes may be organized into
neighborhoods utilizing a common promoter.
4.3.4 Use of BruUV-seq to validate gene fusions
Gene fusions are the products of aberrant recombination of normally separate
genes. Many identified gene fusions are oncogenes known to cause or contribute to
cancer (Rowley, 1973; Kumar-Sinha et al., 2006). Chronic myelogenous leukemia
(CML) is caused by a chromosomal translocation between chromosomes 9 and 22
that fuses the 5’ portion of the BCR gene to the 3’ portion of the ABL1 gene29. In
K562 cells, a CML-derived cell line known to harbor BCR-ABL, Bru-seq revealed
high BCR expression through most of the 5’-part of the gene with a drastic drop in
RNA reads at the known translocation site at the 3’-end of the gene. The ABL1
gene, on the other hand, exhibited low expression at its 5’-end, which increased
dramatically about 10 kb into the gene. In the absence of prior knowledge of a
gene fusion at this locus, the abrupt increase in signal from the ABL1 gene could be
interpreted as initiation from a strong, un-annotated promoter located in the first
intron. However, BruUV-seq showed no UV-induced peak to support this notion,
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but did identify the strong active BCR TSS known to drive BCR-ABL expression.
Thus, BruUV-seq can be used to clarify and validate the existence of gene fusions in
cells, as well as to predict the location of patient-specific translocation junctions.
4.3.5 BruUV-seq and Bru-seq signals are positively correlated
As discussed above, gene size greatly affects the relationship between gene expres-
sion when measured by Bru-seq or BruUV-seq (Figure 4.1b). We reasoned that by
using only short regions downstream of the TSS for measuring expression, this gene
size bias would be eliminated. Indeed, the ratio between Bru-seq and BruUV-seq
signal in the first 5 kb of genes was not correlated to the sizes of the genes. Fur-
thermore, the Bru-seq and BruUV-seq expression measurements within the first 5 kb
of the genes were strongly correlated. The BruUV-seq signal in the first 5 kb after
the TSS was also correlated with Bru-seq expression along the whole length of the
genes, albeit more weakly. This difference was more pronounced for genes expressing
two or more TSS. The positive correlation between the two techniques suggests that
BruUV-seq data are predictive of Bru-seq data and therefore BruUV-seq could be
used as a surrogate for nascent RNA transcription measurements with Bru-seq.
Using a restricted portion of a gene to calculate its expression value, however, is
counterintuitive since one generally wants to use all available data. To determine
if restricting the expression measurement was reasonable, we compared the amount
of variation observed in both approaches. We randomly selected a given number
of reads 10 times from both Bru-seq and BruUV-seq samples to simulate a given
read depth. The median coefficient of variation in gene expression from Bru-seq and
BruUV-seq were very similar, but consistently lower in Bru-seq, regardless of the
simulated read depth assessed. Interestingly, higher doses of UV (100 J/m2) lead
to smaller overall coefficients of variation when compared to lower doses of UV (25
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J/m2). This is likely caused by the greater accumulation of mapped reads within
the first 5 kb downstream of the TSS at higher UV doses (Fig. 4.1e&f) and suggests
that BruUV-seq performs better at higher doses of UV.
4.3.6 Using BruUV-seq to assess induced initiation of transcription
We recently used Bru-seq to investigate transcriptional changes caused by TNF-
mediated induction of the acute inflammatory response (Paulsen et al., 2013b). Here
we explored whether we could use BruUV-seq to assess changes in gene expression
following TNF treatment by measuring the signal in the first 5 kb of genes. NFKB1
is a gene that is induced 9.7-fold by TNF as assessed by Bru-seq (Fig. 4.4a). Us-
ing BruUV-seq to assess the fold difference in transcription reads over the first 5
kb between control and TNF treated cells we observed a 7.8-fold difference. The
LBH gene was found to be down-regulated 5.2-fold by TNF as measured by Bru-seq
and 4.7-fold when measured over the first 5 kb using BruUV-seq (Fig. 4.4b). The
ARHGAP24 gene showed an isoform-specific TNF-induction (Fig. 4.4c) illustrating
the usefulness of BruUV-seq to determine isoform-specific regulation of initiation.
Genome-wide comparisons of TNF-mediated changes in transcription between Bru-
seq and BruUV-seq yielded a strong correlation (Fig 4.4d). Thus, measuring changes
in transcription of the first 5 kb of genes using BruUV-seq can be used as a reason-
able surrogate for measuring changes across the whole gene with Bru-seq. This is
important for large genes, which take more time to complete synthesis following an
acute treatment. In such cases, BruUV-seq captures the induced changes in tran-
scription initiation (and early elongation) more accurately, changes that might be
missed by techniques restricted to whole genes or mature mRNAs.
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4.3.7 UV light increases read density at putative enhancer elements
It has been shown that RNA can be generated from certain putative enhancer
elements and this RNA has been termed eRNA (Kim et al., 2010). It is not well
understood how the eRNA is produced and what function it may have in regulating
genes. The fact that the eRNA is capped and the similarities between enhancers and
promoters depleted of CpG islands (Andersson et al., 2014) would suggest that active
enhancers may function as transcription initiation sites. Assuming that transcription
initiates from certain enhancers, one would expect to observe increased BruUV-seq
signal around them. Indeed, in addition to increased read density at TSSs of genes,
BruUV-seq showed enhancement of RNA reads in narrow peaks in intergenic regions.
One of these peaks was located upstream of the FOS gene in a region of a well-known
enhancer element (Fig. 4.5a). The fold enhancement of reads in this region obtained
by BruUV-seq compared with Bru-seq appeared to be much greater than could be
accounted for by simple redistribution of reads from areas of inhibited elongation
to areas downstream of TSSs. It is possible that the extremely unstable eRNA is
stabilized when associated with RNA polymerases stalled at UV-induced lesions. In
support of this are findings that Bru-labeled RNA was turned over much more slowly
if the cells were UV-irradiated after the Bru-labeling. Interestingly, certain genomic
regions had a high concentration of BruUV-seq peaks that aligned with the enhancer
signatures of high levels of H3K4me1 and H3K27ac and a low level of H3K4me3.
The area in Figure 4.5b is one of such regions that appears as an “enhancer forest”
and is located at a similar genomic position (upstream from THBS1) to a so called
super-enhancer found in mice macrophages (Whyte et al., 2013).
In order to determine if this increased signal around enhancers happened in a
genome-wide fashion, the ENCODE project’s combined genome segmentation anno-
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tation was used (Hoffman et al., 2013). An aggregate view of the reads surrounding
the intergenic enhancer regions demonstrated that the signal was bidirectional, as
expected for eRNA (Fig. 4.5c) (Kim et al., 2010). Accumulation of sequencing reads
in intergenic genomic regions classified as enhancers was greater in BruUV-seq than
in Bru-seq. Furthermore, the enhancement in eRNA signal was greater for the sam-
ple irradiated with the higher UV dose (100 J/m2) than with the lower UV dose
(25 J/m2). Importantly, BruUV-seq demonstrated a greater amount of eRNA signal
when compared to the ENCODE project’s subcellular fractionation mature RNA
libraries (ENCODE Project Consortium et al., 2012), suggesting that BruUV-seq
improves the sensitivity of eRNA detection over other approaches (Fig. 4.5d).
4.3.8 Changes in gene expression are accompanied by changes in eRNA production
A positive correlation has been observed between the levels of eRNA production
and the expression level of their closest gene (Kim et al., 2010). While it would be
reasonable to expect changes in gene expression to be correlated with similar changes
in eRNA production, this has not been conclusively shown. After TNF exposure of
human fibroblasts HF1, we observed a sharp induction of NFKB1 gene expression
as seen with Bru-seq (Fig. 4.5e) (Paulsen et al., 2013b). Using BruUV-seq we
observed two strong peaks about 40-50 kb upstream of the TSS for the NFKB1 gene
that aligned with the enhancer marks H3K4me1 and H3K27ac and the intensity of
these two peaks increased dramatically following TNF treatment. A genome-wide
approach for the identification of enhancers based on the ratio between BruUV-
seq and Bru-seq signal was carried out. Briefly, intergenic regions with BruUV-seq
signal enhancement (UVE regions) were identified using a Hidden Markov Model.
The TNF-induced change in eRNA expression in these UVE regions was correlated to
the TNF-induced change in pre-mRNA expression of their nearest gene. A positive
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correlation was observed (R=0.428), which suggests that changes in gene expression
and eRNA production are correlated genome-wide (Fig. 4.5f). Taken together,
BruUV-seq is a powerful new technique to identify both constitutive and inducible
enhancer elements genome-wide.
4.4 Discussion
Here we present BruUV-seq as a companion technique to Bru-seq where cells are
UV-irradiated prior to metabolic labeling of nascent RNA (Fig. 4.1a). Due to inhi-
bition of transcription elongation, but not transcription initiation, UV pretreatment
redistributes the bromouridine labeling of nascent RNA toward the beginning of
transcription units, and thus TSSs. In addition, ordinarily unstable RNAs appear to
be protected from degradation when persistently bound to stalled RNA polymerases,
leading to the markedly increased yields of reads corresponding to eRNAs. These
effects of UV light form the basis of the BruUV-seq approach and allow for the
identification of active TSSs and enhancer elements genome-wide.
The analysis of Bru-seq and BruUV-seq data in parallel gives novel insight into
nascent transcription and therefore context-dependent gene function. We demon-
strate on a genomic scale that transcription inhibition by UV is related to gene size,
confirming the findings by Sauerbier and Hercules (1978) when estimating genomic
sizes of individual genes (Fig. 4.1b). It has been proposed that UV light may cause
inhibition of transcription initiation (Rockx et al., 2000) but in contrast, our data
suggest that transcription elongation is the primary target of UV-mediated inactiva-
tion of transcription. We were able to identify thousands of active TSSs genome-wide
and hundreds of the genes examined presented more than one active TSS giving rise
to distinct isoforms (Fig. 4.2). We found examples of gene clusters driven by indi-
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vidual promoters (Fig. 4.3a) as well as gene clusters driven by a single TSS (Figs.
4.3b&c). Furthermore, we detected multi-TSS containing genes where the different
TSSs responded differently to a specific stimulus (e.g. Fig. 4.4c). In the K562 cell
line, BruUV-Seq confirmed the presence of the BCR-ABL gene fusion by showing
that this fusion gene initiated from a single TSS in the BCR gene.
In addition to identifying TSS usage, we found that BruUV-seq data from the
first 5 kb of genes could be used to infer transcription levels of the entire gene. This
application of BruUV-seq proved especially important for very large genes or when
genes harbor multiple active TSS, since each TSS can be identified and analyzed
independently without having to wait for mature RNAs to be formed. BruUV-seq
also enabled us to observe treatment-induced changes in eRNA production (Fig.
4.5e). The positive correlation observed in treatment-induced changes in eRNA
and pre-mRNA is extremely important since it might indicate that these in silico
identified sites are in fact regulators of the selected genes. Much effort has been
given to better understand the relationship between regulatory regions and gene
transcription using tools such as DNAse Hypersensitivity Sites (Thurman et al.,
2012), ChIA-PET (Li et al., 2012) and CAGE (Andersson et al., 2014). We believe
that the abilities of BruUV-seq to assess nascent transcription and to enrich for
nascent RNA signal in promoter and enhancer regions makes it a very powerful
technique to explore the mechanisms of gene regulation genome-wide.
4.5 Online Methods
4.5.1 Cell culturing
Human diploid foreskin fibroblasts HF1 (a gift from Mary Davis, University of
Michigan) expressing hTERT (Ljungman and Zhang, 1996; Paulsen et al., 2013b,a;
Veloso et al., 2013, 2014) were grown as monolayers in MEM supplied with 10% fetal
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bovine serum and antibiotics (Invitrogen). K562 cells were grown in suspension in
IMDM with 10% FBS.
4.5.2 UV-irradiation and bromouridine labeling of cells
The media of adherent cells grown on 100 mm plates were removed and 100 µl
of PBS was added to keep the cells from drying out during the UV-irradiation.
Suspension cells were gently pelleted and suspended in 1 ml of PBS and placed in
a 100 mm plates for UV-irradiation at room temperature. Cells were irradiated in
100 mm plates without the lid on with different doses of 254 nm UVC light. The
irradiation source (Philips, New York, NY) generated UVC light with a dose rate of 1
J/m2/s as measured with a UVX radiometer (UVP, Inc. Upland CA). Immediately
following UVC irradiation, the cells were supplied with conditioned media containing
2 mM bromouridine (BrU) (Aldrich) and they were incubated for 30 minutes to label
nascent RNA. Isolation of Bru-containing RNA, cDNA library preparations and deep
sequencing were performed as previously described (Paulsen et al., 2013b,a).
4.5.3 Read mapping and gene annotations
The sequenced reads were initially mapped to human ribosomal DNA complete
repeating unit (U13369.1). Reads that remained unaligned were mapped to the hu-
man genome hg19 build (Paulsen et al., 2013b,a). The RefSeq annotated isoforms
were merged to create a simplified annotation with one entry for each gene. This sim-
plified annotation was used for most analysis in this manuscript. The identification
of multiple TSS usage in genes was carried out using the Ensembl gene annotation
(release 69) (Flicek et al., 2013). Isoforms for a gene with a TSS within 1 kb of each
other were merged into a single isoform, and the most upstream TSS was used.
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4.5.4 Identification of active TSSs
In order to identify active TSSs, a two state Hidden Markov Model (HMM) simi-
lar to the one described by Veloso et al. (2014) was used. The goal was to determine
if a peak in the BruUV-seq signal occurred within 500 bp from the annotated TSS.
For this, the HMM model attempted to recognize a state prior to the TSS (state 1),
characterized by low expression values, and a state after the TSS (state 2), charac-
terized by a large increase in signal. The genomic region from 5 kb upstream to 5
kb downstream of the TSS was split into 250 bp bins. The expression signal within
each bin was measured for the BruUV-seq samples. The expression signal was ini-
tially quantile normalized. Next, a z-score Gamma-equivalent normalization of the
data was carried out. This normalized data was used as the observed output of the
bins. The signal from two sections, 5 kb-2 kb upstream from the TSS and 2 kb-5
kb downstream from the TSS, were used to determine the emission probabilities of
state 1 and 2 consecutively. The only possible transition between states was from 1
to 2, and its probability was set to 0.00001. The model was fit to the data and the
Viterbi algorithm was used to determine the most likely state of each bin using the
R package msm (Jackson, 2011; Maechler et al., 2013). A TSS was considered to be
active if a transition from state 1 to state 2 occurred within 500 bp of the annotated
TSS.
4.5.5 ENCODE RNA-seq data
The ENCODE’s long RNA-seq raw reads (ENCODE Project Consortium et al.,
2012) were downloaded from http://hgdownload.cse.ucsc.edu/goldenPath/hg19/
encodeDCC/wgEncodeCshlLongRnaSeq. In order to carry out a direct comparison
between Bru-seq, BruUV-seq and the ENCODE’s RNA-seq data, the ENCODE’s
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RNA-seq reads were trimmed to 52 base pairs and remapped as single-reads using
the pipeline described in (Paulsen et al., 2013b,a). The following K562 samples
were used: whole cell PolyA-minus replicates 1 and 2 (GEO ID: GSM758577); whole
cell PolyA-plus replicates 1 and 2 (GEO ID: GSM765405); chromatin bound repli-
cates 3 and 4 (GEO ID: GSM765392); nucleoplasm replicates 3 and 4 (GEO ID:
GSM765390); nucleus PolyA-minus replicates 1 and 2 (GEO ID: GSM767844); nu-
cleus PolyA-plus replicates 1 and 2 (GEO ID: GSM765387).
4.5.6 Determining eRNA expression
Two different approaches were taken to determine genomic regions that could
represent enhancers. The first approach used the ENCODE’s combined genome
segmentation data (Hoffman et al., 2013). Only segments determined to be enhancers
(class E) were used in the analysis. In the second approach, we carried a de novo
discovery of regions with BruUV-seq signal enhancement (see 4.5.7). Since we were
interested in measuring eRNA expression, it was very important to avoid mRNA
producing sites. Therefore, only intergenic sites were used. Intergenic sites were
defined as regions that did not overlap genes or their transcription units (defined in
(Paulsen et al., 2013b)). The signal within these sites was used to determine the
expression rate, measured in RPKM.
4.5.7 Identification of UV enhancement peaks
Relative to Bru-seq, BruUV-seq results in an increase in RPKM values just down-
stream of a TSS and a decrease at more distal gene positions (e.g. Fig. 4.2a), which
led us to develop a genome-wide Hidden Markov model with two states: UV enhanced
(UVE) and UV repressed (UVR). Read counts for paired Bru-seq and BruUV-seq
samples were first independently aggregated into 250 bp bins and subjected to wavelet
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smoothing. Paired data were then normalized to a common scale based on total sam-
ple read counts and the fraction of UV reads (fUV ) determined for each bin, where
each read was considered to be a Bernoulli trial with a sample-pair-dependent proba-
bility of being from the BruUV-seq sample. Bins in annotated genes with a Bru-Seq
gene RPKM of at least 0.25 that were more than 20 Kb downstream of the TSS
were then used to determine the cumulative fUV in the presumptive UVR portion
of each gene. The mean and variance of these fUV values were used to calculate the
α and β shape parameters of the binomial distribution with overdispersion of fUV ,
i.e. the beta binomial distribution, for the UVR state. Similar shape parameters
were obtained for the UVE state by reflecting the UVR beta distribution such that
bins with a high probability of being UVR had a low probability of being UVE.
Emissions probabilities for the UVR and UVE states were then calculated for each
bin using these shape parameters and the bin’s normalized Bru-seq and BruUV-seq
read counts. The Viterbi algorithm was finally solved across all genome bins using
a fixed transition probability of 0.005, with sequences of UVE bins taken as UVE
peaks. Importantly, this process only used gene annotations to train the model, and
so could detect a UVE peak at any genome location.
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Figure 4.1: Comparison of Bru-seq and BruUv-seq signal. (a) Experimental outline of the BruUV-
Seq technique. (b) Strong correlation between UV-mediated inhibition of transcription and gene
size. The ratio of integrated transcription reads over whole genes following UV-irradiation in HF1
human fibroblasts compared to mock-irradiated HF1 cells are shown on the Y-axis while gene size is
shown on the X-axis. (c) Reproducibility of BruUV-seq. The RPKM values of the first 5 kb of genes
expressed above 0.5 RPKM were compared between two biological experiments involving human
HF1 fibroblasts in which cells had been UV-irradiated, Bru-labelled and sequenced in parallel. The
Pearson’s correlation coefficient (PCC) between the two replicas was 0.9971. (d) BruUV-seq data
from K562 cells that had been mock-irradiated. (e), irradiated with 25J/m2 or (f) with 100J/m2.
The transcription reads from genes with a length of 50 kb or larger were compiled in an aggregate
view where all the genes had been lined up from their TSS and expressed as relative bin density.
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Figur 4.2: BruUV-seq identifies TSSs genome-wide. (a) BruUV-seq verifies that the TLEA4 gene
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primary transcript of MIR138-1 is initiating transcription from a single TSS about 80 kb upstream
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Figure 4.3: BruUV-seq distinguishes between gene clusters initiating from individual or common
promoters in HF1 cells. (a) Bru-seq (blue) and BruUV-seq (green) data of genes encoding the
zinc-finger proteins ZNF26, ZNF84, ZNF140, ZNF10 and ZNF268 on chromosome 12 are shown.
Each gene uses their individual TSS to direct their transcription. (b) Bru-seq and BruUV-seq data
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BruUV-seq and BruChase (6 h chase) data for the TTTY15 and USP9Y genes transcribing as an
operon from a common TSS. Note that the primary transcript appears to be spliced. The gene
maps are from RefSeq taken from the UCSC web browser.
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Figure 4.5: Use of BruUV-seq to identify active enhancer elements genome-wide. (a) Bru-seq (blue)
and BruUV-seq (green) data for the FOS gene and upstream enhancer element (red arrow) in HF1
cells. (b) Bru-seq and BruUV-seq data for a “enhancer forest” region (red arrows) upstream of the
highly expressed THBS1 gene in HF1 cells. (c) An aggregate view of the reads surrounding 526
intergenic enhancer regions as defined by the ENCODE project’s combined genome segmentation
annotation. It can be seen that the aggregate signal of eRNA was bidirectional and the enhancement
of reads was proportional to the UV dose. (d) Boxplot indicating distribution of expression values
(RPKM) observed in intergenic ENCODE defined enhancer regions in K562. Data includes BruUV-
seq, Bru-seq and ENCODE’s cellular partitioning long RNA-seq samples. (e) Comparison of Bru-seq
(top) and BruUV-seq (bottom) for the NFKB1 gene and upstream region in HF1 cells before and
after treatment with TNF for 1 hour. Enhancer elements activated by TNF are shown with red
arrows. (f) Correlation between TNF-induced changes in eRNA and mRNA expression in human
fibroblasts. Enhancers were identified using a Hidden Markov Model based on the BruUV-seq and
Bru-seq expression profiles and were assigned to their nearest genes.
CHAPTER V
Genome-Wide Transcriptional Effects of the Anti-Cancer
Agent Camptothecin
5.1 Abstract
The anti-cancer drug camptothecin inhibits replication and transcription by trap-
ping DNA topoisomerase I (Top1) covalently to DNA in a “cleavable complex”. To
examine the effects of camptothecin on RNA synthesis genome-wide we used Bru-Seq
and show that camptothecin treatment primarily affected transcription elongation.
We also observed that camptothecin increased RNA reads past transcription termi-
nation sites as well as at enhancer elements. Following removal of camptothecin,
transcription spread as a wave from the 5’-end of genes with no recovery of tran-
scription apparent from RNA polymerases stalled in the body of genes. As a result,
camptothecin preferentially inhibited the expression of large genes such as proto-
oncogenes, and anti-apoptotic genes while smaller ribosomal protein genes, pro-
apoptotic genes and p53 target genes showed relative higher expression. Cockayne
syndrome group B fibroblasts (CS-B), which are defective in transcription-coupled
repair (TCR), showed an RNA synthesis recovery profile similar to normal fibroblasts
suggesting that TCR is not involved in the repair of or RNA synthesis recovery from
Official citation:
Veloso, A., Biewen, B., Paulsen, M.T., Berg, N., Carmo de Andrade Lima, L., Prasad, J., Bedi, K., Magnuson, B.,
Wilson, T.E., Ljungman, M. Genome-Wide Transcriptional Effects of the Anti-Cancer Agent Camptothecin. PLoS
ONE, 2013 8(10): e78190. doi:10.1371/journal.pone.0078190
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transcription-blocking Top1 lesions. These findings of the effects of camptothecin on
transcription have important implications for its anti-cancer activities and may aid
in the design of improved combinatorial treatments involving Top1 poisons.
5.2 Introduction
DNA topoisomerase I (Top1) relaxes torsional tension that is generated in the
DNA helix as a consequence of replication, transcription and chromatin remodel-
ing (Liu and Wang, 1987; Pommier, 2006). The Top1-mediated reaction involves
the covalent binding to DNA, cleavage of one strand of the DNA helix followed by
the passing of the other strand through the break and finally the resealing of the
DNA strand break. The anti-cancer drug camptothecin specifically inhibits Top1
(Hsiang and Liu, 1988) by acting prior to the resealing step, effectively trapping
Top1 covalently bound to the DNA in a “cleavable complex”. Camptothecin and
other Top1 poisons are used for the treatment of ovarian, cervical, colon, pancreatic,
lung, breast, prostate and brain cancers (Pommier, 2013). The anti-cancer activity of
camptothecin is thought to be linked to replication-mediated toxicity (Hsiang et al.,
1989). However, the inhibitory effect of camptothecin on transcription has also been
acknowledged to contribute to toxicity especially in non-dividing cells (Wu and Liu,
1997).
It has been shown that camptothecin-stabilized Top1-DNA complexes retard elon-
gation but not initiation of transcription (Ljungman and Hanawalt, 1996). In re-
sponse to transcription blockage, Top1 is targeted for degradation in an ubiquitin-
dependent manner (Desai et al., 1997) and subsequent residual DNA-bound amino
acid residues may require the action of tyrosyl-DNA phosphodiesterase 1 (TDP1) for
their removal in order for transcription elongation to resume (Plo et al., 2003). Block-
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age of the transcription machinery by Top1 complexes trapped on DNA by camp-
tothecin have been shown to lead to the induction of DNA double strand breaks (Wu
and Liu, 1997) and the formation of DNA-RNA hybrid structures (R-loops) activat-
ing the stress kinase ATM (Sordet et al., 2009; Sakasai et al., 2010). Furthermore,
this transcription stress results in activation of the p53 response pathway (Ljung-
man et al., 1999, 2001; Ljungman and Lane, 2004; Lin et al., 2013) and induction
of 53BP1-mediated DNA damage processing (Sakai et al., 2012). Top2 and PARP1
play overlapping roles to Top1 in non-dividing cells. Combination of Top1 and Top2
or PARP-targeting drugs may be effective in non-dividing tumor cells (Lin et al.,
2013).
Following camptothecin reversal the topoisomerase reaction is completed and tran-
scription complexes are thought to resume elongation. Interestingly, RNA synthesis
recovery from the Dhfr gene in CHO cells following camptothecin removal was found
to resume as a wave in a 5’-3’ direction with no apparent recovery downstream in the
gene suggesting that transcription complexes blocked by trapped Top1 complexes are
unable to resume elongation in this gene following camptothecin reversal (Ljungman
and Hanawalt, 1996). Cells derived from patients with Cockayne’s syndrome (CS)
are hypersensitive to CPT due to more double strand breaks induced during S-phase
(Squires et al., 1993). The CSB protein has been suggested to be involved in the
repair of covalently DNA-linked Top1 (Horibata et al., 2011) and this may explain
why the recovery of total RNA synthesis slower in CS cells (Squires et al., 1993;
Horibata et al., 2011; Lin et al., 2013). However, other studies have found no defect
in RNA synthesis recovery following CSB knockdown (Sakai et al., 2012).
In this study, we explored the effects of camptothecin on RNA synthesis genome-
wide using Bru-Seq. This technique is based on the metabolic labeling of RNA
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using bromouridine (Bru) followed by specific isolation of Bru-labeled nascent RNA,
library preparation and deep sequencing Paulsen et al. (2013b). Our results show
that the Top1 inhibitor camptothecin affects many aspects of transcription where
blockage of transcription elongation combined with the apparent lack of recovery of
synthesis from RNA polymerases blocked in the body of the genes cases a preferential
inhibition of expression of large genes. Furthermore, we find no defect in RNA
synthesis recovery in CS-B cells following camptothecin reversal suggesting that TCR
may not be required for this recovery.
5.3 Materials and Methods
5.3.1 Cell lines, camptothecin treatment and Bru-Seq
hTERT immortalized diploid human foreskin fibroblasts (gift from Dr. Mary
Davis, Department of Radiation Oncology, University of Michigan) (Ljungman and
Zhang, 1996; Ljungman et al., 1999) and CS-B fibroblasts (GM00739, Coriell Cell
Repository) were grown as monolayers in MEM supplied with 10% fetal bovine serum
and antibiotics (Invitrogen). Cells were treated for 45 min with 20µM camptothecin
(Sigma) and labeled for 15 min with 2mM bromouridine either during the last 15
min of camptothecin treatment or following washout. The Bru-Seq and BruChase-
Seq procedures were performed as previously described (Paulsen et al., 2013b). In
short, total RNA was isolated from the cell samples using TRIzol reagent (Invitro-
gen) followed by specific isolation of Bru-labeled RNA using anti-BrdU antibodies
(BD Biosciences) conjugated to magnetic beads (Dynabeads, Goat anti-Mouse IgG,
Invitrogen). The isolated RNA was then converted into a strand-specific DNA li-
brary using the Illumina TruSeq Kit (Illumina) as previously described (Paulsen
et al., 2013b).
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5.3.2 Illumina Hi-Seq sequencing and data analysis
Sequencing of the cDNA libraries was performed by the staff at the University
of Michigan Sequencing Core using the Illumina HiSeq 2000 sequencer. Base calling
was performed using Illumina Casava v1.8.2. and read mapping was performed using
TopHat, accepting only reads that could be mapped uniquely to the genome. We
calculated RPKM values from the Bru-Seq data and plotted the data using a custom-
built browser as previously described (Paulsen et al., 2013b).
5.3.3 Data availability
The primary data used in the analyses will be deposited at NCBI’s Gene Ex-
pression Omnibus at the time of publication. We will upload the original genome
mapping BAM files and the derived synthesis lists as BED files.
5.4 Results
5.4.1 Camptothecin preferentially inhibited RNA synthesis of large genes
We challenged human fibroblasts for 45 min with 20µM camptothecin and labeled
RNA with 2 mM Bru for the last 15 min in the presence of camptothecin. The
sequencing reads from the isolated nascent Bru-containing RNA mapped throughout
genes covering both exons and introns and a relative rate of transcription could be
determined for all genes by integrating the number of reads throughout the gene
dividing it by the length of the gene. The hit density was expressed as “reads
per thousand base pairs per million reads” (RPKM) and represents the relative
distribution of reads for a particular sample. When comparing the read distribution
between the camptothecin-treated and the control sample, we observed that 1142
genes showed a more than 2-fold decreased relative rate of transcription while 919
genes showed a more than 2-fold increased relative transcription rate (Fig. 5.1A and
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B). Whether the genes found to have increased relative rates of transcription are
truly synthesizing at an absolute higher rate is not clear since the data generated
from Bru-Seq represents the distribution of reads rather than absolute expression
values. Therefore, when synthesis is reduced in the body of large genes, sequencing
reads must accumulate elsewhere (in small genes and at the beginning of large genes).
The data show an obvious negative correlation between read intensity and gene
size following camptothecin treatment. The average size of the genes with more
than a 2-fold decreased relative transcription rates was 136,355 bp. (Fig. 5.1C).
However, there was also a subset of smaller genes showing reduced expression after
camptothecin treatment with some histone genes and genes involved in the mitotic
phase of the cell cycle such as CCNB1, CDK1, AURKA and AURKB highly enriched
in this group (Fig. 5.1D). The average genomic size of the 919 genes showing increased
relative transcription rates following camptothecin treatment was 8,927 bp. These
findings are consistent with a mechanism of action for camptothecin as an inhibitor
of transcription elongation without inhibiting transcription initiation.
5.4.2 Camptothecin affected expression of ncRNA and enhancer RNA (eRNA), tran-
scription termination and splicing
In addition to inhibiting the elongation of protein-coding genes, camptothecin
inhibited transcription elongation of primary microRNA transcripts and long non-
coding RNAs (lncRNAs). For many short genes where no inhibition of elongation
was apparent, transcription read-through past the 3’ poly(A) site was prominent
(Fig. 5.2A) suggesting a role of topoisomerase I in transcription termination in these
genes (Durand-Dubief et al., 2011). Some genes showed a more pronounced splicing
activity during the labeling period in the presence of camptothecin compared to
untreated cells (Fig. 5.2B). It is possible that the reduced rate of elongation in the
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presence of camptothecin allows more time for the splice junctions to be identified
and spliced in a co-transcriptional manner (Listerman et al., 2006). However, the
apparent enhancing effect of camptothecin on splicing was not observed for all genes.
Many genes in mammalian cells have been shown to generate divergent promoter
upstream transcripts (PROMPTs) (Preker et al., 2008; Paulsen et al., 2013b). The
expression of some PROMPTs was dramatically enhanced by camptothecin treat-
ment (Fig. 5.2C). Furthermore, many divergently transcribed genes showed coordi-
nate enhancement of initiation, suggesting that the negative superhelicity expected
to accumulate in the wake of transcription in the absence of topoisomerase I activ-
ity enhances transcription initiation. Finally, many known and putative enhancer
elements, such as the 5’ FOS enhancer, showed increased generation of enhancer
RNA (eRNA) in the presence of camptothecin (Fig. 5.2D). The functional conse-
quence of the enhanced generation of eRNA following camptothecin treatment is not
clear since the relative transcription rate of the FOS gene was not induced despite
increased eRNA generated.
5.4.3 Transcription recovers as a wave from the 5’ end following camptothecin re-
moval
The trapping of topoisomerase I on DNA by camptothecin is thought to be a
partially reversible event (Pommier, 2006). To explore whether the removal of camp-
tothecin reverses its effects on transcription, we used Bru-Seq to examine the nascent
RNA transcriptome in cells following drug washout. To get an aggregate picture of
the effect of camptothecin on nascent RNA synthesis of multiple genes, we selected
genes larger than 100 kb that generate a signal > 1 RPKM. We aligned the Bru-
Seq data from the transcriptional start site (TSS) of these genes and observed that
bromouridine-labeling in the presence of camptothecin generated enhancement of
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reads in the first 10 kb of the genes while the signal further downstream in the genes
was severely suppressed (Fig. 5.3A). These results suggest that the inhibition and
trapping of topoisomerase I by camptothecin does not inhibit initiation of transcrip-
tion but severely inhibits elongation. When camptothecin was washed out and cells
were labeled with bromouridine for 15 min in the absence of the drug, transcription
reads spread from the 5’-end into the gene while no recovery of signal was observed
further downstream in the gene. Following washout of the drug and incubation for 15
minutes in drug-free media and then labeling nascent RNA for the following 15 min-
utes, the transcription wave moved further into the gene in a 5’-3’ direction. Again,
no recovery of signal was observed further downstream into the gene. Interestingly,
the transcription wave spreading from the 5’-end and into the body of the genes
had an elongation rate of approximately 1.1-1.3 kb/min (Fig. 5.3). This is a slower
rate than the estimated elongation rate of around 2 kb/min in cells under normal
conditions (Danko et al., 2013). If elongating RNA polymerases collide with trapped
topoisomerases, irreversible DNA damage may be induced that would require further
processing (Wu and Liu, 1997). It is possible that this reduced rate of elongation
observed following camptothecin treatment and washout is due to the requirement of
repair of Top1/camptothecin-induced DNA damage before resumption of elongation
can take place.
5.4.4 No apparent defect in the recovery of RNA synthesis in CS-B cells following
camptothecin reversal
It has been shown that cells derived from Cockayne syndrome patients are hy-
persensitive to camptothecin [17]. This hypersensitivity is linked to an enhanced
induction of DSBs in S-phase as replication forks “collide” with trapped Top1 com-
plexes (Squires et al., 1993). Some studies have also shown that the recovery of
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RNA synthesis is slower in CS cells (Squires et al., 1993; Horibata et al., 2011; Lin
et al., 2013) while other studies have found no defect in RNA synthesis recovery in
CSB-deficient cells (Sakai et al., 2012). Using Bru-Seq we here tested whether the
recovery of nascent RNA synthesis in CS-B fibroblast cells following camptothecin
treatment and reversal differed from the recovery in normal human fibroblasts. Anal-
ysis of the aggregate transcription signal of genes at least 100 kb or longer showed
that CS-B cells recovered RNA synthesis in a wave from the 5’-end of these genes
in a similar fashion as the normal fibroblasts (Fig. 5.4A). This was also apparent for
the individual genes SMAD3, TLE4, POL1, CD44 and MEIS1 (Fig. 5.4). In addi-
tion, no recovery of transcription occurred from the bodies of the genes suggesting
that initially blocked RNA polymerases are not able to resume elongation following
camptothecin removal. The apparent normal recovery of RNA synthesis in these
CS-B cells were in sharp contrast to the defective recovery of nascent RNA synthesis
in these cells following UV-irradiation (unpublished data).
5.4.5 Camptothecin affected cancer-relevant gene expression
Performing DAVID gene enrichment analysis we found that camptothecin-induced
genes coding for elements of the ribosome, mitochondrion and the p53 and apoptosis
signaling pathways were highly represented (Figure 5.5). The set of genes found to
be inhibited shortly after camptothecin treatment was enriched for phosphoproteins,
proto-oncogenes, and genes involved in the mitotic cell cycle, ubiquitin conjugation
and anti-apoptosis. Some representative large proto-oncogenes inhibited by camp-
tothecin are shown in Figure 5.6A. It has been shown that blockage of transcription
elongation by camptothecin triggers a stress response leading to the rapid accu-
mulation of p53 accompanied by phosphorylation of the Ser15 site and acetylation
of the Lys382 site (Ljungman et al., 2001). In support of camptothecin inducing
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a p53 response in human fibroblasts, we found that camptothecin induced genes
in the p53 signaling pathway, including CDKN1A (p21), MDM2, BTG2 and FAS
(Figure 5.6B). Some of these genes were induced already during the camptothecin
treatment while some genes, like CDKN1A and MDM2, showed induced expres-
sion only following reversal of drug treatment. Camptothecin reduced the relative
transcription rates of large anti-apoptotic genes and enhanced expression of a set of
smaller sized pro-apoptotic genes (Figure 5.6C). Pro-apoptotic genes are generally
more compact compared to anti-apoptotic genes (McKay et al., 2004), thus agents
preferentially reducing expression of large genes by blocking transcription elongation
are expected to shift the balance of gene expression in favor of apoptosis. Similar
patterns of increased and decreased relative gene expression following camptothecin
treatment and reversal were found for CS-B cells. There were, however, some dif-
ferences between normal human fibroblasts and the CS-B cells were observed such
as a lack of reduced GLI2 expression and no induction of the p53-regulated genes
DUSP5, FAS, MDM2 and TRIM22 in CS-B cells.
5.5 Discussion
Camptothecin and its derivatives are FDA approved anti-cancer drugs used to
treat a variety of tumors (Pommier, 2013). They act by trapping topoisomerase I
complexes on DNA rather than inhibiting enzymatic function, since RNAi knock-
down of Top1 does not reduce cell survival to the same degree as camptothecin
treatment (Nitiss and Wang, 1988; Pommier, 2013). In this study, we used Bru-Seq
to explore the acute effects of camptothecin on various aspects of transcription and
found that camptothecin (i) inhibited elongation of transcription, (ii) stimulated
transcriptional read-through past the 3-end of small genes, (iii) enhanced expres-
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sion of eRNA from certain enhancer elements (iv) induced the p53 response and (v)
shifted the balance of expression of apoptosis-regulatory genes in favor of apoptosis.
Importantly, transcription recovered with a reduced elongation rate as a wave from
the 5-end of the gene with no apparent recovery of synthesis from RNA polymerases
blocked in the body of the genes. We found no evidence that the recovery of RNA
synthesis was different in CS-B fibroblasts which is in sharp contrast to the recovery
of RNA synthesis in these cells after UV light (unpublished data). Thus, the mecha-
nisms responsible for the recovery of RNA synthesis following camptothecin removal
are fundamentally different from those required following UV-irradiation suggesting
that transcription-coupled repair has no major role in the restart of transcription
following camptothecin removal. It is therefore conceivable that the observed hyper-
sensitivity of CS-B cells to camptothecin is related to some role of the CSB protein
during recovery of replication rather that in the recovery of transcription (Squires
et al., 1993).
The inability of cells to restart transcription from within the body of genes sug-
gests that blocked RNA polymerases are discarded rather than recycled. This will
preferentially set back the expression of large genes even following a limited exposure
of cells to camptothecin. Interestingly, many proto-oncogenes and anti-apoptotic
genes belong to the class of genes preferentially inhibited by camptothecin. The
model that emerges is that poisoning of Top1 by camptothecin results in the inhibi-
tion of large proto-oncogenes, enhanced expression of small pro-apoptotic genes and
activation of the p53 pathway (Figure 5.6D). Knowledge of the size of the oncogenes
that drive carcinogenesis and are important for survival of cancer cells in a given tu-
mor may be used to select patients who would specifically benefit from camptothecin
treatment and to rationally combine camptothecin with other treatment modalities.
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For example, the expression of the large BRCA1-associated RING domain protein 1
gene (BARD1) was reduced by camptothecin. Such suppression would be expected to
suppress homologous recombination and thus should lead to increased susceptibility
to PARP inhibitors or radiation therapy. Indeed, it has been shown that combining
camptothecin with PARP inhibitors or radiotherapy improves tumor control (Chen
et al., 1999; Bowman et al., 2001; Zhang et al., 2011; Pommier, 2013).
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Camptothecin affects transcription termination and
expression of ncRNA and enhancer RNA (eRNA)
For many short genes where no inhibition of elongation was
apparent following camptothecin treatment, transcription read-
through past the annotated 3’ poly(A) site was prominent
(Figure 2A, Figure S3 in File S1). This data supports a role for
topoisomerase I in transcription termination in these genes
[20]. Alternatively, the increased number of reads beyond the
annotated termination sites may result from the induction of
alternative poly(A) sites following camptothecin treatment or
stabilization of the RNA past the 3’-cleavage site. Many genes
in mammalian cells have been shown to generate divergent
promoter upstream transcripts (PROMPTs) [19,21]. The
expression of some PROMPTs was dramatically enhanced by
camptothecin treatment (Figure 2B, Figure S4 A-C in File S1).
Furthermore, many divergently transcribed genes showed
coordinate initiation enhancement, suggesting that the negative
superhelicity expected to accumulate in the wake of
Figure 1.  Gene size is a major contributing factor to the effects of camptothecin on RNA synthesis.  Human fibroblasts were
treated with 20 µM camptothecin for 45 min with 2 mM Bru added during the last 15 min of camptothecin treatment to label nascent
RNA followed by Bru-Seq. (A), Long genes, such as TRIO, exhibit elongation defects, but not transcription initiation, after
camptothecin treatment. (B), Short genes, such as BAMBI, show a relative increase of RNA synthesis following camptothecin
treatment. (C), Effect of camptothecin on relative transcription as a function of gene size. Ratio of Bru-Seq signal of individual genes
in camptothecin-treated over control cells as a function of gene size. Longer genes are inhibited preferentially over shorter genes.
(D), The median length of genes induced >2-fold by camptothecin (919 genes) is 8,927 bp, whereas genes down-regulated >2-fold
(1,145 genes) have a median length of 136,355 bp. The gene maps are from RefSeq Genes (UCSC genome browser).
doi: 10.1371/journal.pone.0078190.g001
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Figure 5.1: Gene size is a major contributing factor to the effects of camptothecin on RNA synthesis.
Hu an fibroblasts were treated with 20µM camptothecin for 45 min with 2 mM Bru added duri g
th last 15 min of a p othecin trea ment to label nascent RNA followed by Bru-Seq. (A), Long
genes, such as TRIO, exhibit elongation defects, but not transcription initiation, after camptothecin
treatment. (B), Short genes, such as BAMBI, show a relative increase of RNA synthesis following
camptothecin treatment. (C), Effect of camptothecin on relative transcription as a function of
gene size. Ratio of Bru-Seq signal of individual genes in camptothecin-treated over control cells
as a function of gene size. Longer genes are inhibited preferentially over shorter genes. (D), The
median length of genes induced > 2-fold by camptothecin (919 genes) is 8,927 bp, whereas genes
down-regulated > 2-fold (1,145 genes) have a median length of 136,355 bp. The gene maps are
from RefSeq Ge es (UCSC genome browser)
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transcription in the absence of topoisomerase I activity may
enhance transcription initiation (Figure S4 D-F). Finally,
camptothecin treatment lead to the production of more
enhancer RNA (eRNA) from many known and putative
enhancer elements, such as the 5’ FOS enhancer (Figure 2C,
Figure S5 in File S1). The functional consequence of the
enhanced generation of eRNA following camptothecin
treatment is not clear since the relative transcription rate of the
FOS gene was not elevated despite the increase in eRNA
generation. In addition to inhibiting the elongation of protein-
coding genes, camptothecin inhibited transcription elongation
of primary microRNA transcripts (Figure 2D) and enhanced or
repressed long non-coding RNAs (lncRNAs) (Figure 2E&F).
Transcription recovers as a wave from the 5’ end
following camptothecin removal
The trapping of topoisomerase I on DNA by camptothecin is
thought to be a partially reversible event [2]. To explore
whether the removal of camptothecin reverses its effects on
transcription, we used Bru-Seq to examine the nascent RNA
transcriptome in cells following drug washout. To get an
aggregate picture of the effect of camptothecin on nascent
RNA synthesis of multiple genes, we selected highly expressed
genes (RPKM greater than 1) and longer than 100 kb and
aligned them by their transcription start sites. We found that
camptothecin induced a strong signal above control within the
first 10 kb of genes followed by a severe drop in signal below
control further downstream (Figure 3A). These results suggest
that the inhibition and trapping of topoisomerase I by
camptothecin does not inhibit initiation of transcription but
strongly inhibits elongation. When camptothecin was washed
out and cells were labeled with bromouridine for 15 min in the
absence of the drug, recovery of transcription spread from the
5’-end into the gene while no recovery of signal was observed
further downstream in the gene. Following washout of the drug
and incubation for 15 minutes in drug-free media and then
labeling nascent RNA for the following 15 minutes, the
transcription wave moved further into the gene in the 3’
direction. Again, no recovery of signal was observed further
downstream into the gene. Interestingly, the rate at which
transcription wave spreading from the 5’-end and into the body
of the genes was approximately 1.1-1.3 kb/min (Figure 3,
Figure 2.  Effect of camptothecin on transcriptional readthrough and synthesis of PROMPTs and eRNA.  As in Figure 1,
human fibroblasts were treated with 20 µM camptothecin for 45 min with 2 mM Bru added during the last 15 min of camptothecin
treatment to label nascent RNA followed by Bru-Seq. (A), Transcriptional readthrough of the termination site of the RHOB gene
induced by camptothecin. (B), Enhanced initiation of the ASCC3 gene and coincident upregulation of divergent upstream PROMPT
RNA. (C), Enhanced expression of eRNA from the 5’-upstream enhancer of FOS by camptothecin. (D), Camptothecin inhibits the
transcription of the primary transcript of miRNA138-1. (E), Camptothecin induces transcription of the ncRNA MALAT1. (F),
Camptothecin inhibits the transcription of a very long unannotated ncRNA on chromosome 2. The gene maps are from RefSeq
Genes (UCSC genome browser).
doi: 10.1371/journal.pone.0078190.g002
Effects of Camptothecin on Transcription
PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e78190
Figure 5.2: Effect of camptothecin on transcriptional readthrough and synthesis of PROMPTs
and eRNA. As in Figure 5.1, human fibroblasts were treated with 20µM camptothecin for 45 min
with 2 mM Bru added during the last 15 min of camptothecin trea ment to label nascent RNA
followed by Bru-Seq. (A), Transcriptional readthrough of the termination site of the RHOB gene
induced by camptothecin. (B), Enhanced initiation of the ASCC3 gene and coincident upregulation
of diverge t upstream PROMPT RNA. (C), Enhanced expression of eRNA from the 5’-upstream
enhancer of FOS by camptothecin. (D), Camptothecin inhibits the transcription of the primary
transcript of miRNA138-1. (E), Camptothecin induces transcription of the ncRNA MALAT1. (F),
Camptothecin inhibits the transcription of a very long unannotated ncRNA on chromosome 2. The
gene maps are from RefSeq Genes (UCSC genome browser).
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Figure 5.3: Effect of camptothecin reversal on RNA synthesis. (A), Aggregate view of RNA synthe-
sis of genes larger than 100 kb in normal human fibroblasts with the genes aligned by transcriptional
start sites (TSS). RNA synthesis recovers as a wave in a 5-to-3 direction following camptothecin
removal with no apparent recovery of RNA polymerases stalled in the body of the genes. Elongation
rates of the recovering transcription wave was estimated to be 1.2 kb/min. (B), Wave of recovery of
RNA synthesis can be seen advancing from the 5-end of the CD44 gene with no apparent recovery
in the body of the gene. The front of the transcription wave extended some 35 kb during the first
30 min recovery resulting in an elongation rate of about 1.2 kb/min. (C) Similar elongation rates
after camptothecin removal were found for the MEISE1 gene. Color key: Blue, control (30 min Bru
labeling); Yellow, Bru labeling during the last 15 min of a 45 min camptothecin treatment; Green,
45 min camptothecin treatment followed by a drug washout and 15 min of Bru labeling; Red, 45
min camptothecin treatment followed by a drug washout, 15 min incubation, and finally 15 min
Bru labeling.
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agents preferentially reducing expression of large genes by
blocking transcription elongation are expected to shift the
balance of gene expression in favor of apoptosis. Similar
patterns of increased and decreased relative gene expression
following camptothecin treatment and reversal were found for
CS-B cells (Figure S8 in File S1). There were, however, some
differences between normal human fibroblasts and the CS-B
cells were observed such as a lack of reduced GLI2 expression
and no induction of the p53-regulated genes DUSP5, FAS,
MDM2 and TRIM22 in CS-B cells.
Discussion
Camptothecin and its derivatives are FDA approved anti-
cancer drugs used to treat a variety of tumors [4]. They act by
trapping topoisomerase I complexes on DNA rather than
inhibiting enzymatic function, since RNAi knockdown of Top1
does not reduce cell survival to the same degree as
camptothecin treatment [4,24]. In this study, we used Bru-Seq
to explore the acute effects of camptothecin on various aspects
of transcription and found that camptothecin (i) inhibited
elongation of transcription, (ii) stimulated transcriptional read-
through past the 3’-end of small genes, (iii) enhanced
expression of eRNA from certain enhancer elements (iv)
induced the p53 response and (v) shifted the balance of
expression of apoptosis-regulatory genes in favor of apoptosis.
Importantly, transcription recovered with a reduced elongation
rate as a wave from the 5’-end of the gene with no apparent
recovery of synthesis from RNA polymerases blocked in the
body of the genes. We found no evidence that the recovery of
RNA synthesis was different in CS-B fibroblasts which is in
sharp contrast to the recovery of RNA synthesis in these cells
after UV light (unpublished data). Thus, the mechanisms
responsible for the recovery of RNA synthesis following
camptothecin removal are fundamentally different from those
required following UV-irradiation suggesting that transcription-
coupled repair has no major role in the restart of transcription
following camptothecin removal. It is therefore conceivable that
the observed hypersensitivity of CS-B cells to camptothecin is
related to some role of the CSB protein during recovery of
replication rather that in the recovery of transcription [18].
The inability of cells to restart transcription from within the
body of genes suggests that blocked RNA polymerases are
discarded rather than recycled. This will preferentially set back
the expression of large genes even following a limited
exposure of cells to camptothecin. Interestingly, many proto-
oncogenes and anti-apoptotic genes belong to the class of
genes preferentially inhibited by camptothecin. The model that
emerges is that poisoning of Top1 by camptothecin results in
the inhibition of large proto-oncogenes, enhanced expression
of small pro-apoptotic genes and activation of the p53 pathway
(Figure 6D). Knowledge of the size of the oncogenes that drive
carcinogenesis and are important for survival of cancer cells in
a given tumor may be used to select patients who would
specifically benefit from camptothecin treatment and to
rationally combine camptothecin with other treatment
modalities. For example, the expression of the large BRCA1-
associated RING domain protein 1 gene (BARD1) was reduced
by camptothecin. Such suppression would be expected to
suppress homologous recombination and thus should lead to
increased susceptibility to PARP inhibitors or radiation therapy.
Indeed, it has been shown that combining camptothecin with
PARP inhibitors or radiotherapy improves tumor control
[4,25–27].
Figure 4.  Effect of camptothecin reversal on RNA synthesis in Cockayne syndrome cells.  (A), Aggregate view of RNA
synthesis of genes larger than 100 kb in CS-B cells with the genes lined up by transcriptional start sites (TSS) as in Figure 3.
Elongation rates of the recovering transcription wave was estimated to be ~1.0-1.3 kb/min. Individual genes in fibroblasts from a CS-
B individual showing similar recovery rates as in fibroblasts from a normal individual for (B), CD44 and (C) MEIS1. Color key as in
Figure 3.
doi: 10.1371/journal.pone.0078190.g004
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Figure 5.4: Effect of camptothecin reversal on RNA synthesis in Cockayne syndrome cells. (A),
Aggregate view of RNA synthesis of genes larger than 100 kb in CS-B cells with the genes lined up
by t anscriptional start sites (TSS) as in Figure 3. Elongation rates of the recovering transcription
wave was estimated to be 1.0-1.3 kb/min. Individual genes in fibroblasts from a CS-B individual
showing similar recovery rates as in fibroblasts from a normal individual for (B), CD44 and (C)
MEIS1. Color key as in Figure 5.3.
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Figure 5.  Pathway enrichment for genes following camptothecin treatment and reversal.  (A) Pathways represented by
genes up-regulated at least 2-fold, and (B) down-regulated at least 2-fold following camptothecin treatment and recovery. Human
fibroblasts were treated with 20 µM camptothecin for 45 minutes and incubated for the last 15 min with 2 mM Bru (“0 min”),
incubated for 15 min with Bru following the removal of camptothecin (“15 min”) or incubated for 15 min with Bru following a 45 min
treatment, a wash and a 15 min recovery (“30 min”). Enrichment analysis was performed using DAVID (david.abcc.ncifcrf.gov) and
the numbers shown represents the p-values for enrichment.
doi: 10.1371/journal.pone.0078190.g005
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Figure 5.5: Pathway enrichment for genes following camptothecin treatment and reversal. (A)
Pathways represented by genes up-regulated at least 2-fold, and (B) dow -regulated at least 2-
fold following camptothecin treatme t a d recovery. Human fibroblasts were treated with 20µM
camptothecin for 45 minutes and incubated for the last 15 min with 2 mM Bru (“0 min”), incubated
for 15 min with Bru following the removal of camptothecin (“5 min”) or incubated for 15 min with
Bru following a 45 min treatment, a wash and a 15 min recovery (“30 min”). Enrichment analysis
was performed using DAVID (david.abcc.ncifcrf.gov) and the numbers shown represents the
p-values for enrichment.
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Figure 6.  Camptothecin preferentially inhibits large genes such as proto-oncogenes and anti-apoptotic genes, enhances
the relative expression of small pro-apoptotic genes and activates the p53 response.  (A), Examples of large proto-
oncogenes inhibited by camptothecin and showing no recovery (or slow recovery) following drug removal. (B), Examples of p53
target genes induced following camptothecin treatment. (C), Examples of large anti-apoptotic genes showing reduced relative
transcription (left) and examples of small pro-apoptotic genes showing enhanced relative transcription following camptothecin
treatment (right). (D), Model of mechanisms by which camptothecin may induce cell death or inhibit cell growth. Camptothecin
triggers a p53 transcriptional response and selectively inhibits large proto-oncogenes and survival genes. The data is color coded
where blue represents control (C), yellow represents 15 min Bru-labeling at the end of a 45 min camptothecin treatment with no
recovery (“0 min”), green represents drug washout and 15 min Bru-labeling immediately after washout (“15 min”) and finally red
represents labeling 15-30 minutes following washout (“30 min”).
doi: 10.1371/journal.pone.0078190.g006
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Figure 5.6: Camptothecin preferentially inhibits large genes such as proto-oncogenes and anti-
apoptotic genes, enha ces the relative expression of ma l pro-apopt ic genes and activates he
p53 response. (A), Examples of large proto-oncogenes inhibited by camptothecin and showing no
recovery (or slow recovery) following drug removal. (B), Examples of p53 target genes induced
following camptothecin treatment. (C), Examples of large anti-apoptotic genes showing reduced
r lative transcription (left) and examples of s all pro-apoptotic genes showing enhance relative
transcription following camptothecin treatment (right). (D), Model of mechanisms by which camp-
tothecin may induce cell death or inhibit cell growth. Camptothecin triggers a p53 transcriptional
response and selectively inhibits large proto-oncogenes and survival genes. The data is color coded
where blue represents control (C), yellow represents 15 min Bru-labeling at the end of a 45 min
camptothecin treatment with no recovery (“0 min”), green represents drug washout and 15 min
Bru-labeling immediately after washout (“15 min”) and finally red represents labeling 15-30 minutes
following washout (“30 min”).
CHAPTER VI
Rate of transcriptional elongation associates with
H3K79me2 and H4K20m1 epigenetic marks
6.1 Abstract
The rate of transcription elongation plays an important role in the timing of
expression of full-length transcripts as well as in the regulation of alternative splicing.
In this study we coupled Bru-seq technology with 5,6-dichlorobenzimidazole 1-β-D-
ribofuranoside (DRB) to estimate the elongation rates of over 2,000 individual genes
in human cells. This technique, BruDRB-seq, revealed gene-specific differences in
elongation rates with a median rate of around 1.5 kb/min. We found that genes
with rapid elongation rates showed higher densities of H3K79me2 and H4K20me1
histone marks compared to slower elongating genes. Furthermore, high elongation
rates had a positive correlation with gene length, low complexity DNA sequence and
distance from nearest active transcription unit. Features that negatively correlated
with elongation rate included the density of exons, long terminal repeats, GC content
of the gene and DNA methylation density in the bodies of genes. Our results suggest
that some static gene features influence transcription elongation rates and that cells
may alter elongation rates by epigenetic regulation. The BruDRB-seq technique
Official citation:
Veloso, A., Kirkconnell, K., Magnuson, B., Biewen, B., Paulsen, M.T., Wilson, T.E., Ljungman, M, Rate of elongation
by RNA polymerase II is associated with specific gene features and epigenetic modifications. Genome Research, In
Press
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offers new opportunities to interrogate mechanisms of regulation of transcription
elongation.
6.2 Introduction
Gene transcription in eukaryotes is the highly regulated process by which RNA
polymerase II (RNAPII) uses DNA as a template to produce RNA. The stages of
transcription include initiation, elongation, and termination, the control of which
influences gene expression. Mechanisms of transcription initiation have been stud-
ied in detail and much is known about transcription factor activation and binding,
pre-initiation complex formation, and RNAPII recruitment (Shandilya and Roberts,
2012). Furthermore, the critical roles of regulatory sequences such as enhancer el-
ements for developmental and tissue-specific gene regulation (Spitz and Furlong,
2012) and the three dimensional organization of the transcription machinery have
been characterized to some level (Sutherland and Bickmore, 2009). However, the im-
portance of regulation of the rate of transcription elongation is poorly understood.
Activation of specific gene programs, such as those regulating early organism de-
velopment, is thought to depend on gene size to accomplish a temporal expression
pattern after simultaneous transcriptional activation (Swinburne and Silver, 2008).
A proposed mechanism to delay the generation of mature RNA is the inclusion of in-
trons of various sizes (Seoighe and Korir, 2011; Takashima et al., 2011). To fine-tune
this timing mechanism in gene expression, cells may adjust the rates of transcription
elongation, splicing, nuclear export, and ribosome access. The rate of transcriptional
elongation has also been tied to alternative splicing patterns, where high transcrip-
tion elongation rates favor exclusion of alternative exons while slow elongation rates
correlate with their inclusion (Close et al., 2012; Shukla and Oberdoerffer, 2012).
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Previous studies have measured in vivo RNAPII elongation rates in mammals
using a variety of techniques including RT-PCR (Singh and Padgett, 2009), tiling
microarrays (Wada et al., 2009), and fluorescent labeling (Darzacq et al., 2007b).
These studies have been limited to a single or a small number of genes and have
reported a wide range of elongation rates. A recent study utilized GRO-seq to
assess elongation rates of a much larger set of genes activated by estradiol or tumor
necrosis factor (TNF) and demonstrated a broad range of transcriptional elongation
rates among the set of activated genes, supporting the notion that elongation rates
may be regulated (Danko et al., 2013).
Here we utilize BruDRB-seq to assess transcription elongation rates genome- wide.
This technique involves the transient inhibition of initiated RNAPII prior to elon-
gation using 5,6-dichlorobenzimidazole1-β-D-ribofuranoside (DRB) (Singh and Pad-
gett, 2009). Following drug removal, RNA polymerases enter the elongation phase
in a synchronized manner and nascent RNA is labeled with bromouridine (Bru),
isolated with anti-BrdU antibodies and subjected to deep sequencing. By measuring
the width of the transcription “wave” generated during the labeling period, the tran-
scription elongation rates of all expressed genes longer than 40 kb were assessed. Our
study provides the largest data set so far reported of genome-wide elongation rates in
multiple cell lines. We found that high transcription elongation rates correlated with
specific gene features as well as with histone modifications such as di-methylation of
lysine 79 of histone H3 (H3K79me2) and mono-methylation of lysine 20 of histone H4
(H4K20me1). These results indicate that cells may be able to fine tune transcription
elongation rates by epigenetic regulation.
135
6.3 Results
6.3.1 Measuring elongation rates globally reveals variation among genes
To study the elongation rates of RNAPII genome-wide, we developed BruDRB-
seq, a technique based on nascent RNA labeling with Bru and assaying by deep
sequencing (Paulsen et al., 2013a,b). Following a 60 minute treatment of the cultured
cells with DRB to arrest RNAPII at promoter-proximal sites, the drug was washed
out and the cells were incubated with Bru for 10 minutes either directly or after a 10
min recovery period. Cells were lysed in TRIzol and total RNA was isolated followed
by specific capturing of Bru-labeled RNA using anti-BrdU antibodies conjugated to
magnetic beads. The captured Bru-labeled RNA was then reverse- transcribed and
the resulting cDNA library was subjected to deep sequencing using the Illumina
HiSeq 2000 platform.
In Figure 6.1A (control), all expressed genes of at least 50 kb in length in the
diploid human fibroblast cell line HF1 are represented by median normalized expres-
sion (an aggregate view). As expected for nascent RNA, the signal was fairly evenly
distributed throughout the first 50 kb of these genes. Following a 60 minute DRB
treatment with Bru labeling during the last 10 minutes of treatment, a substantially
lower yield of reads was obtained indicating that transcription was severely reduced
(Fig. 6.1A, 0 min). Following drug removal, a synchronized wave of transcription was
observed moving out from the promoter (Fig. 6.1A, 10 min) and this wave moved
further during the next 10 min (Fig. 6.1A, 20 min). These results demonstrate both
the reversibility of DRB and synchronicity of transcription recovery.
In order to measure elongation rates of individual genes in a genome-wide fashion,
we used an inference method based on a three state Hidden Markov Model (HMM)
(Day et al., 2007; Danko et al., 2013). The HMM was designed to identify three dis-
136
tinct regions of each gene: (A) the region immediately upstream of the transcription
start site (TSS), (B) the advancing wave, and (C) the region of low transcription
downstream of the advancing transcription wave (Fig. 6.1B). Quantile normalization
was performed on the BruDRB-seq trace prior to HMM analysis to eliminate any
effect of a gene’s expression level on the analysis (see Methods). After applying the
HMM analysis to the data from the 10 min wave in HF1 cells, we ordered the genes
according to their calculated elongation rates and found them to be quite variable
(Fig. 6.1C). Examples of transcription waves moving from the promoters into the
bodies of three individual genes following DRB removal are shown in Figure 6.1D-F.
DRB inhibits the transition of RNAPII from the initiation/promoter paused stage
into the elongation phase by blocking the phosphorylation of the C-terminal domain
(CTD) of RNAPII (Dubois et al., 1994). However, DRB does not inhibit elongating
RNA polymerases and thus, DRB treatment results in a time-dependent clearing
out of transcription from the promoter with a receding wave of unaffected actively
transcribing polymerases. For transcribed genes longer than 200 kb in HF1 cells
treated with DRB for 60 min, the receding transcription wave can be clearly observed
(Fig. 6.2A, yellow). The elongation patterns of two large genes expressed in HF1 cells,
MYO1B and TLE4, are shown in Figure 6.2B and 6.2C, respectively.
By incorporating a fourth state in the Hidden Markov Model representing the
receding wave of transcription, we were able to analyze the correlation between the
advancing and the receding waves. A visual comparison between the states pre-
dicted by the HMM (Fig. 6.2D) and the normalized signal observed in those genes
(Fig. 6.2E) indicates that predictions of the model were reasonably accurate. We
compared elongation rates calculated both via the advancing (state “B”) and the
receding (state “D”) wave and found that they correlate, albeit with high variability
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(Fig. 6.2F). Because the trailing edge of the receding wave is not as well defined as
the advancing wave and because we can include more genes by leaving the receding
wave out of the HMM, we decided to focus on the advancing wave (3-state HMM
predictions) as our metric for elongation.
6.3.2 Elongation rates are similar in different cell lines
Transcription elongation rates have been explored in a limited number of genes and
only in a few cell lines Ardehali et al. (2009); Singh and Padgett (2009); Danko et al.
(2013). In this study, we used five cell lines and BruDRB-seq to assess transcription
elongation rates genome-wide. Three of these cell lines are human fibroblasts and two
cell lines, K562 and MCF-7, are cancer-derived. HF1 and TM cells are normal human
fibroblasts while Cockayne syndrome B cells (CS-B) have a genetic defect in the
ERCC6 gene, which encodes the CSB protein, resulting in a defect in transcription-
coupled DNA repair. It has been suggested that the CSB protein associates with the
elongation transcription complex and in vitro results suggest that CSB enhances the
rate of RNAPII elongation (Selby and Sancar, 1997). The median elongation rate was
found to be similar across the five cell lines, with HF1, CS-B, and K562 being nearly
identical ( 1.25 kb/min), and TM and MCF-7 rates slightly higher than the other
cell lines ( 1.75 kb/min) (Fig. 6.3A). In addition, there was a positive correlation of
elongation rates of individual genes between the cell lines when performing a pair-
wise comparison (Fig. 6.3B). As examples, similar transcription elongation rates for
the ACTN4 and PTEN genes across the five cell lines are shown in Figure 6.3C.
A clustering method was used to identify similarities in the observed elongation
rates across the five cell lines. Quantile-normalized elongation rates of approximately
800 genes expressed in all five cell lines were put into a k-medoids algorithm to
cluster these genes into three groups based on similarities in elongation rates. The
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gene groups selected by the algorithm were clearly distinguished by their overall
elongation rates, with a fast, a slow and a variable intermediate group (Fig. 6.3D).
These observations indicate that elongation rates of individual genes are considerably
conserved among cell lines.
6.3.3 Gene Set Enrichment
To determine whether genes with similar functions or belonging to a particular
pathway have similar transcription elongation rates, we assessed gene enrichment
clustering among genes with similar elongation rates. We centered the average elon-
gation rate along its own mean and provided these values and the gene symbols
as pre-ranked lists to the Gene Set Enrichment Analysis (GSEA) tool (Subrama-
nian et al., 2005). We searched for enrichment in positional, curated (BioCarta and
KEGG), gene ontology, and oncology signature gene sets obtained from the Molecu-
lar Signatures Database. We used the permissive false discovery rate (FDR) p-value
suggested by the authors of GSEA (p <= 25%) (Subramanian et al., 2005), and
focused on the gene sets that were enriched in at least three of the cell lines. We
found that genes related to organic acid and carboxylic acid metabolism were en-
riched among the genes with slow elongation rates. Furthermore, genes related to
regulation of actin cytoskeleton and to leukocyte trans-endothelial migration were
enriched among genes with higher elongation rates.
6.3.4 Gene sequence features correlate to elongation rates
Since at least half of the genes used for the clustering analysis described in Figure
6.3D grouped strongly by elongation rate independent of cell type, we reasoned that
the rate of elongation for some genes may be correlated with specific DNA sequence
features of the transcribed DNA. Certain features, such as splice site sequences and
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sequences with a propensity to form G-quadruplexes, have been implicated to affect
RNAPII elongation rates in vitro (Belotserkovskii et al., 2013). We investigated the
correlation between elongation rates and several sequence features, including GC
content, exon density, regions of repetitive DNA, and sequences computationally
predicted to form non-B DNA structures. For each gene, the density of each feature
from the TSS to the end of the advancing wave was calculated and compared to
its elongation rate. Because several of these features were not randomly distributed
throughout the first 40 kb of the genes, a simple regression analysis was inadequate
to establish a correlation. To confirm that the correlations found with these features
were not solely due to the non-random distribution of the feature, we conducted
a permutation analysis using a FDR-corrected p-value of 0.05 as the threshold for
significance.
In all cell lines analyzed, exon density (and therefore splice site density) was
negatively correlated with elongation rate (Table 6.1). GC content and the density of
long terminal repeat sequences were also negatively correlated with elongation rates
in at least 3 cell lines. It is possible that a higher GC content reduces elongating rates
due to a higher energy requirement for breaking three hydrogen bonds between G and
C versus two for A and T. The only DNA sequence feature to positively correlate
with elongation rate was a high density of low complexity sequences (stretches of
mono- or di-nucleotide repeats).
6.3.5 Role of gene neighborhoods and genomic organization
Gene expression is often determined by whether the gene is located in an open
(euchromatic) or condensed (heterochromatic) chromatin configuration. We asked
whether transcription elongation rates are influenced by proximity to nearby genes,
chromosomal regions, or three-dimensional organization, which we collectively refer
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to as “gene neighborhoods”. To examine the effects of gene neighborhoods on elon-
gation, we compared the measured elongation rates of genes and their proximity to
neighboring genes on either strand both upstream and downstream of the gene (Ta-
ble 6.1). We found a positive correlation between elongation rate and the distance
to other genes. Thus, active transcription nearby has a negative impact on elonga-
tion rate. Interestingly, we also found that gene length is positively correlated with
elongation rate though it is unclear how longer genes are identified or marked for
faster transcription. Next we examined whether there was a correlation between the
elongation rates of neighboring genes and found no statistically significant relation-
ship between the elongation rates of neighboring transcribed genes (Supplemental
Fig. S6.1A). Furthermore, inspection of the distribution of genes and their associ-
ated elongation rates along the different chromosomes suggests that genes with high
or low transcription elongation rates were distributed randomly throughout out the
genome (Supplemental Fig. S6.1B).
The above analyses addressed the influence of gene proximity as defined by a lin-
ear chromosome, but does not consider the three dimensional organization of genes
within the nucleus. Genes that are linearly distant, even on completely different chro-
mosomes, may interact due to long distance DNA looping and may be transcribed
by the same transcription machinery (Dekker et al., 2013). To assess whether genes
associated with each other in the same transcriptional factory have similar elongation
rates, we used publicly available data from chromatin interaction analysis by pair-end
tag sequencing (ChIA-PET) for K562 and MCF-7 cells. The elongation rates of genes
that were shown by ChIA-PET to co-localize to the same transcription machinery
were plotted against each other as gene 1 vs. gene 2 (Supplemental Fig. S6.1C). The
results show that there was no significant correlation between elongation rate and
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chromatin interactions.
6.3.6 Elongation rates are related to epigenetic modifications
While we found that some DNA sequence features correlated with elongation rate
(Table 6.1), some genes showed varied elongation rates across cells lines (Fig. 6.3D).
Thus, the elongation rates of some genes may be regulated in a cell-type specific way
and we hypothesized that cells may regulate transcription elongation rates by specific
epigenetic modifications. We first explored whether the level of DNA methylation in
the body of genes correlated with transcription elongation rates. While methylation
of CpG islands in promoter regions has been implicated in gene silencing, the function
of CpG methylation in the body of genes is poorly understood (Jones, 2012). We
compared elongation rates obtained with BruDRB-seq to published genome-wide
CpG methylation patterns (bisulfite sequencing) data for K562 and MCF-7 cells
(ENCODE) and found that genes with high levels of DNA methylation tended to
elongate at slower rates. This effect, however, was only noticeable when analyzing
CpG sites with high occurrence of methylation (at least 90%), as the correlation
was not significant when including sites with lower occurrence (e.g. at least 50%
methylation) in the analysis.
To explore whether fast or slow transcription elongation rates may associate with
the presence of specific histone modifications, we divided the genes into four quar-
tiles according to elongation rates and compared them with ChIP- seq data available
through ENCODE for different histone marks that have been implicated in tran-
scription regulation (Ernst et al., 2011; ENCODE Project Consortium et al., 2012).
Of the histone marks tested, only H3K79me2 and H4K20me1 were found to show
a significant positive correlation with elongation rates (Fig. 6.4A&B; Supplemental
Fig. S6.2). These histone marks have been shown to be linked to active transcription
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(Rao et al., 2005; Smolle and Workman, 2013) but they have not previously been
shown to influence the rate of elongation. We did not observe a significant corre-
lation between transcription elongation rates and the densities of tri-methylation of
lysine 36 of H3 (H3K36me3) (Fig. 6.4C) or RNAPII (Fig. 6.4D). Since H3K36me3
and RNAPII densities are known to correlate with levels of gene expression, our
data suggest that high elongation rates are not merely reflecting high expression
levels although a weak positive correlation was observed between transcript output
measured with Bru-seq and transcript elongation rate (Kendall’s Tau=0.23, Sup-
plemental Fig. S6.3). We found no significant relationship between the density of
other common histone marks or transcription factors and transcription elongation
rate (Supplemental Fig. S6.2).
6.4 Discussion
Transcription elongation has recently drawn attention due to its potential role in
the timing of gene expression and the regulation of alternative splicing (Mason and
Struhl, 2005; Darzacq et al., 2007b; Singh and Padgett, 2009; Wada et al., 2009;
Danko et al., 2013). Here we describe a novel technique, BruDRB-seq, to measure
RNAPII elongation rates genome-wide. BruDRB-seq is based on DRB-induced arrest
of RNAPII at promoter sites (Singh and Padgett, 2009) followed by synchronized
release after drug removal. In five different human cell lines, median elongation
rate estimationsranged from 1.25-1.75 kb/min. These transcription elongation rates,
which were estimated from over 2000 genes in each cell line, are somewhat lower than
previously estimated in human cells (Singh and Padgett, 2009; Danko et al., 2013).
It is possible that the genes analyzed by Danko et al., which had been induced by
estradiol or TNF, showed a higher elongation rate due to being in an induced state
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where higher transcription and RNAPII densities promoted enhanced elongation
rates. Our results also differ from a previously published study that implicated a
role of the CSB protein in transcription elongation (Selby and Sancar, 1997). In
our study, CS-B fibroblasts did not show a distinctly different elongation rate than
the other cell types suggesting that the CSB protein is not generally required for
promoting rapid transcription elongation in cells, though it may be an important
regulator of elongation for select genes.
Our BruDRB-seq data indicate that there is a broad range of transcription elon-
gation rates in different genes in human cells (Fig. 6.3). However, the elongation
rates for individual genes were reasonably conserved across the different cell lines.
We speculated that this conservation may be driven by specific physical features,
such as DNA sequence, gene length or genomic position. Among the genetic features
linked to elongation rate was exon density, which correlates with slow elongation.
This supports the idea that RNAPII slows down at splice site junctions, which
would promote exon definition and alternative splicing (Shukla and Oberdoerffer,
2012). Although it has been shown that non-B DNA sequences can have a negative
impact on transcription in vitro (Belotserkovskii et al., 2013), we did not find a cor-
relation between elongation rate and potential non-B DNA sequences, though some
of these sequences may not exhibit non- B DNA conformations in vivo. Furthermore,
our results suggest that if a gene is located near another transcribing gene, its tran-
scription elongation rate is decreased. It has been proposed that transcription of a
downstream gene could lead to unwinding of DNA through the induction of negative
supercoiling (Ljungman and Hanawalt, 1992, 1995) which may affect the elongation
of a proximal gene. Conversely, if neighboring genes are simultaneously transcribed
in a head to head fashion, DNA topological barriers could emerge. Indeed, inhi-
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bition of DNA topoisomerase I, which relaxes torsional tension induced during the
transcription process, has been shown to severely inhibit transcription elongation
(Ljungman and Hanawalt, 1996; Veloso et al., 2013). Interestingly, suppression of
the rate of elongation by nearby transcription was independent of the orientation of
transcription. It is possible that the slower elongation rate in gene neighborhoods is
due to competition for limiting pools of ribonucleotides rather than restraints caused
by transcription-induced DNA supercoiling.
Our findings that the rates of transcription elongation of nearby genes or genes in-
teracting via DNA looping did not correlate with each other suggest that elongation
rates are primarily governed by gene-specific features and epigenetic modifications.
We found that H3K79me2 and H4K20me1 were enriched in genes with higher elon-
gation rates (Fig. 6.4), while the density of H3K36me3 marks, which have been
implicated in transcription elongation (Guenther et al., 2007), did not correlate with
elongation rate in our study. Furthermore, we did not observe a strong association
between high elongation rates and high density of RNAPII (Fig. 6.4) or high levels
of transcription in those genes (Supplemental Fig. 6.3). Thus, our data suggest that
high elongation rates are not simply the result of high gene expression but rather,
are governed by specific gene features and epigenetic modifications.
The histone mark H3K79me2 is regulated by the methylase DOT1L (Min et al.,
2003), an epigenetic regulator implicated in somatic cell reprogramming (Onder et al.,
2012). It was found that key genes involved in the induction of a mesenchymal cell
state lost dimethylation of H3K79 without a change in their expression levels during
this transition. It is possible that reducing the density of H3K79me2 marks results in
a reduced elongation rate of these genes and that this is allowing these cells to tran-
sition into a new cell state. DOT1L has also been found to be associated with mixed
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lineage leukemia (MLL) fusion proteins, resulting in aberrant methylation patterns
of H3K79 and dysregulation of MLL targeted genes (Okada et al., 2005). Clinical tri-
als are currently underway using DOT1L-targeting drugs in MLL (Anglin and Song,
2013). Methylation of H4K20 is regulated by the PR-SET7 methyltransferase in
a cell cycle-dependent manner (Nishioka et al., 2002) and these modifications have
been shown to play a role in DNA damage responses by attracting 53BP1 (Beck
et al., 2012). Interestingly, both the H3K79me2 and H4K20me1 histone marks have
been implicated in the regulation of replication origin firing (Tardat et al., 2010; Fu
et al., 2013). Perhaps by regulating transcription elongation rates of long genes by
H3K79 and H4K20 methylation, cells can fine-tune the firing of replication origins.
The size of a gene is a major determinant for how long it will take for tran-
scription to be completed and for the gene to be expressed, and differences in gene
lengths contribute to temporal expression patterns Swinburne and Silver (2008).
Our study shows that transcription elongation rates are associated with the histone
marks H3K79me2 and H4K20me1, providing a potential mechanism by which cells
can fine- tune the temporal gene expression and alternative splicing patterns, despite
fixed gene lengths. Future studies are needed to define the mechanisms by which cells
regulate elongation rates through epigenetic modification and characterize patholog-
ical states whereby transcription elongation rates are dysregulated.
6.5 Methods
6.5.1 Cell culturing
HF1, hTERT immortalized foreskin-derived human fibroblasts, previously called
NF (Paulsen et al., 2013a,b; Veloso et al., 2013), CS-B primary human skin fibroblasts
(Coriell, GM00739) and TM, hTERT immortalized human skin fibroblasts (a gift
from Dr. Tom Misteli, NCI) were grown in MEM supplemented with 10% FBS, L-
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glutamine, vitamin mix and antibiotics. K562 human leukemia cells were grown in
IMDM supplemented with 10% FBS and penicillin/streptomycin. MCF-7 human
breast cancer cells were grown in high-glucose RPMI supplemented with 10% FBS.
6.5.2 Bru-seq and BruDRB-seq
The labeling of nascent RNA with bromouridine (Bru) was carried out as previ-
ously described (Paulsen et al., 2013a,b). The BruDRB-seq protocol differs from the
Bru-seq protocol in that the drug 5,6-dichlorobenzimidazole 1-β-D- ribofuranoside
(DRB, Sigma) is added to the media to a final concentration of 100µM and cells are
incubated for 1 hour at 37◦C. After the incubation with DRB, the cells were washed
with PBS twice and nascent RNA was labeled in conditioned media containing 2 mM
bromouridine (Bru) (Aldrich) for 10 min at 37◦C. The cells were then directly lysed
in TRIzol reagent (Invitrogen). K562 cells were grown in suspension so these cells
were quickly spun down before being lysed in TRIzol. Total RNA was isolated and
the Bru-labeled RNA was isolated from the total RNA by incubation with anti-BrdU
antibodies (BD Biosciences) conjugated to magnetic Dynabeads (Invitrogen) under
entle rotation for 1 hour at room temperature. Finally, cDNA libraries were made
from the Bru-labeled RNA using the Illumina TruSeq library kit and sequenced us-
ing Illumina HiSeq sequencers at the University of Michigan DNA Sequencing Core.
The sequencing and read mapping was carried out as previously described (Paulsen
et al., 2013a,b).
6.5.3 Gene selection for elongation rate analysis
The Ensembl gene annotation (release 69) (Flicek et al., 2013) was used in this
analysis and the annotation data was downloaded using the biomaRt package in
the R environment (Durinck et al., 2005). All transcripts from genes with biotype
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matching “protein coding”, “pseudogene”, “processed transcript” or “lincRNA” were
initially selected to be used in the analysis. Transcripts were selected based on their
length, and the transcript’s minimum acceptable length was 40 kb in the three state
HMM analysis (see “Hidden Markov Model for elongation rate analysis section”) and
150 kb in the four state HMM analysis.
A potential source of error for the HMM analysis is the presence of additional
TSSs either upstream or downstream of a given TSS. To address this issue, we first
selected genes where the value 3’ of the TSS was at least 10 times higher than
the value 5’ of the TSS. Second, we rejected genes that initiated transcription from
an additional TSS within the analysis range (e.g. 40 kb in the three state HMM
analysis). Third, to exclude genes with active unannotated TSSs in the analysis
region, genes were rejected if the TSS-proximal signal was not more than 10 times
the distal signal. Lastly, only genes with Bru-seq expression above 0.5 RPKM were
used in the analysis.
6.5.4 Data processing and normalization for elongation rate analysis
The genomic distance analyzed for each transcript extended from 10 kb upstream
from the TSS to the minimum acceptable transcript length in that analysis (40 kb
in the three state HMM analysis or 150 kb for the four state HHM analysis). This
distance was divided into 250 bp bins and the reads along these bins were used to
determine the RPKM value of each bin. To minimize the effect of any potential
background contamination of unlabeled mature RNA on the elongation rate deter-
minations, the expression signal of bins that overlapped exons was replaced by an
interpolation based on the signal of the adjacent bins that did not overlap exons. In
order to limit the effect of the transcript’s expression value in the elongation rate
analysis, the data was quantile normalized using the R package preprocessCore (Bol-
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stad et al., 2003). Since most of the expression signal accumulated in the advancing
and receding waves, there were a large number of bins that presented very low ex-
pression values and the distribution of binned expression values in the analysis region
was similar to a Gamma distribution. In order to improve the presentation of data
to downstream analyses, a z-score Gamma- equivalent normalization was carried out
using the R package limma (Smyth et al., 2005).
6.5.5 Hidden Markov Model for elongation rate analysis
A Hidden Markov Model was used to determine the elongation rate of each tran-
script. This analysis was carried out in two different ways. In the first analysis, the
position of three states was predicted in genes that were 40 kb or longer. State 1
represented the low signal region upstream from TSS; State 2 represented the ad-
vancing wave with high transcription signal; State 3 represented the low signal region
downstream from the advancing elongation wave (Fig. 6.1B). In the second analysis,
a fourth state was added representing the receding wave (Fig. 6.2D). This second
analysis was applied to genes that were at least 150 kb long. Each gene analysis
region was split into 250 bp bins and bin RPKM values were calculated from the
BruDRB-seq samples. The expression values were normalized (see “Data processing
and normalization for elongation rate analysis”) and used as the observed layer in
the model. The model was trained on regions that were observed to behave as the
desired states in the aggregate view of the data (Fig. 6.1B). The relative bin posi-
tions used to calculate the output probabilities were: (state 1) from 10 kb to 0.5 kb
upstream from the TSS; (state 2) from 0.5 kb to 20 kb downstream from the TSS;
(state 3) from 40 kb to 60 kb (four state analysis) or 30 kb to 40 kb downstream
(three state analysis) from the TSS; (state 4) from 120 kb to 150 kb downstream
from the TSS. The normalized expression values observed in each bins within the
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described ranges were pooled and used to determine the emission probabilities for
each state. The model was set up so that transitions could only occur from state 1
to state 2, state 2 to state 3, and state 3 to state 4 (when analyzing long genes). The
transition probabilities between these states were set to 0.00001.
The emission and transition probabilities were used to fit the multi-state HMM
to the data for the complete analysis region for each transcript using the R package
msm (Jackson, 2011). The most likely state of each bin was estimated using the
Viterbi algorithm. Transcripts where the advancing wave (state 2) began more than
2 kb upstream or downstream from the annotated TSS were removed. Transcripts
where the trough (state 3) began at the annotated TSS and transcripts where a state
3 or state 4 (in the long gene analysis) was not recognized were removed from the
analysis.
6.5.6 Clustering of genes according to elongation rate
In order to compare between cell lines, the measured elongation rates were quantile
normalized. A dissimilarity matrix was then calculated from the quantile normalized
elongation rates using an Euclidean distance. This metric was used for the clustering,
which was carried out using the k-medoids algorithm (also known as partitioning
around medoids, or PAM). The dissimilarity matrix calculation and clustering were
performed using the R package cluster (Maechler et al., 2013).
6.5.7 Enrichment of gene sets according to elongation rate
The tool Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005) was
used to determine if there were gene sets enriched among the genes with higher
or lower elongation rates. The gene set collections used were: positional, curated
(BioCarta and KEGG), gene ontology (biological processes, cellular components
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and molecular functions), and oncogenic signatures (downloaded from the Molec-
ular Signatures Database (MSigDB) version 4; http://www.broadinstitute.org/
gsea/msigdb/index.jsp). GSEA was run on a list of genes ranked according to
elongation rate and gene sets with at least 15 represented genes were selected for
analysis. A false discovery rate (FDR) adjusted p-values threshold of 0.25 was ap-
plied to determine enrichment of a gene set.
6.5.8 Correlation between elongation rate and gene features
To determine if the elongation rates were correlated with different physical prop-
erties of the genes such as DNA sequence, several different features were tested
in a permutation test. Seven features were analyzed: (1) Transcript length (in
base pairs) using the Ensembl annotation (Flicek et al., 2013). (2) Distance to
nearby expressed genes (in base pairs). Genes with an expression level greater
than 0.1 RPKM were considered expressed. Distances were measured to closest
upstream and downstream gene in either the sense or antisense orientation, re-
sulting in a total of four different values. (3) Density of exons. The Ensembl’s
project exon annotation was used (Flicek et al., 2013). All annotated exons were
used and exons that overlapped were merged into a single exon. (4) GC content.
(5) Repetitive DNA (combined length of each class in base pairs). The Repeat-
Masker annotation (http://www.repeatmasker.org/) was downloaded from the
UCSC genome browser (http://genome.ucsc.edu/). The repetitive DNA anno-
tation was simplified to reflect only the major classes (i.e. DNA, LINE, low com-
plexity, LTR, other, RC/Helitron, RNA, rRNA, satellite, scRNA, simple repeat,
SINE, snRNA, srpRNA, tRNA, unknown). Only non-overlapping repetitive regions
were used in the analysis. (6) Non-B DNA (combined length of each class in base
pairs). The Non- B DB v2.0 annotation was used in this analysis (Cer et al.,
151
2013). The classes of non-B DNA used were: A phased repeat, direct repeat, G-
quadruplex motif, inverted repeat, mirror repeat, short tandem repeat, and Z DNA
motif (7) Density of methylated CpG sites. The DNA Methylation by Reduced Rep-
resentation Bisulfite-seq from ENCODE/HudsonAlpha dataset was used (http://
genome.ucsc.edu/cgibin/hgFileUi?db=hg19&g=wgEncodeHaibMethylRrbs). The
tracks used (and their respective GEO accession ID) were: K562 HudsonAlpha
replicates 1 (GSM683856) and 2 (GSM68378), and MCF-7 Standford replicates 1
(GSM720350) and 2 (GSM720353). A CpG site was only used in the analysis if it
was represented in a minimum of 10 reads and if at least 90% of those reads indicated
that that site was in fact methylated.
To assess the correlations between high and low levels of elongation and a partic-
ular DNA or chromatin feature, we divided the feature metric (e.g. exon count) by
the length of elongation (providing a feature density). It was observed that certain
features presented a non-random distribution throughout the length of the gene. For
example, GC content tends to be higher nearby the TSS and decrease as the distance
to the TSS increases until it levels off. Therefore, if one assigned random elongation
rates to genes and measured their GC content there would be a negative correlation.
Due to this limitation, a permutation test was performed by randomly distributing
the observed elongation rates among the genes.
In order to limit the effect of outliers, the 5% most extreme elongation rate values
(top and bottom 2.5%) were excluded from the analysis. Also, features were only
analyzed if they had been measured in at least 20% of the transcripts. The feature
metric was measured for all genes under the new elongation area as determined by the
randomly distributed elongation rates. A regression coefficient between elongation
rate and feature metric was calculated and stored. This process was repeated 2000
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times. Finally, the regression coefficient observed in the original data was compared
to the 2000 permutated regression coefficients. A one-tailed p-value was determined
by measuring the percentage of times that a permutated regression coefficient was
equal to or more extreme than the observed regression coefficient. To account for the
multiple testing, the p-values were FDR-corrected. A corrected regression coefficient
was calculated by subtracting the observed regression coefficient from the median
value of the 2000 permutated regression coefficients.
6.5.9 Long-range promoter interaction and elongation rate
Chromatin Interaction Analysis by Paired-End Tag Sequencing (ChIA-PET) data
was used to determine if the elongation rate of genes in contact with the same tran-
scription machinery is correlated. A regression analysis between elongation rates of
genes believed to be physically in contact with each other as assessed with ChIA-PET
was carried out. The data was downloaded from the UCSC genome browser (http:
//genome.ucsc.edu/cgi-bin/hgFileUi?db=hg19&g=wgEncodeGisChiaPet). The
tracks used (and their respective GEO accession ID) were: K562 POL2 replicates 1
and 2 (GSM970213), and MCF-7 POL2 replicates 3 and 4 (GSM970209). The seg-
ments that were considered to be connected by ChIA-PET analysis were intersected
with the annotation of genes for which elongation rates were measured. Two genes
were considered to be physically connected if two connected segments overlapped the
TSS of the two genes.
6.5.10 Aggregate signal of ChIP-seq data for the elongation rate quartiles
To determine if transcription elongation rates were correlated to the density of spe-
cific histone modifications or proteins, we downloaded the ChIP-seq processed signal
files (in the bigWig file format) from the UCSC genome browser. Data was obtained
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from http://genome.ucsc.edu/cgi-bin/hgFileUi?db=hg19&g=wgEncodeBroadHistone
and http://genome.ucsc.edu/cgi-bin/hgFileUi?db=hg19&g=wgEncodeSydhTfbs
datasets. The tracks used (and their respective GEO accession ID) were: ChIP-
seq input control (GSM733780), H3K4me1 (GSM733692), H3k4me3 (GSM733680),
H3K27ac (GSM733656), H3K9me1 (GSM733777), H3K9me3 (GSM733776), H3K9ac
(GSM733778), H3K27me3 (GSM733658), H3K36me3 (GSM733714), H3K79me2 (GSM733653),
H4K20me1 (GSM733675), CTCF (GSM733719), Pol2 (GSM733643), CCNT2 (GSM935547),
GTF21 (GSM935501), NELF-E (GSM935392), cMyc (GSM935516). This data was
normalized according to (Ram et al., 2011).
A genomic region encompassing 5 kb upstream to 20 kb downstream of the TSS
of all genes for which an elongation rate was recorded was used in the analysis. This
analysis region was split into bins of 250 bp in length. For each bin, the average
ChIP- seq signal of a given data set was calculated and plotted according to each
quadrant of elongation rates.
6.5.11 Data access
All the primary sequencing data files used in this study have been deposited in
NCBIs Gene Expression Omnibus (GEO) with the accession number GSE55534.
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Table 6.1: Correlations between DNA or genomic features and transcription elongation rates. (+)
Positive correlation, (-) negative correlation, (NS) not statistically significant, (NA) not assessed.
Feature HF1 TM CS-B K562 MCF7
Exon density - - - - -
GC content - NS - - -
Long terminal repeats - NS - - NS
CpG methylation NA NA NA - -
Low complexity sequences + + + + +
Gene length + + + + +
Distance from nearby transcription unit + + + + +
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the elongation phase in a synchronized manner, and nascent
RNA is labeled with bromouridine (Bru), isolated with anti-BrdU
antibodies, and subjected to deep sequencing. By measuring the
width of the transcription ‘‘wave’’ generated during the labeling
period, the transcription elongation rates of all expressed genes
longer than 40 kb were assessed. Our study provides the largest
data set so far reported of genome-wide elongation rates in mul-
tiple cell lines. We found that high transcription elongation rates
correlated with specific gene features as well as with histone
modifications such as dimethylation of lysine 79 of histone H3
(H3K79me2) and monomethylation of lysine 20 of histone H4
(H4K20me1). These results indicate that cells may be able to fine-
tune transcription elongation rates by epigenetic regulation.
Results
Measuring elongation rates globally reveals variation among
genes
To study the elongation rates of RNAPII genome-wide, we de-
veloped BruDRB-seq, a technique based on nascent RNA labeling
with Bru and assaying by deep sequencing (Paulsen et al. 2013a,b).
Following a 60-min treatment of the cultured cells with DRB to
arrest RNAPII at promoter-proximal sites, the drugwaswashed out,
and the cells were incubated with Bru for 10 min either directly or
after a 10-min recovery period. Cells were lysed in TRIzol, and total
RNAwas isolated followed by specific capturing of Bru-labeledRNA
using anti-BrdU antibodies conjugated to magnetic beads. The
captured Bru-labeled RNA was then reverse-transcribed, and the
resulting cDNA library was subjected to deep sequencing using
the Illumina HiSeq 2000 platform.
In Figure 1A (control), all expressed genes of at least 50 kb in
length in the diploid human fibroblast cell line HF1 are repre-
sented by median normalized expression (an aggregate view). As
expected for nascent RNA, the signal was fairly evenly distributed
throughout the first 50 kb of these genes. Following a 60-min DRB
treatment with Bru labeling during the last 10 min of treatment,
a substantially lower yield of reads was obtained, indicating that
transcription was severely reduced (Fig. 1A, 0 min). Following
drug removal, a synchronized wave of transcription was observed
moving out from the promoter (Fig. 1A, 10 min), and this wave
Figure 1. Transcription elongation rates measured genome-wide using BruDRB-seq. (A) Aggregate view of nascent RNA reads through the first 50 kb of
large expressed genes in the human fibroblast cell line HF1. (Control) Bru labeling for 30 min. (0 min) Bru labeling during the last 10 min of a 60-min DRB
treatment. (10 min) Appearance of a nascent transcription wave at the 59 end of genes during a 10-min recovery after DRB removal (10-min Bru labeling
during recovery period). (20 min) Advancing nascent transcription wave after a 20-min recovery time following DRB removal (Bru labeling during last
10min of recovery). (B) Aggregate view of BruDRB-seq (10-min recovery) showing the upstream region of TSS having a low signal (A), advancingwave (B),
and region downstream from the advancing wave with low signal (C). (C ) A hidden Markov model was developed to identify advancing waves and
measure their lengths, which are proportional to their elongation rates, having A, B, and C represent the three states of this model. Normalized signals of
genes in HF1 cells ordered by elongation rate for a 10-min recovery following DRB removal are shown. Examples of transcriptional recovery in individual
genes after 0-, 10-, and 20-min recovery after DRB removal in HF1 cells are shown in (D), (E), and (F).
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Figure 6.1: Transcription elongation rates measured genome-wide using Bru RB-seq. (A) Aggre-
gate view of nascent RNA reads through the first 50 kb of large expressed ge es in the human
fibroblast cell line HF1. Control: Bru labeling for 30 min; 0 min: Bru labeling during the last 10
min of a 60 minute DRB treatment; 10 min: appearance of a nascent transcription wave at the 5’-
end of genes during a 10 minute recovery after DRB removal (10 min Bru labeling during recovery
period); 20 min: advancing nascent transcription wave after a 20 minute recovery time following
DRB removal (Bru labeling during last 10 min of recovery). (B) Aggregate view of BruDRB-seq
(10’ recovery) showing the (A), upstream region of TSS having a low signal; (B), the advancing
wave and (C), region downstream of the advancing wave with low signal. (C) A Hidden Markov
Model was developed to identify advancing waves and measure their lengths, which are proportional
to their elongation rates having A, B, and C represent the three states of this model. Normalized
signal of genes in HF1 cells ordered by elongation rate for both a 10- and 20-minute recovery fol-
lowing DRB removal are shown. Examples of transcriptional recovery in individual genes after 0,
10, and 20 min recovery after DRB removal in HF1 cells are shown in (D), (E), and (F).
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moved further during the next 10 min (Fig. 1A, 20 min). These
results demonstrate both the reversibility of DRB and synchro-
nicity of transcription recovery.
In order to measure elongation rates of individual genes in
a genome-wide fashion, we used an inference method based on
a three-state hiddenMarkovmodel (HMM) (Day et al. 2007; Danko
et al. 2013). The HMM was designed to identify three distinct re-
gions of each gene: (A) the region immediately upstream of the
transcription start site (TSS); (B) the advancing wave; and (C) the
region of low transcription downstream from the advancing
transcription wave (Fig. 1B). Quantile normalization was per-
formed on the BruDRB-seq trace prior to HMM analysis to elimi-
nate any effect of a gene’s expression level on the analysis (see
Methods). After applying the HMM analysis to the data from the
10-min wave in HF1 cells, we ordered the genes according to their
calculated elongation rates and found them to be quite variable
(Fig. 1C). Examples of transcription waves moving from the pro-
moters into the bodies of three individual genes following DRB
removal are shown in Figure 1, D–F.
DRB inhibits the transition of RNAPII from the initiation/
promoter paused stage into the elongation phase by blocking the
phosphorylation of the C-terminal domain (CTD) of RNAPII
(Dubois et al. 1994). However, DRB does not inhibit elongating
RNA polymerases, and thus, DRB treatment results in a time-
dependent clearing out of transcription from the promoter with
a receding wave of unaffected actively transcribing polymerases.
For transcribed genes longer than 200 kb in HF1 cells treated with
DRB for 60 min, the receding transcription wave can be clearly
observed (Fig. 2A, yellow). The elongation patterns of two large
genes expressed in HF1 cells, MYO1B and TLE4, are shown in
Figure 2, B and C, respectively.
By incorporating a fourth state in the hidden Markov model
representing the receding wave of transcription, we were able to
analyze the correlation between the advancing and the receding
waves. A visual comparison between the states predicted by the
HMM (Fig. 2D) and the normalized signal observed in those genes
(Fig. 2E) indicates that predictions of the model were reasonably
accurate. We compared elongation rates calculated both via the
advancing (state ‘‘B’’) and the receding (state ‘‘D’’) wave and found
that they correlate, albeit with high variability (Fig. 2F). Because
the trailing edge of the receding wave is not as well defined as the
advancingwave and becausewe can includemore genes by leaving
the receding wave out of the HMM, we decided to focus on the
advancing wave (three-state HMM predictions) as our metric for
elongation.
Elongation rates are similar in different cell lines
Transcription elongation rates have been explored in a limited
number of genes and only in a few cell lines (Ardehali et al. 2009;
Figure 2. The relationship between advancing and receding transcription elongation waves. (A) Aggregate view of 189 genes longer than 200 kb in
HF1 cells during DRB treatment (yellow) or following a 10-min recovery period after DRB treatment (red). Advancing and receding transcription waves in
the large genes MYO1B (B) and TLE4 (C ). (D) A four-state hidden Markov model was developed to take into account this receding wave in large genes.
Genes in HF1 cells were ordered by the length of the advancing wave (state B) and pseudocolored by state (green, A; yellow, B; orange, C; gray, D).
(E ) Normalized signaling for genes ordered according to the length of state B. (F) The relationship between elongation rates calculated by the length of the
advancing wave (state B) and the distance of the trough between the end of the advancing wave and the beginning of the receding wave (state C). (PCC)
Pearson’s correlation coefficient.
Rates of transcription elongation genome-wide
Genome Research 3
www.genome.org
 Cold Spring Harbor Laboratory Press on May 5, 2014 - Published by genome.cshlp.orgDownloaded from 
Figure 6.2: The relationship between advancing and receding transcription elongation waves. (A)
Aggreg te view o 189 gen s l nger a 200 kb in HF1 cells duri g DRB re tm nt (yellow) or
following a 10 minute recovery period after DRB treatment (red). (B) Advancing and receding
transcription waves in the large genes MYO1B and (C) TLE4. (D) A 4-state Hidden Markov
Model was developed to take into account this receding wave in large genes. enes in HF1 cells
were ordered by the length of the advancing wave (state B) and pseudo-colored by state (green: A,
yellow: B, orange: C, gray: D). (E) Normalized signaling for genes ordered according to the length
of state B. (f) The relationship between elongation rates calculated by the length of the advancing
wave (state B) and the distance of the trough between the end of the advancing wave and the
beginning of the receding wave (state C). PCC, Pearson’s Correlation Coefficent.
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Figure 6.3: Comparisons of transcription elongation rates among five cell lines. (A) Cells were
treated with DRB for 60 min followed by drug reversal and immediate incubation with 2 mM
Bru for 10 min. BruDRB-seq was then performed and violin plots illustrating the distribution of
elongation rates in the indicated cell lines are shown (the interquartile ranges are represented by
thick vertical bars and white dots indicate the median values). Sample sizes: HF1 - 2702, CS-B -
1932, TM - 2469, K562 - 2270, MCF-7 - 2399. (B) Grid of pairwise comparisons of elongation rates
between each of five cell lines. Each individual comparison includes those genes with measurable
elongation rates that are expressed in both cell lines. Frequencies and linear regression models are
plotted in the upper-right panels and respective Pearsons correlation coefficients in the lower-left.
(C) Examples of two individual genes showing similar elongation rates in the 5 cell lines. (D) Genes
expressed in all five cell lines (855 genes) were clustered by normalized elongation rate into 3 groups
using the k-medoids method. Genes in Group 1 tend to be faster-elongating in multiple cell lines
and genes in Group 3 tend to be slower in multiple cells. Genes belonging to Group 2 (47% of
total genes) consists of genes with intermediate or variable elongation rates across cell lines. Genes
are colored by percentile ranking within each cell line (100%=highest elongation rate=red). HF1:
human foreskin fibroblasts; CS-B: Cockayne syndrome fibroblasts B; TM: human skin fibroblasts;
K562: myelogenous leukemia; MCF-7: breast cancer.
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pression, our data suggest that high elongation rates are notmerely
reflecting high expression levels, although a weak positive corre-
lation was observed between transcript output measured with
Bru-seq and transcript elongation rate (Kendall’s T = 0.23) (Sup-
plemental Fig. 3). We found no significant relationship between
the density of other common histone marks or transcription fac-
tors and the transcription elongation rate (Supplemental Fig. 2).
Discussion
Transcription elongation has recently drawn attention due to its
potential role in the timing of gene expression and the regulation
of alternative splicing (Mason and Struhl 2005; Darzacq et al. 2007;
Singh and Padgett 2009;Wada et al. 2009; Danko et al. 2013). Here
we describe a novel technique, BruDRB-seq, to measure RNAPII
elongation rates genome-wide. BruDRB-seq is based on DRB-in-
duced arrest of RNAPII at promoter sites (Singh and Padgett 2009),
followed by synchronized release after drug removal. In five differ-
ent human cell lines, median elongation rate estimations ranged
from 1.25 to 1.75 kb/min. These transcription elongation rates,
which were estimated from over 2000 genes in each cell line, are
somewhat lower than previously estimated in human cells (Singh
and Padgett 2009; Danko et al. 2013). It is possible that the genes
analyzed by Danko and coworkers, which had been induced by
estradiol or TNF, showed a higher elongation rate due to being in an
‘‘induced state’’ where higher transcription and RNAPII densities
promoted enhanced elongation rates. Our results also differ from
a previously published study that implicated a role of the CSB pro-
tein in transcription elongation (Selby and Sancar 1997). In our
study, CS-B fibroblasts did not show a distinctly different elongation
rate than the other cell types, suggesting that the CSB protein is not
generally required for promoting rapid transcription elongation in
cells, though it may be an important regulator of elongation for
select genes.
Our BruDRB-seq data indicate that there is a broad range of
transcription elongation rates in different genes in human cells
(Fig. 3). However, the elongation rates for individual genes were
reasonably conserved across the different cell lines. We speculated
Figure 4. Elongation rates are associated with specific histone modifications. Genes expressed in K562 cells were ranked according to elongation rate
and placed into four equal-sized groups (from fastest to slowest: red, green, blue, black). ChIP-seq data for K562 cells were obtained from ENCODE, and
median binned values for each group were plotted as indicated for H3K79me2 (A), H4K20me1 (B), H3K36me3 (C ), and RNA polymerase II (D). In A and B,
genes with faster elongation rates have a higher density of histone modification both near the transcription start site (TSS) and within the gene bodies.
In C and D, neither histone modification nor RNA polymerase II occupancy correlated to transcription elongating rates.
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Figur 6.4: Elongation rates are associated with specific histone modificatio s. Genes expressed
in K562 cells were ranked according to elongation rate and placed into four equal-sized groups
(from fastest to slowest: red, green, blue, black). ChIP-seq data for K562 cells was obtained
from ENCODE and median binned values for each group plotted as indicated for (A) H3K79me2,
(B) H4K20me1, (C) H3K36me3, and (D) RNA polymerase II. In (A) and (B), genes with faster
elongation rates have higher density of his one modification both near th tr nscription start
site (TSS) and within the gene bodies. In (C) and (D), neither histone modification nor RNA
polymerase II occupancy correlated to transcription elongating rates.
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Supplemental Figure 1.  Transcription elongation rates in K562 cells are not related to two- or three-dimensional localization.  (A) Correlation 
between the elongation rate of a particular gene and the elongation rate of its nearest expressing neighbor.  Data point frequency illustrated by a 
colored contour plot where solid line indicates a linear regression model.  (B) Elongation rates of genes in relationship their two-dimensional 
chromosomal location.  Genes were divided into four equal-sized groups according to ranked elongation rates (from slowest to fastest: black circles, 
blue squares, green diamonds, red triangles) and their chromosomal location are denoted for each chromosome.  (C) Correlation between 
elongation rates and three-dimensional association using ChIA-PET data for K562 cells from ENCODE. Data point frequency illustrated by a colored 
contour plot where solid line indicates a linear regression model.
Figure S6.1: Transcriptio elongation ates in K562 cells a e n t related two- or three-dimensional
localization. (A) Correlation between the elongation rate of a particular gene and the elongation rate
of its nearest expressing neighbor. Data point frequency illustrated by a colored contour plot where
solid line indicates a linear regression model. (B) Elongation rates of genes in relationship their
two-dimensional chromosomal location. Genes were divided into four equal-sized groups according
to ranked elongation rates (from slowest to fastest: black circles, blue squares, green diamonds,
red triangles) and their chromosomal location are denoted for each chromosome. (C) Correlation
between elongation rates and three-dimensional association using ChIA-PET data for K562 cells
from ENCODE. Data point frequency illustrated by a colored contour plot where solid line indicates
a linear regression model.
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Supplemental Figure 2.  Comparisons between elongation rate and histone modification or transcription factor binding.  Genes 
expressed in K562 cells were ranked according to elongation rate and placed into four equal-sized groups (from fastest to slowest: 
red, green, blue, black).  CHiP-Seq signal was obtained from ENCODE and median binned values for each group were plotted as 
indicated.  
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Figure S6.2: Comparisons between elongation rate histo e modification r transcripti n factor
binding. Genes expressed in K562 cells were ranked according to elongation rate and placed into
four equal-sized groups (from fastest to slowest: red, green, blue, black). CHiP-Seq signal was
obtained from ENCODE and median binned values for each group were plotted as indicated.
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Supplemental Figure 3.  Relationship between transcription elongation rate and nascent RNA transcription (measured using Bru-
seq in the 40kb analysis region) for the HF1 cell line.  The red  trace indicates a local regression (LOESS) fit and the title indicates 
Kendall's Tau correlation coefficient.
Figure S6.3: Relationship between transcription elongation rate and nascent RNA transcription
(measured using Bru-seq in the 40kb analysis region) for the HF1 cell line. The red trace indicates
a local regression (LOESS) fit and the title indicates Kendall’s Tau correlation coefficient.
CHAPTER VII
Concluding remarks
RNA transcription, processing and degradation are extremely complex and inter-
twined processes. While most modern transcriptomic studies have been built upon
the final product of these processes, there is still a clear necessity to better under-
stand the steps that lead up to mature RNA. In this thesis I have described a suite
of techniques designed to investigate different stages of RNA transcription. These
techniques are based on the metabolic labeling of nascent RNA with bromouridine
(thoroughly described on Chapters II and III). This allows us to specifically capture
and measure the RNA produced during the labeling period.
In response to environmental challenges or stimuli, cells undergo a re-programming
of gene expression. In Chapter III we use Bru-seq and BruChase-seq to interrogate
the effects the pro-inflammatory TNF protein have on both synthesis and stability
of RNA genome-wide. The cells were exposed to TNF for one hour prior to nascent
RNA labeling, and labeled for the next 30 minutes in the presence of TNF. As it
would be expected, we noticed gene synthesis changes that were consistent with
an inflammatory response (section 3.3.7). One of the most interesting aspects of
a visual inspection of the gene expression changes was identifying genes where the
post-induction transcription level was not constant throughout the gene (see figure
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S3.1).
Changes in gene synthesis are caused by a change in the number of polymerases
initiating transcription for that given gene. The change in nascent RNA, there-
fore, should initially be visible directly downstream to the promoter and, with time,
“travel” through the rest of the gene. Given enough time and a constant initiation
rate, the nascent transcription signal of a gene should reach a reasonably constant
level throughout the gene. The fact that we observed genes where this constant level
had not been reached after 1 hour of TNF exposure played an important role in
changing how I think about the genome.
Clearly, one of the main reasons why the signal in the genes in figure S3.1 has not
yet plateaued is their size. These genes are close to 200kb long, which is larger than
the genome size of certain bacteria (Bennett and Moran, 2013). The presence of such
large genes in the human genome certainly puts nascent transcription in perspective.
Treatment induced changes in gene synthesis can only affect the total level of RNA
once that gene is completely transcribed. Therefore, transcription elongation is an
extremely important process regulating RNA production.
In order to further explore RNA synthesis we decided to block transcription elon-
gation. This was carried out in two different ways. In chapter IV, we used UV
radiation to induce transcription elongation inhibiting lesions to the DNA (see sec-
tion 1.5.2). In chapter V, the anti-cancer drug camptothecin was used to inhibit the
functioning of topoisomerase I, which leads to the creation of barriers for elongating
RNAPII (see section 1.5.3). Since both these treatments blocked transcription elon-
gation, their results displayed some very interesting similarities. For example, after
treatment increased signal was observed in shorter genes (figures 5.1C and 4.1). Also,
signal was redistributed into promoters (figures 5.3 and 4.2) and putative enhancer
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elements figures 5.2C and 4.5. This indicates that inhibition of transcription elonga-
tion leads to similar signal redistribution regardless of the inhibition mechanism.
The fact that the effect of transcription elongation inhibitors on gene expression
is affected by gene size is not surprising, but it is interesting. After the removal of
the transcription elongation blocking agent, our data suggested that transcription
needs to restart from the promoter (figures 5.3 and 5.4). This has a particularly
strong effect on large genes, since they take longer to be fully transcribed. Consider
a gene whose transcription takes 2 hours. If it is blocked at the elongation stage
after 1 hour and 50 minutes, the incomplete transcript will probably be degraded
and transcription will have to re-initiate. This could be extremely problematic for
the cell, depending on the importance of the gene for the cell’s overall health.
A major aspect in determining how long it takes for a gene to be transcribed is
the elongation rate of RNAPII. In chapter VI, we used nascent RNA transcription
to calculate genome-wide elongation rates. We found that the abundance of several
sequence patterns was correlated to the elongation rate of RNAPII. For example, the
density of long terminal repeats was negatively correlated with elongation rates (see
table 6.1). Therefore, the sequence composition traversed by RNAPII seems to affect
its elongation rate. More interestingly, we noticed that the abundance of certain
epigenetic modifications was correlated to elongation rate (see figure 6.4). If a causal
relationship exists between these epigenetic modifications and elongation rate, it
would be reasonable to assume that a cell is capable of modifying a gene’s elongation
rate. This could be used as a mechanism to regulate gene expression timing. The
most surprising finding, however, was that the gene’s length and distance to other
gene’s was positively correlated to elongation rate.
It is hard to imagine how these two factors could affect elongation rate. Assum-
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ing non-overlapping genes, a very large gene is, by definition, far away from other
genes transcribing downstream from it. Therefore, it is possible that the main factor
determining this correlation is the distance to other transcribing genes. The advan-
tage of being isolated from other transcribing genes could possibly result from an
inter-gene competition for resources such as nucleotides. Regardless, the differences
in elongation rate found within transcripts is not extremely large 6.3. Therefore, the
transcription of a very large gene (> 300kb) would take much longer than the tran-
scription of a small gene (< 5kb) even if their elongation rates were at the extreme
of the ranges observed in Chapter VI.
Therefore, all of these findings bring us back to the long genes whose TNF-induced
synthesis changes were still unnoticed 1 hour after treatment (figure S3.1). Is it im-
portant for the cell that these gene’s full transcript is completed long after exposure?
Is gene size a mechanism for adjusting the timing of gene expression? There is re-
search that suggests that this could be the case for genes involved in development
(Swinburne and Silver, 2008). But how prevalent is this mechanism? Has gene length
been optimized by evolution for all transcriptomic responses? This also helps putting
gene transcription studies in perspective. When studying treatment induced changes
in gene expression at the total RNA level, the size of the gene is crucial to determine
when changes in expression can be observed. This is particularly true if the time
span after treatment being studied is short.
Time is not only important for the termination of transcription. Treatment in-
duced changes in transcription initiation do no occur at a constant rate through time.
As time passes, the transcription initiation rates can change. Figure S3.1C shows
an interesting example of a gene that was upregulated in the initial stages of the
response to TNF. Later, however, its expression returns to pre-TNF levels. In most
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studies, the expression value for that gene would be calculated by integrating all
signal observed throughout the gene. This approach would basically average out the
gene’s transcription initiation rate for the whole treatment period. Clearly, this is
a simplistic approach that overlooks the complexity of the gene expression program
initiated by TNF exposure.
Therefore, I postulate that a study of gene expression changes is only exhaustive if
one investigates changes both in transcription initiation and in mature RNA produc-
tion at a given time point. This could be accomplished by modifying nascent RNA
sequencing techniques, such as Bru-seq, to measure these different steps of transcrip-
tion. For example, the amount of transcription initiation could be calculated based
on the BruUV-seq signal. As shown in figure 4.4, BruUV-seq can be used to mea-
sure treatment induced changes in gene expression at gene’s promoters. Measuring
mature RNA production could be accomplished by initiating metabolic labeling at
the same time as a treatment and analyzing the RNA that has been labeled and
polyadenylated. In a similar approach, Rabani et al. (2011) studied changes in gene
expression in mouse dendritic cells exposed to lipopolysaccharide in nascent and total
RNA. Since they used RNA-seq, however, their measurement of mature RNA could
be highly influenced by changes in transcript stability and did not directly reflect
how much RNA was produced after the beginning of the treatment.
Overall, the research carried out in this thesis have not only clarified important
biological mechanisms, but also demonstrated the complexity of RNA transcription
regulation through synthesis and stability. Hopefully these techniques will support
further scientific advances and lead to a better understanding of RNA transcription
as whole.
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